Combination therapy with CD40 agonists targeting FAP
Patent Information
- Application Number
- JP2023524957
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2020-11-16
- Filing Date
- 2021-11-15
- Publication Date
- 2024-11-20
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Current immunotherapy treatments for solid tumors, particularly head and neck squamous cell carcinoma (HNSCC), are limited by dose-limiting side effects and on-target/off-tumor effects of CD40 agonist antibodies, necessitating the development of targeted therapies that enhance tumor-specific immune responses while minimizing systemic toxicity.
A bispecific antigen-binding molecule targeting fibroblast activation protein (FAP) and CD40, combined with localized hypofractionated radiotherapy, to activate antigen-presenting cells (APCs) selectively in the tumor stroma, enhancing immune responses and reducing side effects.
The combination therapy effectively suppresses tumor growth and eliminates tumor cells more than either treatment alone, demonstrating improved therapeutic efficacy with reduced toxicity.
Abstract
Description
[Technical Field]
[0001] The present invention relates to combination therapies using FAP-targeted CD40 agonists (particularly bispecific antigen-binding molecules comprising at least one antigen-binding domain specifically capable of binding to fibroblast-activating protein (FAP) and at least one antigen-binding domain specifically capable of binding to CD40) and radiotherapy, as well as the use and methods of using these combination therapies for the treatment of solid tumors. [Background technology]
[0002] Cancer is one of the leading causes of death worldwide. Despite advances in treatment options, the prognosis for patients with advanced cancer remains poor. Therefore, there is a persistent and urgent medical need for optimal treatments that increase cancer patient survival without causing unacceptable toxicity. Recent results from clinical trials have shown that immunotherapy extends overall survival and provides a sustained response in cancer patients. Despite these promising results, current immunotherapy is only effective for a portion of patients, and combination strategies are needed to improve treatment efficacy.
[0003] Radiotherapy (RT) is an important mode of treatment for localized tumors. While RT typically induces cell death primarily through mitosis, it also has complex effects on apoptosis[9] and the tumor microenvironment, and can promote the homing of antigen-presenting cells and effector T cells. Sublethal doses of ionizing radiation have been reported to directly stimulate the expression of major histocompatibility complexes (MHCs), increasing the sensitivity of tumor cells to detection and lysis by specific T cells.
[0004] Head and neck cancer, with over 800,000 new cases annually, is the seventh most common cancer worldwide. Tobacco smoking, alcohol consumption, and human papillomavirus (HPV) infection are major risk factors for developing HNSCC (Chow, Head and Neck Cancer, N. Engl. J. Med. 2020, 382(1), 60-72). HPV-associated head and neck squamous cell carcinoma (HPV) + HNSCC is a distinctive subgroup of head and neck cancers that has improved outcomes compared to HPV-negative HNSCC. + This is due to the combination of the unique biological characteristics of HNSCC and favorable patient traits such as young age and low levels of tobacco and alcohol abuse. These patients have shown increased and sustained benefits from radiotherapy, and dose-tasking trials are currently underway (Ventz et al, Clin. Cancer Res. 2019, 25(24), 7281-7286). However, further optimization of treatment by integrating new combination strategies is needed to increase the treatment index and reduce toxicity. Among these new options, immunomodulation appears to be a promising target, given that HNSCC is one of the ten major immunoinvasive cancers, as characterization of the tumor microenvironment in HNSCC biopsies has revealed it to be. In this regard, the immunostimulatory properties of fractional radiotherapy have been demonstrated, making this treatment mode a good combination partner for immunotherapy (Lhuillier et al, Genome Med. 2019;11(1), 40).
[0005] HPV + Although patients with head and neck squamous cell carcinoma (HNSCC) showed favorable outcomes with radiotherapy, many experienced tumor recurrence over time. Therefore, further optimization of treatment, including novel combination therapies, and reduction of treatment-related toxicity remain necessary.
[0006] Among several costimulatory molecules, CD40, a member of the TNFR family, plays a crucial role in inducing immune responses by inducing the maturation, survival, antigen presentation, cytokine production, and expression of costimulatory molecules in antigen-presenting cells (APCs), and ultimately activating antigen-specific T cell responses by inflammatory cytokines. CD40 modulates immune responses to infections, tumors, and autoantigens, and its expression has been observed on the surface of APCs such as B cells, dendritic cells (DCs), monocytes, and macrophages, as well as platelets and non-hematopoietic cells such as myofibroblasts, fibroblasts, epithelial cells, and endothelial cells (Elgueta R. et al., Immunol Rev. 2009; 229(1): 152-72). The CD40 ligand, CD40L, is activated by CD4 + It is expressed in helper T cells, platelets, monocytes, natural killer cells, mast cells, and basophils (Carbone E. et al., J Exp Med. 1997;185(12): 2053-206 or Elgueta R. et al., Immunol Rev. 2009;229(1):152-72). CD40 and CD40L expression are strongly upregulated in response to various immunostimulatory signals, as well as APC and CD4 + CD40-CD40L interactions with T cells contribute to APC activation and increased antigen-specific CD8+ T cell responses (Bevan MJ., Nat Rev Immunol. 2014;4(8):595-602). Similar immunostimulatory results were observed using CD40 agonist antibodies (Vonderheide RH and Glennie MJ., Clin Cancer Res. 2013;19(5):1035-43).
[0007] Therefore, the use of agonist anti-CD40 antibodies that can mimic the licensing of so-called APCs is a promising strategy in the context of cancer immunotherapy. In particular, the ability of anti-CD40 molecules to activate DCs and subsequently increase (cross)priming of tumor-specific T cells makes them interesting for clinical development. Several agonist anti-CD40 antibodies have been developed in recent years. Specifically, Chi Lob 7 / 4 (CD40 agonist IgG1 chimeric mAb; Cancer Research UK; Chowdhury F. et al., Cancer Immunol Res. 2013;2:229-40), ADC1013 (fully human CD40 agonist IgG1 antibody; Alligator Bioscience and Johnson & Johnson; Mangsbo SM. et al., Clin Cancer Res. 2015 Mar 1;21(5):1115-26), APX-005 (fully humanized CD40 agonist IgG1 mAb; Apexigen; Bjorck P. et al. J Immunother Cancer. 2015; 3(Suppl 2): P198), SEA-CD40 (CD4 agonist IgG1 chimeric mAb; Seattle Genetics; Gardai SJ. et al. AACR 106th Annual Meeting 2015; April) 18-22, abstract 2472), and RO7009789 (fully human CD40 hyperagonist IgG2 mAb) are in or have completed Phase I clinical trials, and dasetuzumab (CD40 partial agonist IgG1 chimeric mAb; Seattle Genetics; Khubchandani S. et al., Curr Opin Investig Drugs. 2009;10,579-87) has completed Phase II clinical trials. Eligible patients in these trials had solid tumors, classical Hodgkin lymphoma (HL), diffuse large B-cell lymphoma (DLBCL), or slowly progressive lymphoma (including follicular lymphoma). While promising initial results were obtained in the clinical development of agonist CD40 antibodies, major challenges in anti-CD40 agonist therapy have become apparent.In various clinical trials, dose-limiting side effects such as cytokine release syndrome, hepatotoxicity, and thromboembolism have been observed, suggesting that the administration schedules and routes used may limit clinical efficacy and allow only local antibody delivery. The lack of monotherapy response is partly due to the strong on-target / off-tumor effect caused by widespread CD40 expression, resulting in dose-limiting toxicity (e.g., cytokine release syndrome). The development of agonist CD40 antibodies that specifically activate APC when CD40 is crosslinked by tumor-specific targets may offer a novel therapeutic option that could reduce side effects, lower dose limits, and generate efficient and sustained anti-cancer immunity.
[0008] Bispecific antigen-binding molecules capable of specifically binding to CD40 and fibroblast-activating protein (FAP) are described in International Publication No. 2018 / 185045, International Publication No. 2020 / 070041, or International Publication No. 2020 / 070035. These molecules combine a portion capable of binding to FAP with a portion capable of agonist binding to CD40. CD40-mediated APC activation is brought about by crosslinking via FAP expressed in tumor stromal cells, and potentially also by crosslinking via FAP moderately expressed in secondary lymphoid tissues. In contrast to bispecific antigen-binding molecules capable of specifically binding to immune checkpoint receptors such as CTLA-4 or PD-1 on activated T cells and CD40, targeting tumor targets such as FAP enables CD40-mediated APC activation primarily in the tumor stroma and tumor dissipation lymph nodes, where fibroblasts express elevated levels of FAP compared to other tissues. Therefore, FAP-targeted agonist CD40 antigen-binding molecules are not only effective, but also highly selective in inducing CD40 receptors at desired sites, while reducing side effects by overcoming the need for FcγR crosslinking.
[0009] The present inventors hereby describe a novel combination therapy using a CD40 agonist targeting FAP (particularly a bispecific antigen-binding molecule comprising at least one antigen-binding domain specifically capable of binding to fibroblast-activating protein (FAP) and at least one antigen-binding domain specifically capable of binding to CD40) and radiotherapy (particularly local fractionated radiotherapy). [Overview of the project]
[0010] The present invention relates to a bispecific agonist CD40-antigen binding molecule (particularly a bispecific agonist CD40-antigen binding molecule comprising at least one antigen-binding domain capable of specifically binding to tumor-associated antigens) and its use in combination with radiotherapy, particularly its use in methods for treating solid tumors in individuals (particularly humans). The combination therapy described herein has been found to be more effective than treatment with the bispecific agonist CD40-antigen binding molecule alone or radiotherapy alone in suppressing tumor growth and eliminating tumor cells.
[0011] Therefore, a bispecific agonist CD40 antigen-binding molecule is provided for use in the treatment of solid tumors in individuals, which is used in combination with radiotherapy and comprises at least one antigen-binding domain capable of specifically binding to a tumor-associated antigen. Specifically, the tumor-associated antigen is fibroblast-activating protein (FAP).
[0012] In some embodiments, the bispecific agonist CD40 antigen-binding molecule comprises at least one antigen-binding domain capable of specifically binding to CD40 and at least one antigen-binding domain capable of specifically binding to fibroblast-activating protein (FAP).
[0013] In some embodiments, the bispecific agonist CD40 antigen-binding molecule is for concurrent or sequential administration with radiotherapy. In some embodiments, the bispecific agonist CD40 antigen-binding molecule is for administration after radiotherapy. In some embodiments, the bispecific agonist CD40 antigen-binding molecule is for single administration after radiation. In some embodiments, the bispecific agonist CD40 antigen-binding molecule is for single administration the day after radiation. In some embodiments, the bispecific agonist CD40 antigen-binding molecule is for administration the day after the completion of radiation. In some embodiments, the radiotherapy includes local radiotherapy. In some embodiments, the local radiotherapy is selected from external beam therapy or near-brightness radiotherapy. In some embodiments, the radiotherapy is external beam therapy. In other embodiments, the radiotherapy is near-brightness radiotherapy. In some embodiments, the radiotherapy includes local fractional radiotherapy at doses in the range of 1.8 to 20 Gy, particularly in the range of 5 to 20 Gy. In some embodiments, radiotherapy includes local fractionated radiation therapy at a dose of 6 Gy, preferably 2 × 6 Gy. In some embodiments, radiotherapy includes local fractionated radiation therapy at a dose in the range of 1.8 to 2.2 Gy, preferably 2 Gy.
[0014] In some embodiments, a bispecific CD40 antigen-binding molecule is provided for use in the treatment of solid tumors in an individual, comprising at least one antigen-binding domain capable of specifically binding to a tumor-associated antigen, wherein the solid tumor is selected from the group consisting of head and neck cancer, melanoma, lung cancer, kidney cancer, breast cancer, colon cancer, ovarian cancer, cervical cancer, pancreatic cancer, liver cancer, prostate cancer, bladder cancer, gastric cancer, and glioblastoma. In some embodiments, the tumor-associated antigen is FAP, and the tumor is characterized by stroma expressing FAP. In some embodiments, the solid tumor to be treated is head and neck cancer or lung cancer. In particular, the solid tumor is head and neck cancer, more specifically HPV +It is head and neck squamous cell carcinoma (HNSCC). In another specific embodiment, the solid tumor is lung cancer, particularly non-small cell lung cancer (NSCLC).
[0015] In some embodiments, a bispecific agonist CD40 antigen-binding molecule for use in the treatment of solid tumors in an organism is an antigen-binding molecule comprising an IgG Fc domain, specifically an IgG1 Fc domain or an IgG4 Fc domain, wherein the Fc domain comprises one or more amino acid substitutions that reduce the binding affinity and / or effector function of the antibody to the Fc receptor. In particular, the bispecific agonist CD40-binding molecule comprises an Fc domain of a human IgG1 subclass having amino acid substitutions L234A, L235A, and P329G (numbered according to the Kabat EU index).
[0016] In some embodiments, a bispecific agonist CD40 antigen-binding molecule for use in the treatment of solid tumors in organisms is a bispecific agonist CD40 antigen-binding molecule comprising at least one antigen-binding domain specifically capable of binding to CD40 and at least one antigen-binding domain specifically capable of binding to fibroblast-activating protein (FAP), wherein the at least one antigen-binding domain specifically capable of binding to CD40 comprises a heavy chain variable region (V) comprising (i) CDR-H1 containing the amino acid sequence of SEQ ID NO: 1, (ii) CDR-H2 containing the amino acid sequence of SEQ ID NO: 2, and (iii) CDR-H3 containing the amino acid sequence of SEQ ID NO: 3. H CD40) and a light chain variable region (V) containing (iv) CDR-L1 containing the amino acid sequence of SEQ ID NO: 4, (v) CDR-L2 containing the amino acid sequence of SEQ ID NO: 5, and (vi) CDR-L3 containing the amino acid sequence of SEQ ID NO: 6. L The molecule includes CD40. In particular, the bispecific agonist CD40 antigen-binding molecule includes at least one antigen-binding domain that can specifically bind to CD40, comprising VH containing the amino acid sequence of SEQ ID NO: 7 and VL containing the amino acid sequence of SEQ ID NO: 8.
[0017] In a further aspect, the bispecific agonist CD40 antigen-binding molecule comprises at least one antigen-binding domain capable of specifically binding to FAP, said at least one antigen-binding domain comprising: (a) (i) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 9, (ii) a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 10, and (iii) a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 11, of a heavy chain variable region (V H FAP), and (iv) a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 12, (v) a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 13, and (vi) a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 14, of a light chain variable region (V L FAP), or (b) (i) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 17, (ii) a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 18, and (iii) a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 19, of a heavy chain variable region (V H FAP), and (iv) a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 20, (v) a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 21, and (vi) a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 22, of a light chain variable region (V L FAP), or (c) (i) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 25, (ii) a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 26, and (iii) a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 27, of a heavy chain variable region (V H FAP), and (iv) a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 28, (v) a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 29, and (vi) a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 30, of a light chain variable region (V L FAP).
[0018] In some aspects, the bispecific agonist CD40 antigen-binding molecule comprises a heavy chain variable region (V H(V) Light chain variable region (V) containing (iv) CDR-L1 containing the amino acid sequence of SEQ ID NO: 12, (v) CDR-L2 containing the amino acid sequence of SEQ ID NO: 13, and (vi) CDR-L3 containing the amino acid sequence of SEQ ID NO: 14 L The molecule includes at least one antigen-binding domain that is specifically capable of binding to FAP, including FAP. In another embodiment, the bispecific agonist CD40 antigen-binding molecule includes a heavy chain variable region (V) comprising (i) CDR-H1 containing the amino acid sequence of SEQ ID NO: 17, (ii) CDR-H2 containing the amino acid sequence of SEQ ID NO: 18, and (iii) CDR-H3 containing the amino acid sequence of SEQ ID NO: 19. H (V) Light chain variable region (V) containing (iv) CDR-L1 containing the amino acid sequence of SEQ ID NO: 20, (v) CDR-L2 containing the amino acid sequence of SEQ ID NO: 21, and (vi) CDR-L3 containing the amino acid sequence of SEQ ID NO: 22 L The molecule comprises at least one antigen-binding domain capable of specifically binding to FAP, including FAP. In yet another embodiment, the bispecific agonist CD40 antigen-binding molecule comprises a heavy chain variable region (V) comprising (i) CDR-H1 containing the amino acid sequence of SEQ ID NO: 25, (ii) CDR-H2 containing the amino acid sequence of SEQ ID NO: 26, and (iii) CDR-H3 containing the amino acid sequence of SEQ ID NO: 27. H (V) Light chain variable region (V) containing (iv) CDR-L1 containing the amino acid sequence of SEQ ID NO: 28, (v) CDR-L2 containing the amino acid sequence of SEQ ID NO: 29, and (vi) CDR-L3 containing the amino acid sequence of SEQ ID NO: 30 L It contains at least one antigen-binding domain that can specifically bind to FAP (FAP).
[0019] In some embodiments, the bispecific agonist CD40 antigen-binding molecule is (a) Heavy chain variable region containing the amino acid sequence of SEQ ID NO: 15 (V H FAP) and the light chain variable region (V) containing the amino acid sequence of SEQ ID NO: 16 L FAP) (b) Heavy chain variable region containing the amino acid sequence of SEQ ID NO: 23 (V H Light chain variable region (V) containing the amino acid sequence of FAP) and SEQ ID NO: 24 LFAP), or (c) Heavy chain variable region containing the amino acid sequence of SEQ ID NO: 31 (V H FAP) and the light chain variable region (V) containing the amino acid sequence of SEQ ID NO: 32 L FAP) It contains at least one antigen-binding domain that is specifically capable of binding to FAP.
[0020] In certain embodiments, the bispecific agonist CD40 antigen-binding molecule has a heavy chain variable region (V) containing the amino acid sequence of SEQ ID NO: 15. H FAP) and the light chain variable region containing the amino acid sequence of SEQ ID NO: 16 (V L It contains at least one antigen-binding domain that can specifically bind to FAP (FAP).
[0021] Therefore, in a particular embodiment, the bispecific agonist CD40 antigen-binding molecule comprises (i) at least one antigen-binding domain that can specifically bind to CD40, and a heavy chain variable region (V) containing the amino acid sequence of SEQ ID NO: 7. H CD40) and the light chain variable region containing the amino acid sequence of SEQ ID NO: 8 (V L (ii) an antigen-binding domain including CD40, and (ii) at least one antigen-binding domain that can specifically bind to FAP, wherein the heavy chain variable region (V) includes the amino acid sequence of SEQ ID NO: 15. H FAP) and the light chain variable region (V) containing the amino acid sequence of SEQ ID NO: 16 L Includes an antigen-binding domain (FAP).
[0022] In another embodiment, the bispecific agonist CD40 antigen-binding molecule comprises (i) at least one antigen-binding domain that can specifically bind to CD40, and a heavy chain variable region (V) containing the amino acid sequence of SEQ ID NO: 7. H CD40) and the light chain variable region containing the amino acid sequence of SEQ ID NO: 8 (V L (ii) an antigen-binding domain including CD40, and (ii) at least one antigen-binding domain that can specifically bind to FAP, wherein the heavy chain variable region (V) includes the amino acid sequence of SEQ ID NO: 23. H Light chain variable region (V) containing the amino acid sequence of FAP) and SEQ ID NO: 24L The molecule comprises an antigen-binding domain including FAP. In another embodiment, the bispecific agonist CD40 antigen-binding molecule comprises (i) at least one antigen-binding domain that can specifically bind to CD40, wherein the heavy chain variable region (V) includes the amino acid sequence of SEQ ID NO: 7. H CD40) and the light chain variable region containing the amino acid sequence of SEQ ID NO: 8 (V L (ii) an antigen-binding domain including CD40, and (ii) at least one antigen-binding domain that can specifically bind to FAP, wherein the heavy chain variable region (V) includes the amino acid sequence of SEQ ID NO: 31. H FAP) and the light chain variable region (V) containing the amino acid sequence of SEQ ID NO: 32 L Includes an antigen-binding domain (FAP).
[0023] In some embodiments, the bispecific agonist CD40 antigen-binding molecule is a) At least two Fab fragments that can specifically bind to CD40, wherein the C-terminus of the Fab fragment is fused to the N-terminus of the Fc region, and (b) A single antigen-binding domain capable of specifically binding to FAP, wherein the N-terminus of the antigen-binding domain is fused to the C-terminus of the above Fc region. Includes.
[0024] In some embodiments, the bispecific agonist CD40 antigen-binding molecule is a) At least two Fab fragments that can specifically bind to CD40, wherein the C-terminus of the Fab fragment is fused to the N-terminus of the Fc region, and (b) A cross-fab fragment that can specifically bind to FAP, and which is fused to the C-terminus of the Fc region. Includes.
[0025] In certain embodiments, the bispecific agonist CD40 antigen-binding molecule comprises a cross-fab fragment specifically capable of binding to FAP, with the VH-C kappa chain of the cross-fab fragment fused to the C-terminus of the Fc region. In certain embodiments, the bispecific agonist CD40 antigen-binding molecule comprises two Fab fragments specifically capable of binding to CD40, with the C-terminus of each Fab fragment fused to the N-terminus of the Fc region. In certain embodiments, the bispecific agonist CD40 antigen-binding molecule is characterized by divalent binding to CD40 and monovalent binding to FAP.
[0026] In another embodiment, the bispecific agonist CD40 antigen-binding molecule is characterized by tetravalent or trivalent binding to CD40 and monovalent binding to FAP. In some embodiments, the bispecific agonist CD40 antigen-binding molecule is characterized by tetravalent binding to CD40 and monovalent binding to FAP. In some embodiments, the bispecific agonist CD40 antigen-binding molecule comprises four Fab fragments capable of specifically binding to CD40, where each pair of Fab fragments is fused to each other and fused at the N-terminus of the Fc region at its C-terminus.
[0027] In some embodiments, the bispecific agonist CD40 antigen-binding molecule is intended for use in the treatment of solid tumors, where (i) an individual has an increased survival rate when treated with a therapeutically effective amount of the bispecific agonist CD40 antigen-binding molecule in combination with radiotherapy, compared to an individual treated with the bispecific agonist CD40 antigen-binding molecule as monotherapy or with radiotherapy as monotherapy, or (ii) the size of the solid tumor in the individual is reduced by a greater amount than the additive amount of reduction in size due to treatment with the bispecific agonist CD40 antigen-binding molecule as monotherapy and radiotherapy as monotherapy.
[0028] In a further embodiment, a composition for use in the treatment of solid tumors is provided, comprising a pharmaceutically effective amount of a bispecific agonist CD40 antigen-binding molecule, wherein the treatment comprises combination therapy with radiotherapy, and the bispecific agonist CD40 antigen-binding molecule comprises at least one antigen-binding domain capable of specifically binding to a tumor-associated antigen. In particular, the tumor-associated antigen is FAP.
[0029] In some embodiments, pharmaceutical compositions are provided for use in the treatment of solid tumors in individuals in combination with radiotherapy, comprising a pharmaceutically effective amount of a bispecific agonist CD40 antigen-binding molecule, wherein the bispecific agonist CD40 antigen-binding molecule comprises at least one antigen-binding domain capable of specifically binding to a tumor-associated antigen. In particular, the tumor-associated antigen is FAP.
[0030] In another embodiment, the use of a bispecific agonist CD40 antigen-binding molecule in the manufacture of a pharmaceutical for treating solid tumors in an organism is provided, wherein the bispecific agonist CD40 antigen-binding molecule is intended for use in combination with radiotherapy and comprises at least one antigen-binding domain capable of specifically binding to a tumor-associated antigen.
[0031] In another embodiment, a method is provided for treating a solid tumor in an individual, comprising administering an effective amount of a bispecific agonist CD40 antigen-binding molecule and an effective amount of radiotherapy to the target, wherein the bispecific agonist CD40 antigen-binding molecule comprises at least one antigen-binding domain capable of specifically binding to a tumor-associated antigen.
[0032] In all of these embodiments, the individual is preferably human. [Brief explanation of the drawing]
[0033] [Figure 1]Figure 1A shows a schematic diagram of an antigen-binding molecule that specifically binds to human CD40. Here, the VL-CH1 chain is fused to the C-terminus of the Fc knob chain (tetravalent binding to CD40, monovalent binding to FAP). In the control molecule with the same structure, the FAP binding site is replaced by the VH and VL domains of the germline control DP47. Figure 1B shows a schematic diagram of a bispecific FAP-CD40 antibody in a 4+1 format, consisting of four CD40 binding sites combined with one FAP binding site as VH and VL domains. Here, the VH domain is fused to the C-terminus of the Fc knob chain at its N-terminus, and the VL domain is fused to the C-terminus of the Fc hole chain at its N-terminus (tetravalent binding to CD40, monovalent binding to FAP). In the control molecule, the FAP binding site is replaced by the VH and VL domains of the germline control DP47. Figure 1C is a schematic diagram of a bispecific CD40 antibody having amino acid substitutions L234A, L235A, and P329G ("P329G LALA", EU numbering) in the Fc domain of the IgG heavy chain (bivalent binding to CD40). Figure 1D shows a schematic diagram of a 2+1 format bispecific FAP-CD40 antibody consisting of two CD40 binding sites combined with one FAP binding site as a crossover Fab fragment, where the VL-CH1 chain is fused at the C-terminus of the Fc knob chain (bivalent for CD40, monovalent for FAP). The black dots represent knob-into-hole mutations. In the control molecule, the FAP binding site is replaced by the VH and VL domains of the germline control DP47. [Figure 2A-2B]Figures 2A to 2H show the efficacy of a bispecific FAP-CD40 antibody (P1AD9139, Figure 1B), either alone or in combination with radiotherapy (RT), in an orthotopic head and neck tumor mouse model (mEERL95) with FAP-expressing stroma. Figure 2A is a scheme showing the treatment schedule applied to an established submental mEERL95 mouse tumor. Figure 2B shows the survival rate of mEERL95 tumor-carrying mice treated with the indicated antibody DP47-CD40((P1AE2425)) compared to the untreated group, using a log-rank test (p=0.233). Radiotherapy alone (2×6Gy) did not significantly increase survival probability, similar to FAP-CD40 therapy alone (p=0.024) (p=0.001), but the combination of RT (2×6Gy) and FAP-CD40 therapy resulted in a higher survival probability (p=0.0006). A log-rank test was used to compare the indicated groups with untreated mice for statistical analysis. n=5-6 mice / group. [Figure 2C-2H] The mEERL95 tumor growth curves (expressed as tumor volume) for the indicated treatment groups are shown. The number of mice that rejected the tumor is shown for each group (Figure 2C: untreated mice, Figure 2D: control mice treated with DP47-CD40, Figure 2E: mice treated with FAP-CD40, Figure 2F: mice treated with RT (2 × 6 Gy) and DP47-CD40, Figure 2H: mice treated with RT (2 × 6 Gy) and FAP-CD40). [Figure 2I-2L] Further experimental mEERL95 tumor growth curves (expressed as tumor volume) are shown, comparing one dose (Figure 2K) or two doses (Figure 2L) of anti-FAP-CD40 in combination with fractional radiotherapy, and also comparing them with no treatment (Figure 2I) and radiotherapy alone (Figure 2J). [Figure 3A-3F]Figures 3A to 3G relate to a second experiment comparing bispecific FAP-CD40 antibody therapy with conventional anti-CD40 agonist antibody therapy. mEERL95 tumor growth curves are shown for mice treated with the indicated therapies, including non-targeted anti-CD40 (FGK4.5) mAb and the corresponding IgG-matched control antibody (IgG Ctr). Figure 3A: Mice treated with IgG Ctr; Figure 3B: Mice treated with anti-CD40 mAb; Figure 3C: Mice treated with anti-CD40 mAb and RT (2 × 6 Gy); Figure 3D: Mice treated with IgG Ctr and RT (2 × 6 Gy); Figure 3E: Mice treated with FAP-CD40; Figure 3F: Mice treated with RT (2 × 6 Gy) and FAP-CD40. A one-way ANOVA study was used to compare the weight difference of mice treated with the indicated therapies compared to the control group. n=5-10 mice / group. [Figure 3G] The percentage change in weight over 72 hours following the treatment described is shown. [Figure 4A-4C] Figures 4A to 4K show experimental results investigating the effect of FAP expression by tumor bed fibroblasts on the efficiency of FAP-CD40. Figure 4A shows a comparison of DAPI, FAP, and αSMA immunofluorescence staining in TC-1 tumor cells and mEERL95 submental tumor cells 10 days after inoculation. Figure 4B shows the FAP mRNA levels from mEERL95 and TC-1 submental tumors measured by qPCR, and Figure 4C shows the CD40 mRNA levels from mEERL95 and TC-1 submental tumors measured by qPCR. [Figure 4D-4H] Figure 2A shows the TC-1 tumor growth curves (expressed as tumor volume) of mice treated according to the schedule shown. The number of mice that rejected the tumor is shown for each group. Figure 4D: Untreated mice, Figure 4E: Mice treated with FAP-CD40, Figure 4F: Mice treated with RT (2 × 6 Gy), Figure 4G: Mice treated with RT (2 × 6 Gy) and FAP-CD40. Figure 4H shows how the bispecificity of FAP-CD40 accumulates in TC-1 tumors and mEERL95 tumors. Quantification of fluorescence emission obtained from the tumors is shown. FI: Fluorescence intensity. n=2-3 mice / group. [Figure 4I-4K]Figure 4I shows the results of intravascular coagulation (IHC) of FAP performed in cervical lymph nodes 10 days after inoculation with mEERL95 and TC-1 cells in the submental region. Figure 4J shows the percentage of FAP-positive cells (FRC) and the MFI (Mean Fluorescence Intensity) of FAP measured by flow cytometry 10 days after inoculation in the FRC (gp38+CD31-) of cervical lymph nodes from naive, mEERL95, and TC-1 tumor-carrying mice. MFI: Mean fluorescence intensity. Mann-Whitney test; ***: p<0.001; n=5-10 mice / group. [Figure 5A-5C] The results of the tumor rechallenge experiment are shown in Figures 5A to 5C. Figure 5A is a scheme showing the sequential tumor rechallenge schedule in long-term responders to combination therapy with RT (2 × 6 Gy) and anti-FAP-CD40. The tumor growth curves after sequential rechallenge of mEERL95 tumor cells (Figure 5B) and TC-1 tumor cells (Figure 5C) in the right flank (1 × 10⁶ cells) and left flank (1 × 10⁵ cells) are shown, respectively. [Figure 5D-5E] The results of tumor rechallenge experiments are shown in Figures 5D to 5E. Combination therapy resulted in tumor-specific memory formation. Figure 5D shows the percentage of tetramer-positive CD8 T cells from PMBCs in cured mice restimulated with E7 peptide for 8 days. Figure 5E shows the percentage of tetramer-positive CD8 T cells in TILs in mEERL95-carrying mice obtained 6 days after the aforementioned treatment. **: p<0.01, ***: p<0.001; Kruskal-Wallis test used for statistical analysis. Mean ± SEM; n=5-8 mice / group. [Figure 6A-6B] Figures 6A to 6F describe further experiments using transgenic mice expressing the human CD40 receptor (huCD40 Tg mice) and anti-human FAP-CD40 in a 2+1 format (P1AE2302). Figure 6A is a scheme showing the treatment schedule for mEERL95 tumor-carrying huCD40 Tg mice. Figure 6B summarizes the survival rates of mEERL95-carrying huCD40 transgenic mice with the indicated treatments. The number of mice that rejected the tumor is shown for each group. Log-rank test; ns: not significant, **: p<0.01, ***: p<0.001; n=10 mice / group. [Figure 6C-6F] Figures 6C to 6F describe further experiments using transgenic mice expressing the human CD40 receptor (huCD40 Tg mice) and anti-human FAP-CD40 in a 2+1 format (P1AE2302). The tumor growth curves for MEERL95-carrying huCD40 transgenic mice in the aforementioned treatments are shown for untreated mice (Figure 6C), mice treated with anti-human FAP-huCD40 (Figure 6D), mice treated with RT (2 × 6 Gy) alone (Figure 6E), and mice treated with RT (2 × 6 Gy) and anti-human FAP-huCD40 in combination (Figure 6F). [Figure 7] Figures 7A to 7H show the results of the analysis of cellular and molecular immune components related to the antitumor effect of the experimental treatment described in Figure 2A. Flow cytometry analysis of the immune populations indicated in the tumor 18 days after mEERL95 tumor cell inoculation (i.e., 7 days after FAP-CD40 treatment). The number of immune cells is shown for CD45+ cells (Figure 7A), CD8 T cells (Figure 7B), regulatory T cells (Treg, Figure 7C), CD4 T cells (Figure 7F), dendritic cells (Figure 7G), and NK cells (Figure 7H) per 1 mg of tumor. The CD8 / Treg ratio and CD8 / macrophage ratio are shown in Figures 7D and 7E, respectively. [Figures 8A-8F] Figures 8A, 8B, and 8C show a comparison of IFNγ, TNFα, and granzyme B production by tumor-infiltrating CD8 lymphocytes after 16 hours of restiration in mEERL95 tumor cells, as measured by intracellular FACS staining, between an untreated mouse group and a mouse group treated with RT and FAP-CD40, respectively. Figures 8D, 8E, and 8F show IFNγ, TNFα, and granzyme B production by tumor-infiltrating CD4 lymphocytes, respectively. [Figure 8G-8I] Figure 8G shows the frequency of Ki67-positive cells, and Figure 8H shows PD1 expression in CD8 T cell populations infiltrating tumors under different treatments. Figure 8I shows the frequency of CD62L CD44 double-positive cells (memory phenotype) in the CD8 T cell population of cervical lymph nodes. [Figures 9A-9C]Figures 9A, 9B, and 9C show the levels of chemokines CXCL9 and CXCL10 and cytokine (INFγ) in the tumor microenvironment 8 days after treatment with different therapies, measured in multiplex, respectively. [Figure 9D-9E] Figures 9D and 9E show the percentage of dendritic cells (CD11c+ MHCII+) expressing the surface maturation markers CD80 and CD86, respectively, from mEERL95 tumors 4 days after the indicated treatment. Statistical analysis was performed using the Mann-Whitney test, one-way ANOVA, or Kruskal-Wallis test. Mean ± SEM. *: p<0.05, **: p<0.01, ***: p<0.001. n=3-6 samples / group. [Figure 9G-9H] Figure 9G shows the quantification of FAP+ regions and locations under different conditions in mEERL95 tumors 7 days after the treatment described. Figure 9H is a heatmap of gene signatures associated with DC maturation that were differentially expressed in the tumor microenvironment 4 days after the treatment described. [Figure 10A-10E] In Figures 10A and 10B, T lymphocytes in mEERL95 tumor-carrying mice were depleted using anti-CD8β, anti-CD4, or corresponding isotype control antibodies starting 48 hours prior to administration of combination therapy. CD8 T lymphocyte depletion was shown to result in the loss of the curative effect observed with combination therapy. Tumor recurrence occurred in mice with CD4 T lymphocyte depletion, indicating a crucial role of CD4 T cells in the formation of a sustained antitumor response. Figures 10A to 10D show mEERL95 tumor growth curves (expressed as tumor volume) for untreated mice (Figure 10A) and those treated with combination therapy of RT (2 × 6 Gy) and FAP-CD40, with depletion in the untreated (Figure 10B), and with CD8 T cell depletion (Figure 10C) or CD4 T cell depletion (Figure 10D). Figure 10E shows the survival time of mice treated with combination therapy containing the depletion antibodies indicated. Log-rank test; ns: not significant, **: p<0.01, ***: p<0.001; n=7 mice / group. [Figure 10F-10I]Combination therapy was tested in the absence of cross-priming DCs. Figures 10F and 10G show the mEERL95 tumor growth curves of Batf3- / - mice (lacking cDC1) treated with no treatment or in combination with RT (2 × 6 Gy) and FAP-CD40. Figures 10H and 10I show the mEERL95 tumor growth curves of tumor-carrying wild-type mice treated with no treatment or in combination with RT (2 × 6 Gy) and FAP-CD40, respectively. These indicate that cross-priming DCs are necessary for a robust protective response mediated by FAP-CD40. [Figure 11A-11C] The mEERL95 tumor growth curves for untreated mice and mice treated with combination therapy of RT (2 × 6 Gy) and FAP-CD40 in addition to an IL-12 blocking antibody or a corresponding isotype-matched control are shown in Figures 11A, 11B, and 11C, respectively. [Figure 11D-11G] The number of mice in each treatment group and the number of mice that rejected the tumor are shown. Serum levels of the corresponding chemokines in mice from each treatment group, measured by multiplex 21 days after tumor injection, are shown in Figures 11D (CXCL9 level), 11E (CXCL10 level), 11F (CCL4 level), and 11G (CCL22 level). Statistical analysis was performed using one-way ANOVA or the Kruskal-Wallis test. Mean ± SEM. *: p<0.05, **: p<0.01. n=5-9 samples / group. [Figure 12]Figures 12A to 12C show the efficacy of a bispecific FAP-CD40 antibody (P1AD9139, Figure 1B), either alone or in combination with radiotherapy (RT), in an orthotopic SV2-OVA lung tumor model with FAP-expressing stroma. Figure 12A is a scheme showing the treatment schedule applied to established SV2-OVA mouse tumors. Figure 12B shows the percentage decrease in normal lung volume for each treatment group. The decrease in vital capacity was observed considerably later in the group of mice receiving radiotherapy (RT, 2 × 6 Gy) (n=7) than in the untreated animals (n=7). In the group receiving both RT (2 × 6 Gy) and FAP-CD40 treatment (twice on days 14 and 18), the decrease in lung volume was observed only after day 41, which was considerably later than with RT alone. Figure 12C shows the survival rate of SV2-OVA tumor-carrying mice treated with the control antibody DP47-CD40((P1AE2425)) compared to the untreated group, using a log-rank test. While radiotherapy (2 × 6 Gy) alone increased survival, the combination of FAP-CD40 treatment and radiotherapy (2 × 6 Gy) resulted in a significant increase in survival. [Modes for carrying out the invention]
[0034] definition Unless otherwise defined, technical and scientific terms used herein have the same meanings as they are commonly used in the art to which this invention pertains. For the purposes of interpreting this specification, the following definitions apply, and wherever appropriate, a term used in the singular also includes the plural, and conversely, a term used in the plural also includes the singular.
[0035] As used herein, the term “antigen-binding molecule” refers in its broadest sense to a molecule that specifically binds to an antigenic determinant. Examples of antigen-binding molecules include antibodies, antibody fragments, and scaffold antigen-binding proteins.
[0036] The term "antibody" as used herein is used in its broadest sense and encompasses a variety of antibody structures, including but not limited to monoclonal antibodies, polyclonal antibodies, monospecific and multispecific antibodies (e.g., bispecific antibodies), and antibody fragments, as long as they exhibit the desired antigen-binding activity.
[0037] As used herein, the terms “antigen-binding domain capable of specifically binding to tumor-associated antigens” or “molecular portion capable of specifically binding to tumor-associated antigens” refer to polypeptide molecules that specifically bind to antigenic determinants. In some embodiments, antigen-binding domains can activate signaling via their target cell antigens. In certain embodiments, antigen-binding domains can guide the entity to which they bind (e.g., CD40 agonists) to a target site, for example, a specific type of tumor cell or tumor stroma having an antigenic determinant. Antigen-binding domains capable of specifically binding to target cell antigens include antibodies and fragments thereof, as further defined herein. Furthermore, antigen-binding domains capable of specifically binding to target cell antigens include scaffold antigen-binding proteins, as further defined herein, for example, binding domains based on design repeat proteins or design repeat domains (see, for example, International Publication No. 2002 / 020565). In particular, the target cell antigen is FAP.
[0038] With respect to an antibody or a fragment thereof, the term "antigen-binding domain capable of specifically binding to an antigen" refers to a portion of a molecule that contains a region that specifically binds to some or all of an antigen and is complementary to some or all of the antigen. An antigen-binding domain capable of specific antigen binding may be provided, for example, by one or more antibody variable domains (also called antibody variable regions). Specifically, an antigen-binding domain capable of specific antigen binding includes an antibody light chain variable region (VL) and an antibody heavy chain variable region (VH). In another embodiment, an "antigen-binding domain capable of specifically binding to a target cell antigen" may be either a Fab fragment or a cross-Fab fragment.
[0039] As used herein, the term “monoclonal antibody” refers to an antibody obtained from a substantially homogeneous population of antibodies; that is, the individual antibodies in the population are identical and / or bind to the same epitope, except for possible variant antibodies, such as those containing naturally occurring mutations or those arising during the manufacture of the monoclonal antibody preparation. Such variants are usually present in small amounts. In contrast to polyclonal antibody preparations, which typically contain different antibodies against different determinants (epitopes), each monoclonal antibody in a monoclonal antibody preparation is against a single determinant on an antigen.
[0040] As used herein, the term “monospecific” antibody refers to an antibody having one or more binding sites that each bind to the same epitope of the same antigen. The term “bispecific” means that an antigen-binding molecule can specifically bind to at least two different antigenic determinants. Typically, a bispecific antigen-binding molecule contains two antigen-binding sites, each of which is specific to a different antigenic determinant. In certain embodiments, a bispecific antigen-binding molecule can simultaneously bind to two antigenic determinants, particularly two antigenic determinants expressed on two different cells. Furthermore, the bispecific antigen-binding molecules described herein may also form part of a multispecific antibody.
[0041] As used in this application, the term "~valent" indicates that an antigen-binding molecule that is specific to one antigenic determinant contains a specific number of binding sites that are specific to one antigenic determinant. Accordingly, the terms "divalent," "tetravalent," and "hexavalent" indicate that an antigen-binding molecule contains two, four, and six binding sites, respectively, that are specific to a particular antigenic determinant. In certain embodiments of the present invention, a bispecific antigen-binding molecule may be monovalent to a particular antigenic determinant (i.e., the molecule has only one binding site for the antigenic determinant), or the molecule may be divalent, trivalent, or tetravalent to a particular antigenic determinant (i.e., the molecule has two, three, or four binding sites, respectively, for the antigenic determinant).
[0042] The terms “full-length antibody,” “intact antibody,” and “whole antibody” are used interchangeably herein to refer to antibodies having a structure substantially similar to that of a naturally occurring antibody. “Natural antibody” refers to naturally occurring immunoglobulin molecules with a variety of structures. For example, a natural IgG class antibody is a heterotetrameric glycoprotein with approximately 150,000 daltons, composed of two disulfide-linked heavy chains and two light chains. From the N-terminus to the C-terminus, each heavy chain has a variable region (VH), also called a variable heavy chain domain or heavy chain variable domain, followed by three constant domains (CH1, CH2, and CH3), also called heavy chain constant regions. Similarly, from the N-terminus to the C-terminus, each light chain has a variable region (VL), also called a variable light chain domain or light chain variable domain, followed by a light chain constant domain (CL), also called a light chain constant region. The heavy chain of an antibody may be assigned to one of five types called α(IgA), δ(IgD), ε(IgE), γ(IgG), or μ(IgM), some of which may be further divided into subtypes such as γ1(IgG1), γ2(IgG2), γ3(IgG3), γ4(IgG4), α1(IgA1), and α2(IgA2). The light chain of an antibody may be assigned to one of two types called kappa (κ) and lambda (λ) based on the amino acid sequence of its constant domain.
[0043] An "antibody fragment" refers to a molecule other than an intact antibody, including a portion of an intact antibody that binds to the antigen to which the intact antibody binds. Examples of antibody fragments include, but are not limited to, Fv, Fab, Fab', Fab'-SH, F(ab')2; diabodies, triabodies, tetrabodies, cross-Fab fragments; linear antibodies; single-chain antibody molecules (e.g., scFv); and single-domain antibodies. For a review of specific antibody fragments, see Hudson et al., Nat Med 9, 129-134 (2003). For a review of scFv fragments, see, for example, Plueckthun, The Pharmacology of Monoclonal Antibodies, vol. 113, Rosenburg and Moore eds., Springer-Verlag, New York, pp. 269-315 (1994). Also, see International Publication No. 93 / 16185 and U.S. Patents No. 5571894 and 5587458. For a description of Fab and F(ab')2 fragments containing salvage receptor-binding epitope residues and exhibiting extended in vivo half-lives, see U.S. Patent No. 5,869,046. Diabodies are antibody fragments containing two antigen-binding sites that are bivalent or bispecific; see, for example, EP No. 404097; International Publication No. 1993 / 01161; Hudson et al., Nat Med 9, 129-134 (2003), and Hollinger et al., Proc Natl Acad Sci USA 90, 6444-6448 (1993). Triabodies and tetrabodies are also described in Hudson et al., Nat Med 9, 129-134 (2003). Single-domain antibodies are antibody fragments containing all or part of the heavy chain variable domain or all or part of the light chain variable domain of an antibody. In certain embodiments, the single-domain antibody is a human single-domain antibody (see, for example, Domantis, Waltham, Massachusetts; U.S. Patent No. 6,248,516).Antibody fragments can be produced by a variety of techniques, including, but not limited to, proteolytic digestion of intact antibodies and production by recombinant host cells (e.g., Escherichia coli or phages), as described herein.
[0044] Papain digestion of the intact antibody produces two identical antigen-binding fragments called "Fab" fragments, each containing the heavy chain variable domain and light chain variable domain, as well as the constant domain of the light chain and the first constant domain (CH1) of the heavy chain, respectively. Therefore, as used herein, the term "Fab fragment" refers to a light chain fragment containing the VL domain and constant domain of the light chain (CL), and an antibody fragment containing the VH domain and first constant domain (CH1) of the heavy chain. The Fab' fragment differs from the Fab fragment in that several residues are added to the carboxyl terminus of the heavy chain CH1 domain, which contains one or more cysteines derived from the antibody hinge region. Fab'-SH is a Fab' fragment in which one or more cysteine residues of the constant domain retain a free thiol group. Pepsin treatment yields an F(ab')2 fragment having two antigen-binding sites (two Fab fragments) and a portion of the Fc region.
[0045] The terms "crossover Fab fragment," "xFab fragment," or "crossover Fab fragment" refer to Fab fragments in which the heavy chain variable region and the light chain variable region are exchanged, or the heavy chain constant region and the light chain constant region are exchanged. Crossover Fab molecules can have two different chain compositions and are included in the bispecific antibodies of the present invention. On the other hand, the variable region of the Fab heavy chain and the variable region of the light chain are exchanged, that is, the crossover Fab molecule includes a peptide chain composed of a light chain variable region (VL) and a heavy chain constant region (CH1), and a peptide chain composed of a heavy chain variable region (VH) and a light chain constant region (CL). This crossover Fab molecule is a crossover Fab (VLVH)It is also called [another name]. On the other hand, when the heavy chain constant region and light chain constant region of Fab are swapped, the crossover Fab molecule contains a peptide chain composed of a heavy chain variable region (VH) and a light chain constant region (CL), and a peptide chain composed of a light chain variable region (VL) and a heavy chain constant region (CH1). This crossover molecule is called crossover Fab. (CLCH1) It is also called [another name].
[0046] A "single-chain Fab fragment" or "scFab" is a polypeptide comprising an antibody heavy chain variable domain (VH), an antibody constant domain 1 (CH1), an antibody light chain variable domain (VL), an antibody light chain constant domain (CL), and a linker, wherein the antibody domain and the linker have one of the following sequences from the N-terminus to the C-terminus: a) VH-CH1-linker-VL-CL, b) VL-CL-linker-VH-CH1, c) VH-CL-linker-VL-CH1, or d) VL-CH1-linker-VH-CL; and the linker is a polypeptide of at least 30 amino acids, preferably 32 to 50 amino acids. The single-chain Fab fragment is stabilized by a native disulfide bond between the CL domain and the CH1 domain. In addition, these single-chain Fab molecules can be further stabilized by the creation of interchain disulfide bonds through the insertion of cysteine residues (for example, at position 44 of the variable heavy chain and position 100 of the variable light chain, according to Kabat numbering).
[0047] A "crossover single-chain Fab fragment" or "x-scFab" is a polypeptide comprising an antibody heavy chain variable domain (VH), an antibody constant domain 1 (CH1), an antibody light chain variable domain (VL), an antibody light chain constant domain (CL), and a linker, wherein the antibody domain and the linker have one of the following sequences from the N-terminus to the C-terminus: a) VH-CL-linker-VL-CH1 and b) VL-CH1-linker-VH-CL; VH and VL together form an antigen-binding site that specifically binds to a certain antigen, and the linker is a polypeptide of at least 30 amino acids. In addition, these x-scFab molecules can be further stabilized by the creation of interchain disulfide bonds by the insertion of cysteine residues (e.g., at position 44 of the variable heavy chain and position 100 of the variable light chain according to Kabat numbering).
[0048] A "single-chain variable fragment (scFv)" is a variable region of the antibody's heavy chain (V) linked using a short linker peptide of 10 to approximately 25 amino acids. H ) and light chain variable region (V L It is a fusion protein of ). The linker is usually rich in glycine for flexibility and rich in serine or threonine for solubility, V H The N-terminus and V L The C-terminus or vice versa can be attached. This protein has its constant region removed and a linker introduced, but retains the specificity of the original antibody. scFv antibodies are described, for example, by Houston, JS, Methods in Enzymol. 203 (1991) 46-96). In addition, the antibody fragment contains a single-chain polypeptide that has the characteristics of a VH domain (i.e., can assemble together with the VL domain) or the characteristics of a VL domain (i.e., can be assembled together with the VH domain into a functional antigen-binding site), thereby giving the antigen-binding properties of a full-length antibody.
[0049] "Scaffold antigen-binding proteins" are known in this art, and for example, fibronectin and engineered ankyrin repeat proteins (DARPin) have been used as alternative scaffolds for antigen-binding domains. See, for example, Gebauer and Skerra, Engineered protein scaffolds as next-generation antibody therapeutics. Curr Opin Chem Biol 13:245-255 (2009) and Stumpp et al., Darpins: A new generation of protein therapeutics. Drug Discovery Today 13:695-701 (2008). In one aspect of the present invention, the scaffold antigen-binding protein is CTLA-4 (epibody), lipocalin (anticalin), a protein A-derived molecule, such as the Z-domain (afibody), A-domain (avimer / maxibody) of protein A, serum transferrin (transbody); a design ankyrin repeat protein (DARPin), a variable domain of the antibody light chain or heavy chain (single-domain antibody, sdAb), a variable domain of the antibody heavy chain (nanobody, aVH), V NAR Fragment, fibronectin (adonectin), C-type lectin domain (tetranectin); variable domain (V) of novel antigen receptor beta-lactamase NAR The group consists of fragments, human gamma-crystallin or ubiquitin (affilin molecules); Kunitz-type domains and microbodies of human protease inhibitors, such as proteins derived from the Nottin family, peptide aptamers, and fibronectin (adonectin). CTLA-4 (cytotoxic T lymphocyte-associated antigen 4) is mainly CD4 +It is a CD28 family receptor expressed on T cells. Its extracellular domain has a variable domain-like Ig fold. Different binding properties can be conferred by substituting the loop corresponding to the antibody's CDR with a heterologous sequence. CTLA-4 molecules engineered to have different binding specificities are also known as organisms (e.g., U.S. Patent No. 7166697). Organisms are approximately the same size as the isolated variable region of an antibody (e.g., a domain antibody). For further details, see Journal of Immunological Methods 248(1-2), 31-45 (2001). Lipokalin is a family of extracellular proteins that carry small hydrophobic molecules such as steroids, pyrine, retinoids, and lipids. Lipokalin has a robust beta-sheet secondary structure with multiple loops at the open end of a conical structure, which can be engineered to bind to different target antigens. Antikarin is 160-180 amino acids in size and is derived from lipokalin. For further details, see Biochim Biophys Acta 1482:337-350 (2000), U.S. Patent No. 7,250,297, and U.S. Patent Application Publication No. 20070224633. The afibody is a scaffold derived from protein A of Staphylococcus aureus and can be engineered to bind to antigens. This domain consists of a 3-helix bundle of approximately 58 amino acids. The library was generated by randomization of surface residues. For details, see Protein Eng. Des. Sel. 2004, 17, 455-462, and European Patent Application Publication No. 1641818. The avimer is a multi-domain protein derived from the A-domain scaffold family. The native domain of approximately 35 amino acids adopts a defined disulfide-bonded structure. Diversity is created by shuffling the native variations shown by the A-domain family. For further details, see Nature Biotechnology 23(12), 1556-1561 (2005) and Expert Opinion on Investigational Drugs 16(6), 909-917 (June 2007).Transferrin is a monomeric serum transport glycoprotein. Transferrin can be engineered to bind to different target antigens by inserting peptide sequences into a permissible surface loop. An example of an engineered transferrin scaffold is a transbody. For further details, see J. Biol. Chem 274, 24066-24073 (1999). Engineered ankyrin repeat proteins (DARPin) are derived from ankyrin, a family of proteins that mediate the binding of intrinsic membrane proteins of the cytoskeleton. A single ankyrin repeat is a 33-residue motif consisting of two alpha helices and one beta-turn. Engineered ankyrin repeat proteins can be engineered to bind to different target antigens by randomizing the residues of the first alpha helix and the beta-turn of each repeat. Its binding surface can be increased by increasing the number of modules (a method of affinity maturation). For further details, see J.Mol.Biol.332,489-503(2003), PNAS 100(4),1700-1705(2003) and J.Mol.Biol.369,1015-1028(2007), and U.S. Patent Application Publication No. 20040132028. A single-domain antibody is an antibody fragment consisting of a single monomeric variable antibody domain. The first single domain is obtained from the variable domain of a camel-derived antibody heavy chain (nanobody or V). H (H fragment). Furthermore, the term single-domain antibody refers to an autonomous human heavy chain variable domain (aVH) or shark-derived V NARThis includes fragments. Fibronectin is an engineerable scaffold that can be manipulated to bind to antigens. Adnectin consists of a backbone with the native amino acid sequence of the 10th domain of 15 repeat units of human fibronectin type III (FN3). It is possible to engineer the three loops at one end of the beta sandwich so that adnectin can specifically recognize the therapeutic target of interest. For further details, see Protein Eng. Des. Sel. 18, 435-444 (2005), U.S. Patent Application Publication No. 20080139791, International Publication No. 2005056764, and U.S. Patent No. 6818418. Peptide aptamers are combinatorial recognition molecules consisting of a constant scaffold protein, typically thioredoxin (TrxA) containing a constrained variable peptide loop inserted at the active site. For further details, see Expert Opin. Biol. Ther. 5, 783-797 (2005). Microbodies are derived from naturally occurring microproteins 25-50 amino acid length containing 3-4 cysteine crosslinks, examples of which include KalataBI, conotoxin, and Nottin. Microproteins have loops that can be engineered to contain up to 25 amino acids without affecting their overall fold. For further details on engineered Nottin domains, see International Publication No. 2008098796.
[0050] An antigen-binding molecule that binds to the same epitope as the reference molecule is defined as an antigen-binding molecule that blocks the binding of the reference molecule to that antigen by 50% or more in a competitive assay, and conversely, the reference molecule blocks the binding of the antigen-binding molecule to that antigen by 50% or more in a competitive assay. An antigen-binding molecule that does not bind to the same epitope as the reference molecule is defined as an antigen-binding molecule that does not block the binding of the reference molecule to that antigen by 50% or more in a competitive assay, and conversely, the reference molecule does not block the binding of the antigen-binding molecule to that antigen by 50% or more in a competitive assay.
[0051] The term "antigen-binding domain" refers to a portion of an antibody-binding molecule that specifically binds to part or all of an antigen and contains a region complementary to part or all of the antigen. When the antigen is large, the antigen-binding molecule may bind only to a specific portion of the antigen, which is called an epitope. The antigen-binding domain may be provided by, for example, one or more variable domains (also called variable regions). Preferably, the antigen-binding domain includes an antibody light chain variable region (VL) and an antibody heavy chain variable region (VH).
[0052] As used herein, the term “antigenic determinant” is synonymous with “antigen” and “epitope,” and refers to a site on a polypeptide macromolecule to which an antigen-binding moiety binds, forming an antigen-antigen complex (e.g., a conformal configuration consisting of a continuous sequence of amino acids or different regions of discontinuous amino acids). Useful antigenic determinants can be found, for example, on the surface of tumor cells, on the surface of virus-infected cells, on the surface of other diseased cells, on the surface of immune cells, free in serum, and / or within the extracellular matrix (ECM). Unless otherwise specified, proteins useful as antigens herein are any native protein derived from any vertebrate source, including mammals such as primates (e.g., humans) and rodents (e.g., mice and rats). In certain embodiments, the antigen is a human protein. When referring to a particular protein herein, the term “full-length,” including both raw proteins and any form of protein obtained from intracellular processing, is included. The term also includes naturally occurring variants of proteins, such as splice variants or allele variants.
[0053] "Specific binding" means that the binding is selective to the antigen and can be distinguished from undesirable or nonspecific interactions. The ability of an antigen-binding molecule to bind to a specific antigen can be measured by enzyme-linked immunosorbent assay (ELISA) or other techniques well known to those skilled in the art, such as surface plasmon resonance (SPR) (analyzed with a BIAcore instrument) (Liljeblad et al., Glyco J 17, 323-329 (2000)) and classical binding assays (Heeley, Endocr Res 28, 217-229 (2002)). In some embodiments, the degree of binding of an antigen-binding molecule to an unrelated protein is less than 10% of the binding of the antigen-binding molecule to the antigen, as measured, for example, by SPR. In certain embodiments, the molecule that binds to the antigen has a dissociation constant (Kd) of ≤1 μM, ≤100 nM, ≤10 nM, ≤1 nM, ≤0.1 nM, ≤0.01 nM, or ≤0.001 nM (e.g., 10 -8 M or less, for example, 10 -8 M~10 -13 M, for example 10 -9 M~10 -13 M) is the answer.
[0054] "Affinity" or "binding affinity" refers to the strength of the sum of non-covalent interactions between a single binding site of a molecule (e.g., an antibody) and its binding partner (e.g., an antigen). As used herein, unless otherwise specified, "binding affinity" refers to the intrinsic binding affinity that reflects the 1:1 interaction between members of a binding pair (e.g., an antibody and an antigen). In general, the affinity of molecule X for its partner Y can be expressed by the dissociation constant (Kd), which is the ratio of the dissociation rate constant to the binding rate constants (koff and kon, respectively). Thus, equivalent affinities may include different rate constants, as long as the ratio of these rate constants is the same. Affinity can be measured by methods common in the art, including those described herein. A specific method for measuring affinity is surface plasmon resonance (SPR).
[0055] A "affinity-mature" antibody refers to an antibody that has one or more modifications in one or more hypervariable regions (HVR or CDR) compared to a parent antibody that does not have such modifications. Such modifications improve the antibody's affinity for the antigen.
[0056] As used herein, "tumor-associated antigen" refers to the antigenic determinants presented on the surface of target cells, particularly target cells within a tumor, such as cancer cells or tumor stromal cells. Specifically, tumor-associated antigens are fibroblast-activating proteins (FAPs).
[0057] The term “fibroblast-activating protein (FAP),” also known as prolyl endopeptidase FAP or seplacase (EC 3.4.21), refers, unless otherwise specified, to any natural FAP derived from any vertebrate source, including mammals such as primates (e.g., humans), non-human primates (e.g., cynomolgus monkeys), and rodents (e.g., mice and rats). This term encompasses both “full-length,” raw FAP and any form of FAP obtained from intracellular processing. This term also encompasses naturally occurring variants of FAP, such as splice variants or allele variants. In certain embodiments, the antigen-binding molecule of the present invention is specifically capable of binding to human, mouse, and / or cynomolgus monkey FAP. The amino acid sequence of human FAP is shown in UniProt (www.uniprot.org) accession number Q12884 (version 149, SEQ ID NO: 34) or NCBI (www.ncbi.nlm.nih.gov / ) RefSeq NP_004451.2. The extracellular domain (ECD) of human FAP extends from amino acid position 26 to 760. The amino acid sequence of His-tagged human FAP ECD is shown in SEQ ID NO: 35. The amino acid sequence of mouse FAP is shown in UniProt accession number P97321 (version 126, SEQ ID NO: 36) or NCBI RefSeq NP_032012.1. The extracellular domain (ECD) of mouse FAP extends from amino acid position 26 to 761. SEQ ID NO: 37 shows the amino acid sequence of His-tagged mouse FAP ECD. SEQ ID NO: 38 shows the amino acid sequence of His-tagged cynomolgus monkey FAP ECD. Preferably, the anti-FAP binding molecule of the present invention is bound to the extracellular domain of FAP.
[0058] The term "variable region" or "variable domain" refers to a domain in the antibody heavy or light chain that is involved in the binding of an antigen-binding molecule to an antigen. The variable domains (VH and VL, respectively) of the heavy and light chains of natural antibodies typically have similar structures, and each domain contains four conserved framework regions (FRs) and three hypervariable regions (HVRs). See, for example, Kindt et al., Kuby Immunology, 6th ed., WH Freeman and Co., p. 91 (2007). In some cases, a single VH or VL domain is sufficient to confer antigen-binding specificity.
[0059] As used herein, the terms “hypervariable region” or “HVR” refer to each of the regions of an antibody variable domain that are hypervariable within a sequence and determine antigen-binding specificity, such as “complementarity-determining regions” (CDRs).
[0060] Generally, an antibody contains six CDRs, three located in the VH (CDR-H1, CDR-H2, CDR-H3) and three located in the VL (CDR-L1, CDR-L2, CDR-L3). Illustrative CDRs as used herein include: (a) Hypervariable loops present at amino acid residues 26-32 (L1), 50-52 (L2), 91-96 (L3), 26-32 (H1), 53-55 (H2), and 96-101 (H3) (Chothia and Lesk, J. Mol. Biol. 196:901-917 (1987)); (b) CDRs present at amino acid residues 24-34 (L1), 50-56 (L2), 89-97 (L3), 31-35b (H1), 50-65 (H2), and 95-102 (H3) (Kabat et al., Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, MD (1991)); and (c) Antigen contact sites located at amino acid residues 27c-36 (L1), 46-55 (L2), 89-96 (L3), 30-35b (H1), 47-58 (H2), and 93-101 (H3) (MacCallum et al. J. Mol. Biol. 262: 732-745 (1996)).
[0061] Unless otherwise specified, the designation of a CDR is determined in accordance with Kabat et al., cited above. A person skilled in the art will understand that the designation of a CDR may also be determined in accordance with Chothia, cited above, McCallum, cited above, or any other scientifically recognized nomenclature.
[0062] The term "framework" or "FR" refers to variable domain residues other than hypervariable region (HVR) residues. The variable domain FR typically consists of the following four FR domains: FR1, FR2, FR3, and FR4. Therefore, HVR and FR sequences generally appear in the order FR1-H1(L1)-FR2-H2(L2)-FR3-H3(L3)-FR4 in the VH (or VL) region.
[0063] The term "chimeric" antibody refers to an antibody in which a portion of the heavy chain and / or light chain originates from a specific source or species, while the remaining portion of the heavy chain and / or light chain originates from a different source or species.
[0064] The "class" of an antibody refers to the type of constant domain or constant region in its heavy chain. Antibodies have five main classes: IgA, IgD, IgE, IgG, and IgM, some of which can be further divided into subclasses (isotypes), such as IgG1, IgG2, IgG3, IgG4, IgA1, and IgA2. The heavy chain constant domains corresponding to different classes of immunoglobulins are called α, δ, ε, γ, and μ, respectively.
[0065] A “humanized” antibody refers to a chimeric antibody containing amino acid residues from a non-human HVR and amino acid residues from a human FR. In certain embodiments, the humanized antibody contains at least one, typically two, substantially all of the variable domains, with all or substantially all of the HVR (e.g., CDR) corresponding to that of a non-human antibody and all or substantially all of the FR corresponding to that of a human antibody. The humanized antibody may optionally contain at least a portion of the antibody constant region derived from a human antibody. The “humanized form” of an antibody (e.g., a non-human antibody) refers to an antibody that has undergone humanization. Other forms of “humanized antibodies” as encompassed in the present invention are those in which the constant region has been further modified or altered from the constant region of the original antibody to produce the properties according to the present invention, particularly with respect to C1q binding and / or Fc receptor (FcR) binding.
[0066] The terms “Fc domain” or “Fc region” as used herein are used to refer to the C-terminal region of an antibody heavy chain, including at least a portion of the constant region. This term includes both the natural sequence Fc region and the variant Fc region. The IgG Fc region includes the IgG CH2 and IgG CH3 domains. Typically, the “CH2 domain” of the human IgG Fc region extends from approximately position 231 to approximately position 340. In some embodiments, a carbohydrate chain is bound to the CH2 domain. The CH2 domain as used herein may be either the natural sequence CH2 domain or the variant CH2 domain. The “CH3 domain” includes the sequence of residues from the C-terminus of the Fc region to the CH2 domain (i.e., from approximately position 341 to approximately position 447 of IgG). The CH3 region as used herein may be either a native sequence CH3 domain or a variant CH3 domain (for example, a CH3 domain in which a “nob” is introduced on one chain and a “hole” corresponding to the other chain is introduced; see U.S. Patent No. 5,821,333, expressly incorporated herein by reference). Such variant CH3 domains may be used to facilitate heterodimerization of two non-identical antibody heavy chains as described herein. In some embodiments, the human IgG heavy chain Fc region extends from Cys226 or Pro230 to the carboxyl terminus of the heavy chain. However, the C-terminal lysine (Lys447) of the Fc region may or may not be present. Unless otherwise specified herein, the numbering of amino acid residues in the Fc region or constant region is as follows: Kabat et al., Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of It follows the EU numbering system, also known as the EU Index, as described in Health, Bethesda, MD, 1991.
[0067] The “knob-into-hole” technique is described, for example, in U.S. Patent No. 5,731,168, U.S. Patent No. 7,695,936, Ridgway et al., Prot Eng 9, 617-621 (1996), and Carter, J Immunol Meth 248, 7-15 (2001). Generally, the method involves introducing a bump ("knob") at the interface of a first polypeptide and a corresponding cavity ("hole") at the interface of a second polypeptide, so that the bump can be positioned within a cavity to promote heterodimer formation and prevent homodimer formation. The bump is constructed by replacing a small amino acid side chain from the interface of the first polypeptide with a larger side chain (e.g., tyrosine or tryptophan). By replacing the large amino acid side chain with a small amino acid side chain (e.g., alanine or threonine), a compensatory cavity of the same or similar size as the bump is created at the interface of the second polypeptide. The ridges and cavities can be created by modifying the nucleic acid encoding the polypeptide, for example by site-directed mutagenesis or by peptide synthesis. In specific embodiments, the knob modification includes the amino acid substitution T366W in one of the two subunits of the Fc domain, and the hole modification includes the amino acid substitutions T366S, L368A and Y407V in the other of the two subunits of the Fc domain. In further specific embodiments, the subunit of the Fc domain containing the knob modification further includes the amino acid substitution S354C, and the subunit of the Fc domain containing the hole modification further includes the amino acid substitution Y349C. The introduction of these two cysteine residues forms a disulfide bridge between the two subunits of the Fc region, thereby further stabilizing the dimer (Carter, J Immunol Methods 248, 7-15 (2001)).
[0068] The “region corresponding to the Fc region of immunoglobulins” is intended to include naturally occurring allelic variants of the Fc region of immunoglobulins and variants that produce substitutions, additions, or deletions but have modifications that do not substantially reduce the effector function of the immunoglobulin (e.g., antibody-dependent cytotoxicity). For example, one or more amino acids can be deleted from the N-terminus or C-terminus of the Fc region of immunoglobulins without substantially impairing biological function. Such variants may be selected according to general rules known in the art to have minimal impact on activity (see, for example, Bowie, JU et al., Science 247:1306-10 (1990)).
[0069] The term "effector function" refers to the biological activity function attributable to the Fc region of an antibody, which varies depending on the antibody isotype. Examples of antibody effector functions include C1q binding and complement-dependent cell-mediated cytotoxicity (CDC), Fc receptor binding, antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-dependent phagocytosis (ADCP), cytokine secretion, antigen uptake by antigen-presenting cells via immune complexes, downregulation of cell surface receptors (e.g., B cell receptors), and B cell activation.
[0070] Fc receptor-binding-dependent effector function can be mediated by the interaction between the Fc region of an antibody and the Fc receptor (FcR), a specialized cell surface receptor on hematopoietic cells. Fc receptors belong to the immunoglobulin superfamily and have been shown to mediate both the removal of antibody-coated pathogens by phagocytosis of immune complexes and the lysis of corresponding antibody-coated red blood cells and various other cellular targets (e.g., tumor cells) by antibody-dependent cell-mediated cytotoxicity (ADCC) (see, for example, Van de Winkel, J. Gand Anderson, CL, J. Leukoc. Biol. 49 (1991) 511-524). FcRs are characterized by their specificity for immunoglobulin isotypes, and the Fc receptor for IgG antibodies is called FcγR. Fc receptor binding is described, for example, in Ravetch, J. Vand Kinet, JP, Annu. Rev. Immunol. 9 (1991) 457-492, Capel, P. J, et al., Immunomethods 4 (1994) 25-34; de Haas, M., et al., J. Lab. Clin. Med. 126 (1995) 330-341; and Gessner, J. E., et al., Ann. Hematol. 76 (1998) 231-248.
[0071] Receptor crosslinking of IgG antibodies (FcγR) to the Fc region induces a wide variety of effector functions, including phagocytosis, antibody-dependent cell-mediated cytotoxicity, release of inflammatory mediators, and regulation of immune complex clearance and antibody production. In humans, three classes of FcγR are characterized as follows: -FcγRI(CD64) binds to monomeric IgG with high affinity and is expressed in macrophages, monocytes, neutrophils, and eosinophils. Modification of the Fc region IgG at at least one of the amino acid residues E233-G236, P238, D265, N297, A327, and P329 (numbered according to Kabat's EU index) reduces binding to FcγRI. Substitution of IgG2 residues at positions 233-236 with IgG1 and IgG4 reduces binding to FcγRI by 10. 3The level was reduced by 1 / 2, and the response of human monocytes to antibody-sensitized erythrocytes disappeared (Armour, KL, et al., Eur. J. Immunol. 29 (1999) 2613-2624).
[0072] -FcγRII(CD32) binds to complex IgG with moderate to low affinity and is widely expressed. This receptor can be divided into two subtypes: FcγRIIA and FcγRIIB. FcγRIIA is found in many cells involved in killing (e.g., macrophages, monocytes, neutrophils) and is thought to be able to activate the killing process. FcγRIIB appears to play a role in the inhibitory process and is found in B cells, macrophages, as well as mast cells and eosinophils. On B cells, FcγRIIB appears to suppress further immunoglobulin production and isotype switching to, for example, the IgE class. On macrophages, FcγRIIB acts to inhibit phagocytosis mediated by FcγRIIA. On eosinophils and mast cells, the B form may help suppress the activation of these cells via IgE bound to its other receptor. Reduced binding to FcγRIIA is observed, for example, with antibodies containing an IgG Fc region having a mutation in at least one of the following amino acid residues: E233-G236, P238, D265, N297, A327, P329, D270, Q295, A327, R292, and K414 (numbered according to Kabat's EU index).
[0073] -FcγRIII(CD16) binds to IgG with moderate to low affinity and exists in two forms. FcγRIIIA is found on NK cells, macrophages, eosinophils, and some monocytes and T cells, and mediates ADCC. FcγRIIIB is highly expressed on neutrophils. Reduced binding to FcγRIIIA is observed, for example, with antibodies containing an IgG Fc region with mutations in at least one of the following amino acid residues: E233-G236, P238, D265, N297, A327, P329, D270, Q295, A327, S239, E269, E293, Y296, V303, A327, K338, and D376 (numbered according to Kabat's EU index).
[0074] The mapping of the binding site for the Fc receptor on human IgG1, the aforementioned mutation sites, and methods for measuring binding to FcγRI and FcγRIIA are described in Shields, RL, et al. J. Biol. Chem. 276 (2001) 6591-6604.
[0075] The term "ADCC" or "antibody-dependent cell-mediated cytotoxicity" refers to a function mediated by Fc receptor binding, and the lysis of target cells by the antibodies reported herein in the presence of effector cells. The ability of an antibody to induce the initial steps mediated by ADCC is investigated by measuring the binding of the antibody to Fcγ receptor-expressing cells, such as FcγRI and / or FcγRIIA or recombinant NK cells (which essentially express FcγRIIIA). In particular, binding to FcγR on NK cells is measured.
[0076] An "activated Fc receptor" is an Fc receptor that, following involvement by the Fc region of an antibody, triggers a signaling event that stimulates receptor-hosting cells to perform effector functions. Activated Fc receptors include FcγRIIIa (CD16a), FcγRI (CD64), FcγRIIa (CD32), and FcαRI (CD89). A specific activated Fc receptor is human FcγRIIIa (see UniProt accession number P08637, version 141).
[0077] As used herein, the term “CD40” refers to any natural CD40 derived from any vertebrate source, including mammals such as primates (e.g., humans) and rodents (e.g., mice and rats), unless otherwise specified. This term includes not only “full-length” raw CD40 but also any form of CD40 resulting from intracellular processing. This term also encompasses naturally occurring variants of CD40, such as splice variants or allele variants. The amino acid sequence of an exemplary human CD40 is shown in SEQ ID NO: 33 (Uniprot P25942, version 200), and the amino acid sequence of an exemplary mouse CD40 is shown in SEQ ID NO: 39 (Uniprot P27512, version 160). The CD40 antigen is a 50 kDa cell surface glycoprotein belonging to the tumor necrosis factor receptor (TNF-R) family. (Stamenkovic et al. (1989), EMBO J. 8: 1403-10). CD40 is expressed in many normal and tumor cell types, including B lymphocytes, dendritic cells, monocytes, macrophages, thymic epithelium, endothelial cells, fibroblasts, and smooth muscle cells. CD40 is expressed in all B lymphomas and in 70% of all solid tumors, and is upregulated within antigen-presenting cells (APCs) by maturation signals such as IFN-gamma and GM-CSF. CD40 activation also induces the differentiation of monocytes into functional dendritic cells (DCs) and enhances the cytolytic activity of NK cells via APC-CD40-induced cytokines. Therefore, CD40 plays a crucial role in initiating and enhancing the immune response by inducing APC maturation, helper cytokine secretion, co-stimulatory molecule upregulation, and enhancement of effector function.
[0078] As used herein, the term “CD40 agonist” includes any portion that agonizes the CD40 / CD40L interaction. As used in this context, CD40 preferably refers to human CD40, and therefore a CD40 agonist is preferably a human CD40 agonist. Typically, this portion will be an agonist CD40 antibody or antibody fragment.
[0079] The terms “anti-CD40 antibody,” “anti-CD40,” “CD40 antibody,” and “antibody that specifically binds to CD40” refer to an antibody that can bind to CD40 with sufficient affinity to be useful as a diagnostic and / or therapeutic agent in targeting CD40. In some embodiments, the degree of binding of an anti-CD40 antibody to unrelated non-CD40 proteins is less than about 10% of the binding of the antibody to CD40, as measured, for example, by radioimmunoassay (RIA) or flow cytometry (FACS). In certain embodiments, the antibody that binds to CD40 has a molecular weight of ≤1 μM, ≤100 nM, ≤10 nM, ≤1 nM, ≤0.1 nM, ≤0.01 nM, or ≤0.001 nM (e.g., 10 -6 M or less, for example, 10 -68 M~10 -13 M, for example 10 -8 M~10 -10 The dissociation constant (K) of M D ) has.
[0080] The term "peptide linker" refers to a peptide containing one or more amino acids, typically about 2 to 20 amino acids. The peptide linker may be one known in the art or one described in this specification. A suitable non-immunogenic linker peptide is, for example, (G4S) n (SG4) n Or G4 (SG4) nIt is a peptide linker, where "n" is generally a number from 1 to 10, typically 2 to 4, especially 2, that is, the peptide is selected from the group consisting of GGGGS (SEQ ID NO: 40), GGGGSGGGGS (SEQ ID NO: 41), SGGGGSGGGG (SEQ ID NO: 42), and GGGGSGGGGSGGGG (SEQ ID NO: 43), but also includes sequences GSPGSSSSGS (SEQ ID NO: 44), (G4S)3 (SEQ ID NO: 45), (G4S)4 (SEQ ID NO: 46), GSGSGSGS (SEQ ID NO: 47), GSGSGNGS (SEQ ID NO: 48), GGSGSGSG (SEQ ID NO: 49), GGSGSG (SEQ ID NO: 50), GGSG (SEQ ID NO: 51), GGSGNGSG (SEQ ID NO: 52), GGNGSGSG (SEQ ID NO: 53), and GGNGSG (SEQ ID NO: 54). Particularly interesting peptide linkers are (G4S)(SEQ ID NO: 40), (G4S)2 or GGGGSGGGGS(SEQ ID NO: 41), (G4S)3(SEQ ID NO: 45), and (G4S)4(SEQ ID NO: 46).
[0081] As used in this application, the term "amino acid" refers to the group of naturally occurring carboxy-α-amino acids, including alanine (3-letter code: ala, 1-letter code: A), arginine (arg, R), asparagine (asn, N), aspartic acid (asp, D), cysteine (cys, C), glutamine (gln, Q), glutamic acid (glu, E), glycine (gly, G), histidine (his, H), isoleucine (ile, I), leucine (leu, L), lysine (lys, K), methionine (met, M), phenylalanine (phe, F), proline (pro, P), serine (ser, S), threonine (thr, T), tryptophan (trp, W), tyrosine (tyr, Y), and valine (val, V).
[0082] "Fused" or "linked" means that the constituent components (e.g., the antibody heavy chain and Fab fragment) are linked by peptide bonds, either directly or via one or more peptide linkers.
[0083] The "amino acid sequence identity percentage (%)" relative to a reference polypeptide (protein) sequence is defined as the percentage of amino acid residues in a candidate sequence that are identical to the amino acid residues in the reference polypeptide sequence, after the sequences have been aligned and gaps introduced if necessary to obtain the maximum sequence identity percentage, and assuming that no conservative substitutions are considered part of the sequence identity. Alignment for determining the amino acid sequence identity percentage can be achieved in various ways within the scope of the art, for example, using computer software that is publicly available, such as BLAST, BLAST-2, ALIGN, SAWI, or Megalign (DNASTAR) software. Those skilled in the art can determine appropriate parameters for aligning the sequences, including algorithms necessary to achieve the maximum alignment over the entire length of the sequences being compared. However, in this specification, the amino acid sequence identity % values are generated using the sequence comparison computer program ALIGN-2. The ALIGN-2 sequence comparison computer program was created by Genentech, Inc., and its source code, along with user documentation, has been filed with the U.S. Copyright Office, Washington DC, 20559, and is registered under U.S. Copyright Registration No. TXU510087. The ALIGN-2 program is publicly available from Genentech (South San Francisco, California) or can be compiled from its source code. For use on UNIX operating systems, including Digital UNIX V4.0D, the ALIGN-2 program needs to be compiled. All sequence comparison parameters are set by the ALIGN-2 program and do not change. In situations where ALIGN-2 is used for amino acid sequence comparison, the amino acid sequence identity % of a given amino acid sequence A to, with, or relative to a given amino acid sequence B (or, a given amino acid sequence A having or containing a specific amino acid sequence identity % to, with, or relative to a given amino acid sequence B) is calculated as follows: 100 x fraction X / Y In the formula, X is the number of amino acid residues that were determined to be a perfect match in the alignment of A and B by the sequence alignment program ALIGN-2, and Y is the total number of amino acid residues in B. It will be understood that if the length of amino acid sequence A is not equal to the length of amino acid sequence B, the amino acid sequence identity % of A to B is not equal to the amino acid sequence identity % of B to A. Unless otherwise specified, all amino acid sequence identity % values used herein are obtained using the ALIGN-2 computer program as described in the preceding paragraph.
[0084] In certain embodiments, amino acid sequence variants of the bispecific antigen-binding molecule provided herein are intended. For example, it may be desirable to improve the binding affinity and / or other biological properties of the antigen-binding molecule. Amino acid sequence variants of the bispecific antigen-binding molecule can be prepared by introducing appropriate modifications to the nucleotide sequence encoding the molecule or by peptide synthesis. Such modifications include, for example, deletions from and / or insertions of residues in the amino acid sequence of the bispecific antigen-binding molecule, and / or substitutions thereof. Deletions, insertions, and substitutions can be arbitrarily combined to obtain the final antigen-binding molecule, as long as the final antigen-binding molecule has the desired characteristics (e.g., antigen-binding ability). Sites targeted for substitutional mutagenesis include CDRs and frameworks (FRs). Conservative substitutions are shown under the heading “Preferred Substitutions” in Table A and further described below based on the type of amino acid side chain (1) to (6). Amino acid substitutions can be introduced into the molecule of interest, and the product can be screened for desired activity, such as retention / improvement of antigen-binding ability, decreased immunogenicity, or improvement of ADCC or CDC. TIFF2023549316000002.tif175170 Amino acids can be classified according to the following common side-chain characteristics. (1) Hydrophobic: norleucine, Met, Ala, Val, Leu, Ile; (2) Neutral hydrophilic: Cys, Ser, Thr, Asn, Gln; (3) Acidic: Asp, Glu; (4) Basicity: His, Lys, Arg; (5) Residues that affect chain orientation: Gly, Pro; (6) Aromatic: Trp, Tyr, Phe
[0085] Non-conservative substitutions involve exchanging a member of one of these types for a member of another type.
[0086] The term "amino acid sequence variant" includes substantial variants in which amino acid substitutions exist in one or more hypervariable region residues of a parent antigen-binding molecule (e.g., a humanized or human antibody). Generally, one or more variants obtained as a result of selection for further testing will have alterations (e.g., improvements) to certain biological properties (e.g., increased affinity, decreased immunogenicity) and / or substantially retain certain conserved biological properties of the parent antigen-binding molecule compared to the parent antigen-binding molecule. Exemplary substitution variants are affinity-matured antibodies, which can be readily generated using affinity-mature techniques based on phage display, such as those described herein. In short, one or more CDR residues are mutated, the variant antigen-binding molecule is presented on a phage, and screened for specific biological activity (e.g., binding affinity). In certain embodiments, substitutions, insertions, or deletions may occur within one or more CDRs, provided that these changes do not substantially reduce the ability of the antigen-binding molecule to bind to the antigen. For example, conservative changes that do not substantially reduce binding affinity (e.g., conservative substitutions provided herein) can be made within a CDR. A useful method for identifying antibody residues or regions that can be targeted for mutagenesis is called "alanine scanning mutagenesis" and is described in Cunningham and Wells (1989) Science, 244:1081-1085. This method involves identifying residues or groups of target residues (e.g., charged residues such as Arg, Asp, His, Lys, and Glu) and replacing them with neutral or negatively charged amino acids (e.g., alanine or polyalanine) to determine whether the antibody-antigen interaction is affected. Further substitutions can be introduced at the positions of amino acids that are functionally sensitive to the initial substitution. Alternatively, or in addition to this, the crystal structure of the antigen-antigen binding molecule complex is used to identify contact points between the antibody and antigen. Such contact residues and adjacent residues may be targeted or excluded as candidates for substitution. Variants may be screened to determine whether they contain desired properties.
[0087] Amino acid insertions include amino-terminus and / or carboxyl-terminus fusions ranging in length from one residue to polypeptides containing 100 or more residues, as well as intrasequence insertions of single or multiple amino acid residues. Examples of terminal insertions include antigen-binding molecules with an N-terminal methionyl residue. Other insertion variants of antigen-binding molecules include fusions of polypeptides to the N-terminus or C-terminus that extend the serum half-life of the antigen-binding molecule.
[0088] In certain embodiments, the antigen-binding molecules provided herein are modified to increase or decrease the degree of glycosylation of the antibody. Glycosylated variants of the molecule are conveniently obtained by altering the amino acid sequence so that one or more glycosylation sites are generated or removed. If the antigen-binding molecule contains an Fc region, the sugar (carbohydrate) bound to it can be altered. Typically, innate antibodies produced by mammalian cells contain branched, bibranched oligosaccharides that are usually bound to Asn297 of the CH2 domain of the Fc region by an N-bond. See, for example, Wright et al. TIBTECH 15:26-32 (1997). Oligosaccharides may include various carbohydrates, such as mannose, N-acetylglucosamine (GlcNAc), galactose, and sialic acid, as well as fucose bound to the GlcNAc of the "stem" of the bibranched oligosaccharide structure. In some embodiments, modification of the oligosaccharide in the antigen-binding molecule may be done to create variants with specific improved properties. In one embodiment, variants of an antigen-binding molecule are provided having a sugar chain structure lacking fucose (directly or indirectly) bound to the Fc region. Such fucosylated variants may have improved ADCC function. See, for example, U.S. Patent Application Publication No. 2003 / 0157108 (Presta, L.) or U.S. Patent Application Publication No. 2004 / 0093621 (Kyowa Hakko Kogyo Co., Ltd.). Further variants of the antigen-binding molecule of the present invention include those containing a bifid oligosaccharide, for example, a bifid oligosaccharide bound to the Fc region being bifid by GlcNAc. Such variants may have reduced fucosylation and / or improved ADCC function. See, for example, International Publication No. 2003 / 011878 (Jean-Mairet et al.), U.S. Patent No. 6602684 (Umana et al.), and U.S. Patent Application Publication No. 2005 / 0123546 (Umana et al.). A variant is also provided which has at least one galactose residue in the oligosaccharide bound to the Fc region.Such antibody variants possess improved CDC function and are described, for example, in International Publication No. 1997 / 30087 (Patel et al.); International Publication No. 1998 / 58964 (Raju, S.); and International Publication No. 1999 / 22764 (Raju, S.).
[0089] In certain embodiments, it may be desirable to produce cysteine-modified variants of the antigen-binding molecule of the present invention, for example, “thioMAb” in which one or more residues of the molecule are substituted with cysteine residues. In certain embodiments, the substituted residues occur at accessible sites of the molecule. By substituting these residues with cysteine, a reactive thiol group is positioned at an accessible site of the antibody, and this reactive thiol group can be used to conjugate the antibody to other parts, such as the drug part or the linker-drug part, to produce an immunoconjugate. In certain embodiments, one or more of the following residues may be substituted with cysteine: V205 (Kabat numbering) of the light chain; A118 (EU numbering) of the heavy chain; and S400 (EU numbering) of the heavy chain Fc region. The cysteine-modified antigen-binding molecule may be produced, for example, as described in U.S. Patent No. 7521541. An “immunoconjugate” is an antibody conjugated to one or more heterologous molecules, including but not limited to cytotoxic agents.
[0090] The terms “nucleic acid” or “polynucleotide” include any compound and / or substance containing polymers of nucleotides. Each nucleotide consists of a base, specifically a purine or pyrimidine base (i.e., cytosine (C), guanine (G), adenine (A), thymine (T), or uracil (U)), a sugar (i.e., deoxyribose or ribose), and a phosphate group. Often, nucleic acid molecules are described by the sequence of bases. Thus, the bases represent the primary structure (linear structure) of the nucleic acid molecule. The sequence of bases is typically represented from 5' to 3'. In this specification, the term nucleic acid molecule includes, for example, deoxyribonucleic acid (DNA), including complementary DNA (cDNA) and genomic DNA, ribonucleic acid (RNA), especially messenger RNA (mRNA), synthetic forms of DNA or RNA, and mixed polymers containing two or more of these molecules. Nucleic acid molecules may be linear or cyclic. The term nucleic acid molecule further includes both sense and antisense strands, as well as single-stranded and double-stranded forms. Furthermore, nucleic acid molecules described herein may contain natural or non-natural nucleotides. Examples of non-natural nucleotides include modified nucleotide bases or chemically modified residues having derivatized sugar or phosphate backbone links. Nucleic acid molecules also include DNA and RNA molecules suitable as vectors for the direct expression of the antibodies of the present invention in vitro and / or in vivo (e.g., in a host or patient). Such DNA (e.g., cDNA) or RNA (e.g., mRNA) vectors may be modified or not. For example, mRNA can be chemically modified to enhance the stability of the RNA vector and / or the expression of the encoded molecule so that the mRNA can be injected into a target for antibody production in vivo (see, for example, Stadler ert al, Nature Medicine 2017, doi:10.1038 / nm.4356, published online June 12, 2017, or European Patent No. 2101823).
[0091] "Isolated" nucleic acids refer to nucleic acid molecules that have been separated from their natural environment. Isolated nucleic acids include nucleic acid molecules that are normally found in cells containing nucleic acid molecules, but these nucleic acid molecules are located outside of chromosomes or in chromosomal locations different from their natural chromosomal locations.
[0092] "Isolated nucleic acids encoding a bispecific antigen-binding molecule or antibody" means one or more nucleic acid molecules encoding the heavy and light chains (or fragments thereof) of a bispecific antigen-binding molecule or antibody, and such one or more nucleic acid molecules are contained in a single vector or separate vectors, and such one or more nucleic acid molecules are present in one or more locations within a host cell.
[0093] A nucleic acid or polynucleotide having a nucleotide sequence that is at least, for example, 95% "identical" to the reference nucleotide sequence of the present invention means that the nucleotide sequence of the polynucleotide is identical to the reference nucleotide sequence, except that the nucleotide sequence of the polynucleotide may contain up to 5 point mutations per 100 nucleotides of the reference nucleotide sequence. In other words, to obtain a polynucleotide having a nucleotide sequence that is at least 95% identical to the reference nucleotide sequence, up to 5% of the nucleotides in the reference sequence may be deleted or substituted with other nucleotides, or up to 5% of the total nucleotides in the reference sequence may be inserted into the reference sequence. Such modifications to the reference sequence may occur at the 5' or 3' terminal position of the reference nucleotide sequence, or at any position between these terminal positions, and may be individually scattered among residues in the reference sequence or scattered in one or more consecutive groups within the reference sequence. In practice, whether any particular polynucleotide sequence is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to the nucleotide sequence of the present invention can be determined using conventionally known computer programs, such as those described above for polypeptides (e.g., ALIGN-2).
[0094] The term “expression cassette” refers to a polynucleotide produced by recombinant or synthetic means using a set of specific nucleic acid elements that enable the transcription of a particular nucleic acid within a target cell. Recombinant expression cassettes can be incorporated into plasmids, chromosomes, mitochondrial DNA, plastid DNA, viruses, or nucleic acid fragments. Typically, the recombinant expression cassette portion of an expression vector includes the nucleic acid sequence to be transcribed and a promoter, among other sequences. In certain embodiments, the expression cassette of the present invention includes a polynucleotide sequence or fragment thereof encoding the bispecific antigen-binding molecule of the present invention.
[0095] The term “vector” or “expression vector” is synonymous with “expression construct” and refers to a DNA molecule used to introduce and induce the expression of a specific gene to which it manipulatively binds within a target cell. The term includes vectors as self-replicating nucleic acid structures, and vectors incorporated into the genome of the host cell into which they are introduced. The expression vector of the present invention comprises an expression cassette. The expression vector enables the transcription of a large amount of stable mRNA. Once the expression vector enters the target cell, the ribonucleic acid molecule or protein encoded by the gene is produced by the cellular transcription and / or translation mechanism. In some embodiments, the expression vector of the present invention comprises an expression cassette containing a polynucleotide sequence encoding the bispecific antigen-binding molecule or fragment thereof of the present invention.
[0096] The terms “host cell,” “host cell line,” and “host cell culture” are used interchangeably and refer to cells into which exogenous nucleic acids have been introduced and their offspring. Host cells include “transformed organisms” and “transformed cells,” which include primary transformed cells and offspring derived from primary transformed cells, regardless of passage number. Offspring may contain mutations, although they may not be completely identical to the parent cells in terms of nucleic acid content. This specification includes mutant offspring that have the same function or biological activity as those screened or selected in the initially transformed cells. Host cells are any type of cell line that can be used to generate the bispecific antigen-binding molecules of the present invention. Host cells include cultured cells, such as mammalian cultured cells such as CHO cells, BHK cells, NS0 cells, SP2 / 0 cells, YO myeloma cells, P3X63 mouse myeloma cells, PER cells, PER.C6 cells, or hybridoma cells, yeast cells, insect cells, and plant cells, but also include cells contained in transgenic animals, transgenic plants, or cultured plants or animal tissues.
[0097] An "effective dose" of a drug refers to the amount necessary to produce a physiological change in the cells or tissues to which it is administered.
[0098] The combination therapy according to the present invention has a synergistic effect. A “synergistic effect” of two compounds means that the combined effect of the two drugs is greater than the sum of their individual effects and is statistically different from the control or the monotherapy. In another embodiment, the combination therapy disclosed herein has an additive effect. An “additive effect” of two compounds means that the combined effect of the two drugs is the sum of their individual effects and is statistically different from both the control and / or the monotherapy.
[0099] The "therapeutic effective dose" of a drug, such as a pharmaceutical composition, refers to the amount that is effective in the dosage and duration required to achieve the desired therapeutic or preventive outcome. For example, the therapeutic effective dose of a drug may eliminate, reduce, delay, minimize, or prevent the side effects of a disease.
[0100] The "individual" or "subject" is a mammal. Mammals include, but are not limited to, domesticated animals (e.g., cattle, sheep, cats, dogs, horses), primates (e.g., humans, and non-human primates such as monkeys), rabbits, and rodents (e.g., mice and rats). In particular, the individual or subject is a human.
[0101] The term "pharmaceutical composition" refers to a preparation in which the biological activity of the active ingredients contained herein is effective, and which does not contain additional ingredients that are unacceptably toxic to the subject to which the preparation is administered.
[0102] A "pharmaceutically acceptable carrier" refers to a component of a pharmaceutical composition other than the active ingredient that is non-toxic to the target substance. Pharmaceutically acceptable additives include, but are not limited to, buffers, stabilizers, or preservatives.
[0103] The term "package insert" is used to refer to the instructions that are typically included in the product packaging of a therapeutic product, and which include information about the indications, usage, dosage, administration, combination therapy, contraindications and / or precautions for use of such therapeutic product.
[0104] As used herein, “treatment” (and grammatical variations such as “treat” or “treating”) refers to a clinical intervention that attempts to alter the natural course of an individual being treated, and may be performed for preventive purposes or in the course of clinicopathology. Desired effects of treatment include, but are not limited to, preventing the onset or recurrence of a disease, alleviating symptoms, reducing the direct or indirect pathological consequences of the disease, preventing metastasis, slowing the rate of disease progression, improving or alleviating the disease state, and achieving remission or improving prognosis. In some embodiments, the molecules of the present invention are used to delay the onset of a disease or slow the progression of a disease.
[0105] The terms “cancer” and “malignant” refer to or describe a physiological condition in mammals typically characterized by uncontrolled cell proliferation, i.e., a solid tumor or proliferative disorder such as melanoma. “Tumor” includes one or more cancerous cells. As used herein, “solid tumor” refers to an abnormal mass of tissue that does not typically contain cysts or fluid areas. Solid tumors can be benign or malignant. Examples of cancer include, but are not limited to, carcinoma, lymphoma, blastoma, sarcoma, and leukemia or lymphoid malignancies. More specific examples of such cancers include breast cancer, squamous cell carcinoma (e.g., epithelial squamous cell carcinoma), small cell lung cancer, non-small cell lung cancer ("NSCLC"), adenocarcinoma of the lung, and lung cancer including squamous cell carcinoma of the lung, peritoneal cancer, hepatocellular carcinoma, gastric or stomach cancer including gastrointestinal cancer, pancreatic cancer, glioblastoma, cervical cancer, ovarian cancer, liver cancer, bladder cancer, liver cancer, breast cancer, colon cancer, rectal cancer, colorectal cancer, endometrial or uterine cancer, salivary gland cancer, kidney or renal cancer, prostate cancer, vulvar cancer, thyroid cancer, liver cancer, anal cancer, penile cancer, and head and neck cancer. In a preferred embodiment, the cancer is head and neck cancer.
[0106] Referring to tumors or cancers as "Stage 0," "Stage 1," "Stage 2," "Stage 3," or "Stage 4," and the various substages within this classification, indicates a classification of tumors or cancers using the overall stage grouping or Roman numeral staging methods known in the art. The actual stage of cancer depends on the type of cancer, but generally, stage 0 cancer is an in situ lesion, stage 1 cancer is a small, localized tumor, stages 2 and 3 cancer are locally advanced tumors showing local lymph node involvement, and stage IV cancer represents metastatic cancer. The specific stages for each type of tumor are known to experienced clinicians.
[0107] "Advanced" cancer is cancer that has spread outside of its original site or organ, either through local invasion or metastasis. Therefore, the term "advanced" cancer includes both locally advanced and metastatic diseases. "Refractory" cancer is cancer that progresses despite the administration of antitumor agents, such as chemotherapy drugs, to the cancer patient. An example of a refractory cancer is platinum-resistant cancer. "Recurrent" cancer is cancer that has grown again in either the original site or a distal site after responding to initial therapy, such as surgery. "Locally recurrent" cancer is cancer that recurs after treatment in the same location where it was previously treated. "Operable" or "resectable" cancer is cancer that is limited to the primary organ and suitable for surgery (resection). "Non-resectable" or "unresectable" cancer cannot be removed (resected) by surgery.
[0108] Preferably, “patient” or “subject” is a human patient. The patient may be a “cancer patient,” that is, a person who has or is at risk of developing one or more manifestations of cancer, particularly head and neck cancer.
[0109] The "patient population" refers to a group of cancer patients. Such a population can be used to demonstrate the statistically significant efficacy and / or safety of drugs such as pertuzumab. "Relapsed" patients are those who have signs or symptoms of cancer after remission. Optionally, patients are those who have relapsed after adjuvant or neoadjuvant therapy.
[0110] As used herein, the terms “combination therapy,” “combination treatment,” or “in combination” refer to any form of simultaneous or parallel treatment with at least two different therapeutic agents.
[0111] In this specification, "neoadjuvant therapy" or "preoperative therapy" refers to therapy performed before surgery. The goal of neoadjuvant therapy is to provide immediate systemic treatment, potentially eradicating micrometastases that would otherwise proliferate if systemic therapy were administered after surgery, following the standard sequence. Neoadjuvant therapy may also help reduce tumor size, thereby enabling complete resection of tumors that were initially unresectable or preservation of organs and their functions. Furthermore, neoadjuvant therapy allows for in vivo evaluation of drug efficacy, which may guide the selection of subsequent treatment options.
[0112] In this specification, “adjuvant therapy” refers to treatment administered after curative surgery when no evidence of residual disease is detected, in order to reduce the risk of disease recurrence. The objective of adjuvant therapy is to prevent cancer recurrence and, therefore, reduce the likelihood of cancer-related death. In this specification, adjuvant therapy specifically excludes neoadjuvant therapy.
[0113] "Chemotherapy" refers to the use of chemotherapy drugs that are useful in treating cancer.
[0114] "Chemotherapy agents" are compounds useful in the treatment of cancer, regardless of their mechanism of action. Classification of chemotherapeutic agents includes, but is not limited to, alkylating agents, antimetabolites, spindle toxin plant alkaloids, cytotoxic / antitemocyte antibiotics, topoisomerase inhibitors, antibodies, photosensitizers, and kinase inhibitors.
[0115] Exemplary CD40 agonists targeting FAP for use in the present invention A bispecific agonist CD40 antigen-binding molecule containing at least one antigen-binding domain capable of specifically binding to tumor-associated antigens is provided, along with its use in combination with radiotherapy, particularly in methods for treating solid tumors in organisms.
[0116] In some embodiments, a bispecific agonist CD40 antigen-binding molecule for use in the treatment of solid tumors in organisms is a bispecific agonist CD40 antigen-binding molecule comprising at least one antigen-binding domain specifically capable of binding to CD40 and at least one antigen-binding domain specifically capable of binding to fibroblast-activating protein (FAP), wherein the at least one antigen-binding domain specifically capable of binding to CD40 comprises a heavy chain variable region (V) comprising (i) CDR-H1 containing the amino acid sequence of SEQ ID NO: 1, (ii) CDR-H2 containing the amino acid sequence of SEQ ID NO: 2, and (iii) CDR-H3 containing the amino acid sequence of SEQ ID NO: 3. H CD40) and a light chain variable region (V) containing (iv) CDR-L1 containing the amino acid sequence of SEQ ID NO: 4, (v) CDR-L2 containing the amino acid sequence of SEQ ID NO: 5, and (vi) CDR-L3 containing the amino acid sequence of SEQ ID NO: 6. L The molecule includes CD40. In particular, the bispecific agonist CD40 antigen-binding molecule includes at least one antigen-binding domain that can specifically bind to CD40, comprising VH containing the amino acid sequence of SEQ ID NO: 7 and VL containing the amino acid sequence of SEQ ID NO: 8.
[0117] In a further embodiment, the bispecific agonist CD40 antigen-binding molecule comprises at least one antigen-binding domain that is specifically capable of binding to FAP and includes the following: (a) A heavy chain variable region (V) containing (i) CDR-H1 containing the amino acid sequence of SEQ ID NO: 9, (ii) CDR-H2 containing the amino acid sequence of SEQ ID NO: 10, and (iii) CDR-H3 containing the amino acid sequence of SEQ ID NO: 11. H (V) Light chain variable region (V) containing (iv) CDR-L1 containing the amino acid sequence of SEQ ID NO: 12, (v) CDR-L2 containing the amino acid sequence of SEQ ID NO: 13, and (vi) CDR-L3 containing the amino acid sequence of SEQ ID NO: 14 L FAP), or (b) A heavy chain variable region (V) containing (i) CDR-H1 containing the amino acid sequence of SEQ ID NO: 17, (ii) CDR-H2 containing the amino acid sequence of SEQ ID NO: 18, and (iii) CDR-H3 containing the amino acid sequence of SEQ ID NO: 19 H(V) Light chain variable region (V) containing (iv) CDR-L1 containing the amino acid sequence of SEQ ID NO: 20, (v) CDR-L2 containing the amino acid sequence of SEQ ID NO: 21, and (vi) CDR-L3 containing the amino acid sequence of SEQ ID NO: 22 L FAP), or (c) A heavy chain variable region (V) containing (i) CDR-H1 containing the amino acid sequence of SEQ ID NO: 25, (ii) CDR-H2 containing the amino acid sequence of SEQ ID NO: 26, and (iii) CDR-H3 containing the amino acid sequence of SEQ ID NO: 27 H (V) Light chain variable region (V) containing (iv) CDR-L1 containing the amino acid sequence of SEQ ID NO: 28, (v) CDR-L2 containing the amino acid sequence of SEQ ID NO: 29, and (vi) CDR-L3 containing the amino acid sequence of SEQ ID NO: 30 L FAP).
[0118] In some embodiments, the bispecific agonist CD40 antigen-binding molecule comprises a heavy chain variable region (V) containing (i) CDR-H1 containing the amino acid sequence of SEQ ID NO: 9, (ii) CDR-H2 containing the amino acid sequence of SEQ ID NO: 10, and (iii) CDR-H3 containing the amino acid sequence of SEQ ID NO: 11. H (V) Light chain variable region (V) containing (iv) CDR-L1 containing the amino acid sequence of SEQ ID NO: 12, (v) CDR-L2 containing the amino acid sequence of SEQ ID NO: 13, and (vi) CDR-L3 containing the amino acid sequence of SEQ ID NO: 14 L The molecule includes at least one antigen-binding domain that is specifically capable of binding to FAP, including FAP. In another embodiment, the bispecific agonist CD40 antigen-binding molecule includes a heavy chain variable region (V) comprising (i) CDR-H1 containing the amino acid sequence of SEQ ID NO: 17, (ii) CDR-H2 containing the amino acid sequence of SEQ ID NO: 18, and (iii) CDR-H3 containing the amino acid sequence of SEQ ID NO: 19. H (V) Light chain variable region (V) containing (iv) CDR-L1 containing the amino acid sequence of SEQ ID NO: 20, (v) CDR-L2 containing the amino acid sequence of SEQ ID NO: 21, and (vi) CDR-L3 containing the amino acid sequence of SEQ ID NO: 22 LIt comprises at least one antigen-binding domain capable of specifically binding to FAP, including (FAP). In yet another aspect, the bispecific agonist CD40 antigen-binding molecule comprises: (i) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 25, (ii) a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 26, and (iii) a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 27 in the heavy chain variable region (V H (FAP), and (iv) a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 28, (v) a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 29, and (vi) a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 30 in the light chain variable region (V L It comprises at least one antigen-binding domain capable of specifically binding to FAP, including (FAP).
[0119] In some aspects, the bispecific agonist CD40 antigen-binding molecule comprises at least one antigen-binding domain capable of specifically binding to FAP, including: (a) a heavy chain variable region (V H FAP) comprising the amino acids of SEQ ID NO: 15 and a light chain variable region (V L FAP) comprising the amino acids of SEQ ID NO: 16, (b) a heavy chain variable region (V H FAP) comprising the amino acids of SEQ ID NO: 23 and a light chain variable region (V L FAP), or (c) a heavy chain variable region (V H FAP) comprising the amino acids of SEQ ID NO: 31 and a light chain variable region (V L FAP), or (d) a heavy chain variable region (V H FAP) comprising the amino acids of SEQ ID NO: 80 and a light chain variable region (V L FAP).
[0120] In one aspect, the bispecific agonist CD40 antigen-binding molecule has a heavy chain variable region (V H FAP) comprising the amino acid sequence of SEQ ID NO: 80 and a light chain variable region (V LIt comprises at least one antigen-binding domain capable of specifically binding to FAP, including (FAP).
[0121] In certain embodiments, the bispecific agonist CD40 antigen-binding molecule comprises a heavy-chain variable region (V) having the amino acid sequence of SEQ ID NO: 15 H FAP) and a light-chain variable region (V) having the amino acid sequence of SEQ ID NO: 16 L FAP), and comprises at least one antigen-binding domain capable of specifically binding to FAP.
[0122] Thus, in certain embodiments, the bispecific agonist CD40 antigen-binding molecule comprises: (i) at least one antigen-binding domain capable of specifically binding to CD40, the antigen-binding domain comprising a heavy-chain variable region (V) having the amino acid sequence of SEQ ID NO: 7 H CD40) and a light-chain variable region (V) having the amino acid sequence of SEQ ID NO: 8 L CD40), and (ii) at least one antigen-binding domain capable of specifically binding to FAP, the antigen-binding domain comprising a heavy-chain variable region (V) having the amino acid sequence of SEQ ID NO: 15 H FAP) and a light-chain variable region (V) having the amino acid sequence of SEQ ID NO: 16 L FAP).
[0123] In other embodiments, the bispecific agonist CD40 antigen-binding molecule comprises: (i) at least one antigen-binding domain capable of specifically binding to CD40, the antigen-binding domain comprising a heavy-chain variable region (V) having the amino acid sequence of SEQ ID NO: 7 H CD40) and a light-chain variable region (V) having the amino acid sequence of SEQ ID NO: 8 L CD40), and (ii) at least one antigen-binding domain capable of specifically binding to FAP, the antigen-binding domain comprising a heavy-chain variable region (V) having the amino acid sequence of SEQ ID NO: 23 H FAP) and a light-chain variable region (V) having the amino acid sequence of SEQ ID NO: 24 LThe molecule comprises an antigen-binding domain including FAP. In yet another embodiment, the bispecific agonist CD40 antigen-binding molecule comprises (i) at least one antigen-binding domain that can specifically bind to CD40, wherein the heavy chain variable region (V) includes the amino acid sequence of SEQ ID NO: 78. H CD40) and the light chain variable region containing the amino acid sequence of SEQ ID NO: 79 (V L (ii) an antigen-binding domain including CD40, and (ii) at least one antigen-binding domain that can specifically bind to FAP, wherein the heavy chain variable region (V) includes the amino acid sequence of SEQ ID NO: 23. H Light chain variable region (V) containing the amino acid sequence of FAP) and SEQ ID NO: 24 L Includes an antigen-binding domain (FAP).
[0124] In another embodiment, the bispecific agonist CD40 antigen-binding molecule comprises (i) at least one antigen-binding domain that can specifically bind to CD40, and a heavy chain variable region (V) containing the amino acid sequence of SEQ ID NO: 7. H CD40) and the light chain variable region containing the amino acid sequence of SEQ ID NO: 8 (V L (ii) an antigen-binding domain including CD40, and (ii) at least one antigen-binding domain that can specifically bind to FAP, wherein the heavy chain variable region (V) includes the amino acid sequence of SEQ ID NO: 23. H Light chain variable region (V) containing the amino acid sequence of FAP) and SEQ ID NO: 24 L The molecule comprises an antigen-binding domain including FAP. In another embodiment, the bispecific agonist CD40 antigen-binding molecule comprises (i) at least one antigen-binding domain that can specifically bind to CD40, wherein the heavy chain variable region (V) includes the amino acid sequence of SEQ ID NO: 7. H CD40) and the light chain variable region containing the amino acid sequence of SEQ ID NO: 8 (V L (ii) an antigen-binding domain including CD40, and (ii) at least one antigen-binding domain that can specifically bind to FAP, wherein the heavy chain variable region (V) includes the amino acid sequence of SEQ ID NO: 31. H FAP) and the light chain variable region (V) containing the amino acid sequence of SEQ ID NO: 32 L Includes an antigen-binding domain (FAP).
[0125] In some embodiments, the bispecific agonist CD40 antigen-binding molecule is a) At least two Fab fragments that can specifically bind to CD40, wherein the C-terminus of each fragment is fused to the N-terminus of the Fc region, and (b) A single antigen-binding domain that is specifically capable of binding to FAP, wherein the N-terminus of the antigen-binding domain is fused to the C-terminus of the Fc region. Includes.
[0126] In some embodiments, the bispecific agonist CD40 antigen-binding molecule is a) At least two Fab fragments that can specifically bind to CD40, wherein the C-terminus of the Fab fragment is fused to the N-terminus of the Fc region, and (b) A cross-fab fragment that can specifically bind to FAP, and which is fused to the C-terminus of the Fc region. Includes.
[0127] In certain embodiments, the bispecific agonist CD40 antigen-binding molecule comprises a cross-fab fragment specifically capable of binding to FAP, with the VH-C kappa chain of the cross-fab fragment fused to the C-terminus of the Fc region. In certain embodiments, the bispecific agonist CD40 antigen-binding molecule comprises two Fab fragments specifically capable of binding to CD40, with the C-terminus of each Fab fragment fused to the N-terminus of the Fc region. In certain embodiments, the bispecific agonist CD40 antigen-binding molecule is characterized by divalent binding to CD40 and monovalent binding to FAP.
[0128] In one embodiment, the bispecific agonist CD40 antigen-binding molecule comprises (a) two light chains and two heavy chains of an antibody containing two Fab fragments specifically capable of binding to the CD40 and Fc domains, and (b) VH and VL domains specifically capable of binding to a target cell antigen, wherein the VH domain and VL domain are each linked to one of the C-terminuses of the two heavy chains via a peptide linker.
[0129] In a further embodiment, the following bispecific agonist CD40 antigen-binding molecules are provided: (a) Two heavy chains, each heavy chain comprising the VH and CH1 domains of a Fab fragment that can specifically bind to CD40 and the Fc region subunit, (b) Two light chains, each light chain comprising the VL and CL domains of a Fab fragment that can specifically bind to CD40, and (c) A cross-fab fragment that can specifically bind to FAP, comprising a VL-CH1 chain and a VH-CL chain, wherein the VH-CL chain is linked to the C-terminus of one of the two heavy chains of (a).
[0130] In one embodiment, the VH-CL (VH-C kappa) chain is linked to the C-terminus of the Fc knob heavy chain.
[0131] In a particular embodiment, the present invention provides a bispecific antigen-binding molecule comprising (a) two light chains each containing the amino acid sequence of SEQ ID NO: 62, one light chain containing the amino acid sequence of SEQ ID NO: 61, a first heavy chain containing the amino acid sequence of SEQ ID NO: 63, and a second heavy chain containing the amino acid sequence of SEQ ID NO: 64.
[0132] In another embodiment, the bispecific agonist CD40 antigen-binding molecule is characterized by tetravalent or trivalent binding to CD40 and monovalent binding to FAP. In some embodiments, the bispecific agonist CD40 antigen-binding molecule is characterized by tetravalent binding to CD40 and monovalent binding to FAP. In some embodiments, the bispecific agonist CD40 antigen-binding molecule comprises four Fab fragments capable of specifically binding to CD40, where each pair of Fab fragments is fused to each other and fused at the N-terminus of the Fc region at its C-terminus.
[0133] Radiation therapy In aspects of the present invention, the FAP-targeted CD40 agonist described herein is used in combination with radiotherapy.
[0134] Radiotherapy, or radiation therapy (often abbreviated as RT), is a treatment that uses ionizing radiation, which is generally used as part of cancer treatment to control or kill malignant cells, and is usually delivered by a linear accelerator. Radiotherapy may be effective when several types of cancer are localized to a single area of the body. It may also be used as part of an adjuvant to prevent tumor recurrence after surgery to remove a primary malignant tumor (e.g., early-stage breast cancer). Radiotherapy has synergistic effects with chemotherapy and has been used before, during, and after chemotherapy in cancers that are susceptible to its effects.
[0135] Radiation therapy is commonly applied to cancerous tumors because it has the ability to control cell proliferation. Ionizing radiation damages the DNA of cancerous tissue, leading to cell death. Shaped radiation beams can be delivered to the tumor from several angles, crossing it and providing a much higher absorbed dose than the surrounding healthy tissue, while preserving normal tissue (such as skin or organs that radiation must pass through to treat the tumor). In addition to the tumor itself, aspiration lymph nodes may also be included in the radiation field if they are clinically or radiologically involved with the tumor or if there is a risk of metastasis of a occult malignant tumor. It is necessary to include margins of normal tissue surrounding the tumor, taking into account the uncertainty of daily setup and the movement of the tumor within the body. These uncertainties can be due to movement within the body and the movement of the outer skin mark relative to the tumor's location and dissemination. The response of cancer to radiation is expressed by radiosensitivity. Highly radiosensitive cancer cells die rapidly with moderate doses of radiation. This includes leukemia, most lymphomas, and germ cell tumors. Most epithelial cancers are moderately radiosensitive and require a considerably high dose (60-70 Gy) of radiation to achieve a cure. Some types of cancer are highly radioresistant; that is, they require a dose far greater than the clinically safe amount to achieve a cure. It is important to distinguish between the radiosensitivity of a tumor, which is a laboratory measurement to some extent, and the radiation "healing power" of cancer in actual clinical practice. For example, leukemia is generally not curable with radiation therapy because it disseminated throughout the body. Lymphoma may be curable if it is localized to one part of the body. Similarly, many tumors with normal moderate radioresponsiveness are routinely treated with radiation therapy at a dose that is curative if treated early. Cancers such as skin cancer, head and neck cancer, breast cancer, non-small cell lung cancer, cervical cancer, and prostate cancer are often not curable with radiation therapy because it cannot treat the entire body.
[0136] The response of a tumor to radiotherapy depends on its size. Very large tumors respond less to radiation than smaller tumors or microscopic lesions. Various strategies are employed to overcome this result. The most common method is surgical resection before radiotherapy. This is most commonly seen in the treatment of breast cancer, where adjuvant radiotherapy is performed after a mastectomy. Another method involves shrinking the tumor with neoadjuvant chemotherapy before curative radiotherapy. A third method involves increasing the radiosensitivity of the cancer by administering specific drugs during a series of radiotherapy treatments. Examples of radiosensitizers include cisplatin, nimorazole, and cetuximab.
[0137] Radiation therapy usually causes minimal or no side effects, although short-term pain may recur for a few days after treatment due to edema compressing nerves in the treated area. High doses can cause various side effects during treatment (acute side effects), months to years after treatment (long-term side effects), and after retreatment (cumulative side effects). The nature, severity, and duration of side effects depend on the organ being irradiated, the treatment itself (type of radiation, dose, fractionation), and the individual patient. The main side effects reported include fatigue and mild to moderate skin irritation, similar to sunburn. Fatigue often occurs during a series of treatments and can persist for several weeks after treatment is completed. Irritated skin recovers, but it may not regain its previous elasticity. Radiation side effects are often limited to the area of the patient's body being treated and are dose-dependent. For example, high doses of head and neck radiation may be associated with cardiovascular complications, thyroid dysfunction, and pituitary axis dysfunction. Therefore, lower doses of radiation therapy may be preferred.
[0138] The radiation dose used in photon radiotherapy is measured in grays (Gy) and varies depending on the type and stage of cancer being treated. Typical doses for solid epithelial tumors range from 60 to 80 Gy, while lymphomas are treated with doses ranging from 20 to 40 Gy. Prophylactic doses are usually in the range of 45 to 60 Gy and are fractionated into 1.8 to 2 Gy doses (for breast and head and neck cancers). When a radiation oncologist selects the dose, many factors are considered, including whether the patient is receiving chemotherapy, their comorbidities, and whether the radiotherapy is administered before or after surgery. The delivery parameters of the prescribed dose are determined during treatment planning (part of the dosimetry). Treatment planning is generally performed on a dedicated computer using specialized treatment planning software. Depending on the method of radiation delivery, multiple angles or sources may be used to total the required dose. The planner will attempt to deliver a uniform prescribed dose to the tumor while minimizing the dose to surrounding healthy tissue.
[0139] The total dose is fractionated (irradiated over time) for several important reasons. Fractionation gives normal cells time to recover, while tumor cells typically have lower repair efficiency between irradiations. Fractionation also allows tumor cells that were in a relatively radioresistant stage of the cell cycle after a single treatment to cycle to a sensitive stage before the next fractionation. Similarly, tumor cells that have been in a chronic or acute hypoxic state (i.e., are relatively radioresistant) are reoxygenated between fractionations, improving the killing power of the tumor cells. A typical fractionation schedule for adults is 1.8–2 Gy per day, 5 days a week. Depending on the type of cancer, a fractionation schedule that is too long can allow the tumor to begin regrowth, and for tumor types including head and neck and cervical squamous cell carcinoma, it is preferable to complete radiotherapy within a certain time frame. Smaller fraction sizes reduce the incidence and severity of delayed side effects in normal tissue; therefore, a typical fraction size for children is 1.5–1.8 Gy per day. In some cases, fractionated irradiation twice a day is used towards the end of a series of treatments. This schedule is known as simultaneous boost irradiation or hyperfractionation and is used for tumors that regenerate rapidly, especially when the tumor is small. Tumors in the head and neck region, in particular, exhibit this behavior.
[0140] One fractionated radiotherapy schedule that has become increasingly used and is being researched is the low-fractionation radiotherapy method. This is a type of radiotherapy in which the total dose of radiation is divided into high doses. Typical doses vary greatly depending on the type of cancer, ranging from 1.8 Gy / fraction to 20 Gy / fraction, with the latter being a typical dose for stereotactic treatment of subcranial lesions (stereotactic body radiotherapy, also known as SABR (stereotactic ablative body radiotherapy) or SRS (stereotactic radiosurgery) for intracranial lesions). Low-fractionation radiotherapy with doses in the range of 5 to 20 Gy is preferred. Depending on the cancer being treated, low-fractionation radiotherapy with doses in the range of 1.8 to 2.2 Gy may be particularly noteworthy. The rationale for low-fractionation radiotherapy is to reduce the probability of local recurrence by not giving clonalable cells the time necessary to proliferate, and to utilize the radiosensitivity of some tumors. In particular, stereotactic radiotherapy aims to destroy clonalable cells through ablation, that is, by delivering a dose intended to directly destroy clonalable cells, rather than repeatedly interfering with the division process of clonalable cells (apoptosis) as in conventional radiotherapy.
[0141] Local radiotherapy has two forms: external beam radiotherapy and internal beam radiotherapy. External beam radiotherapy (EBRT) is the most common form of radiotherapy. An external source of ionizing radiation is directed at a specific part of the patient's body. In contrast to close-range radiotherapy (brachytherapy) and unsealed brachytherapy, where the radiation source is inside the body, EBRT irradiates the tumor from outside the body. Orthovoltage ("superficial") X-rays are used for the treatment of skin cancer and superficial structures. X-rays and electron beams are the most widely used sources in EBRT.
[0142] Internal radiotherapy (proximity radiotherapy) is a form of radiotherapy in which a sealed radiation source is placed inside or next to the area requiring treatment. The advantage of proximity radiotherapy is that the radiation only affects a very localized area around the radiation source. Therefore, exposure to healthy tissue far from the source is reduced, and tumors can be treated with relatively high doses of localized radiation while minimizing the possibility of unnecessary damage to surrounding healthy tissue. In addition, even if the patient or the tumor moves during treatment, the radiation source can maintain its correct position relative to the tumor.
[0143] Whole-body radiotherapy and radioisotope therapy (RIT) are also forms of radiotherapy. Targeting can be achieved through the chemical properties of isotopes such as radioactive iodine, which are specifically absorbed by the thyroid gland (up to 1000 times more than other organs in the body), or by conjugating the radioactive isotope to another molecule or antibody and guiding it to the target tissue. Radioactive isotopes are delivered by intravenous infusion (into the bloodstream) or ingestion. For example, metaiodobenzylguanidine (MIBG) is administered intravenously for the treatment of neuroblastoma, iodine-131 is administered orally for the treatment of thyroid cancer or thyroidopathy, and hormone-binding lutetium-177 and yttrium-90 are administered intravenously (peptide receptor radionuclide therapy) for the treatment of neuroendocrine tumors. In addition, microspheres of radioactive yttrium-90 or holmium-166 are injected into the hepatic artery to perform radioembolization of liver tumors or liver metastases. These microspheres are used in a treatment method known as selective internal irradiation therapy. Microspheres, approximately 30 μm in diameter (about one-third the size of a human hair), are delivered directly to the arteries supplying blood to the tumor. These treatments involve first inserting a catheter into the femoral artery in the leg and guiding it to the target site, after which the treatment is administered. Because the blood supplying nutrients to the tumor directly delivers these microspheres to the tumor, a more selective approach than conventional systemic chemotherapy is possible. Currently, there are three different types of microspheres: SIR-Sphere, TheraSphere, and QuiremSphere. The primary use of total body radiotherapy is the treatment of bone metastases from cancer. Radioactive isotopes selectively migrate to the site of damaged bone, preserving undamaged, healthy bone. Commonly used isotopes for treating bone metastases include radium-223, strontium-89, and samarium ( 153 Sm) Lexidronum.
[0144] Preparation of bispecific antigen-binding molecules for use in the present invention The therapeutic agents of the present invention used in combination include a multispecific antigen-binding molecule, such as a bispecific antigen-binding molecule. A multispecific antibody is a monoclonal antibody having binding specificity to at least two different sites. In certain embodiments, the binding specificity is for different antigens. In certain embodiments, the binding specificity is for different epitopes on the same antigen. A bispecific antigen-binding molecule can be prepared as a full-length antibody or an antibody fragment.
[0145] Techniques for producing multispecific antibodies include, but are not limited to, recombinant co-expression of two immunoglobulin heavy-light chain pairs having different specificities (see Milstein and Cuello, Nature 305: 537 (1983)), International Publication No. 93 / 08829, and Traunecker et al., EMBO J.10:3655 (1991)) and the "knob-in-hole" operation (see, for example, U.S. Patent No. 5731168). For recombinant production, one or more polynucleotides encoding a bispecific antigen-binding molecule or a polypeptide fragment thereof are provided. One or more polynucleotides encoding a bispecific antigen-binding molecule are isolated and inserted into one or more vectors for cloning and / or expression in host cells. Such polynucleotides can be readily isolated and sequenced using conventional procedures. In one embodiment of the present invention, a vector, preferably an expression vector, comprising one or more polynucleotides of the present invention is provided. Expression vectors containing the coding sequence of a bispecific antigen-binding molecule (fragment), along with appropriate transcription / translation regulatory signals, can be constructed using methods well known to those skilled in the art. Such methods include recombinant DNA techniques in vitro, synthetic techniques, and recombination / genetic engineering in vivo. See, for example, Maniatis et al., MOLECULAR CLONING: A LABORATORY MANUAL, Cold Spring Harbor Laboratory, NY (1989); and Ausubel et al., CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, Greene Publishing Associates and Wiley Interscience, NY (1989). The expression vector may be a plasmid, part of a virus, or a nucleic acid fragment. The expression vector contains an expression cassette in which a polynucleotide or polypeptide fragment (i.e., coding region) encoding a bispecific antigen-binding molecule is cloned and operably bound to a promoter and / or other transcription or translation regulatory elements.In the context of the present invention, a "coding region" is a part of a nucleic acid consisting of codons that are translated into amino acids. A "stop codon" (TAG, TGA, or TAA) is not translated into an amino acid, but if present, it is considered part of the coding region. However, any adjacent sequences, such as promoters, ribosome binding sites, transcription terminators, introns, and 5' and 3' untranslated regions, are not part of the coding region. Two or more coding regions may be present in a single polynucleotide construct (e.g., on a single vector) or in separate polynucleotide constructs (e.g., on separate (different) vectors). Furthermore, any vector may contain a single coding region or two or more coding regions; for example, a vector of the present invention may encode one or more polypeptides that are separated into a final protein post-translation or concurrently with translation by proteolytic cleavage. In addition, the vectors, polynucleotides, or nucleic acids of the present invention may encode heterologous coding regions fused to or unfused to polynucleotides encoding the bispecific antigen-binding molecule of the present invention, or a polypeptide fragment thereof, or a variant or derivative thereof. Heterogeneous coding regions include, but are not limited to, specialized elements or motifs such as secretory signal peptides or heterogeneous functional domains. Manipulative binding is when the coding region of a gene product, such as a polypeptide, is bound to one or more regulatory sequences in such a manner that the expression of the gene product is under the influence or control of one or more regulatory sequences. Two DNA fragments (such as a polypeptide coding region and a promoter bound to it) are "manipulatively bound" if the induction of promoter function results in the transcription of mRNA encoding the desired gene product, and the nature of the binding between the two DNA fragments does not interfere with the ability of the expression regulatory sequences to induce gene product expression or the ability of the DNA template to be transcribed. Therefore, if a promoter can transcribe a nucleic acid encoding a polypeptide, the promoter region is manipulatively bound to that nucleic acid. The promoter may be a cell-specific promoter that induces substantial transcription of DNA only in a given cell.Cell-specific transcription can be induced by manipulating the connection of other transcriptional regulatory elements besides promoters, such as enhancers, operators, repressors, and transcription termination signals, to polynucleotides.
[0146] Appropriate promoters and other transcriptional regulatory regions are disclosed herein. Various transcriptional regulatory regions are known to those skilled in the art. These include, but are not limited to, transcriptional regulatory regions that function in vertebrate cells, such as promoter and enhancer segments from cytomegalovirus (e.g., the earliest promoter in combination with intron A), Simian virus 40 (e.g., the early promoter), and retroviruses (e.g., Rous sarcoma virus). Other transcriptional regulatory regions include regions derived from vertebrate genes such as actin, heat shock proteins, bovine growth hormone, and the 5' flanking region and internal region of the rabbit alphaglobin gene, as well as other sequences that can regulate gene expression in eukaryotic cells. Further suitable transcriptional regulatory regions include tissue-specific promoters and enhancers, and induced promoters (e.g., promoter-induced tetracycline). Similarly, various translational regulatory elements are known to those skilled in the art. These include, but are not limited to, ribosome binding sites, translation start and termination codons, and viral elements (in particular, intrasequence ribosome entry sites or IRESs, also known as CITE sequences). Expression cassettes may also include other features such as the origin of replication and / or chromosomal integration elements, such as retroviral long-terminal repeats (LTRs) or adeno-associated virus (AAV) reverse-terminal repeats (ITRs).
[0147] Polynucleotides and nucleic acid coding regions may be coupled with additional coding regions encoding secretory peptides or signal peptides that induce the secretion of polypeptides encoded by the polynucleotides. For example, if the secretion of a bispecific antigen-binding molecule or a polypeptide fragment thereof is desired, the DNA encoding the signal sequence can be placed upstream of the nucleic acid encoding the bispecific antigen-binding molecule or polypeptide fragment thereof. According to the signal hypothesis, proteins secreted by mammalian cells have a signal peptide or secretory leader sequence that is cleaved from the mature protein when the transport of the growing protein chain across the coarse endoplasmic reticulum begins. Those skilled in the art will know that polypeptides secreted by vertebrate cells generally have a signal peptide fused to the N-terminus of the polypeptide, which is cleaved from the translated polypeptide to produce the secretory or “mature” form of the polypeptide. In certain embodiments, native signal peptides, such as immunoglobulin heavy chain or light chain signal peptides, are used, or functional derivatives of their sequences that retain the ability to induce the secretion of polypeptides that operably bind thereto are used. Alternatively, heterologous mammalian signal peptides or their functional derivatives may be used. For example, the wild-type leader sequence may be replaced with the leader sequence of human tissue plasminogen activator (TPA) or mouse β-glucuronidase. DNA encoding a short protein sequence (e.g., histidine tag) that can be used to facilitate subsequent purification, or DNA encoding a short protein sequence that can be used to assist in labeling the fusion protein, may be contained within or at both ends of the polynucleotide encoding the bispecific antigen-binding molecule or its polypeptide fragment of the present invention. In some embodiments, a host cell comprises a vector containing a polynucleotide encoding (or part thereof) the bispecific antigen-binding molecule of the present invention (e.g., transformed or transfected with the vector). As used herein, the term “host cell” refers to any type of cell line that is engineerable to produce the bispecific antigen-binding molecule or its fragment. Host cells suitable for replication of the antigen-binding molecule and for assisting its expression are well known in the art.Such cells may, where appropriate, be transfected or transduced with a specific expression vector, and cells containing a large amount of vector can be grown and seeded in a large fermenter to obtain sufficient quantities of antigen-binding molecules for clinical application. Suitable host cells include prokaryotes, such as Escherichia coli, or various eukaryotic cells, such as Chinese hamster ovary cells (CHO), insect cells, etc. For example, polypeptides may be produced in bacteria, especially when glycosylation is not required. After expression, the polypeptides can be isolated as a soluble fraction from the bacterial cell paste and then purified. In addition to prokaryotes, eukaryotic microorganisms such as filamentous fungi or yeasts are suitable cloning or expression hosts for polypeptide-encoding vectors, including fungal and yeast strains, whose glycosylation pathways are "humanized," resulting in the production of polypeptides with partially or completely human glycosylation patterns. See Gerngross, Nat Biotech 22, 1409-1414 (2004) and Li et al., Nat Biotech 24, 210-215 (2006).
[0148] Host cells suitable for the expression of (glycosylated) polypeptides also originate from multicellular organisms (invertebrates and vertebrates). Examples of invertebrate cells include plant cells and insect cells. Several baculovirus strains have been identified and may be used in combination with insect cells, particularly for the transfection of armyworm cells. Plant cell cultures can also be used as hosts. See, for example, U.S. Patents 5,959177, 6040498, 6420548, 7125978, and 6417429 (which describe PLANTIBODIES® technology for antibody production in transgenic plants). Vertebrate cells can also be used as hosts. For example, mammalian cell lines adapted for growth in suspension may be useful. Other examples of useful mammalian host cell lines include the SV40(COS-7) transformed monkey kidney CV1 cell line; human embryonic kidney cells (e.g., 293 or 293T cells described in Graham et al., J Gen Virol 36, 59 (1977)); baby hamster kidney cells (BHK); mouse Sertoli cells (e.g., TM4 cells described in Mather, Biol Reprod 23, 243-251 (1980)); monkey kidney cells (CV1); African green monkey kidney cells (VERO-76); human cervical cancer cells (HELA); canine kidney cells (MDCK); buffalo rat liver cells (BRL 3A); human lung cells (W138); human liver cells (Hep G2); mouse mammary tumor cells (MMT 060562); TRI cells (e.g., those described in Mather et al., Annals NYAcad Sci 383, 44-68 (1982)); and MRC. These include 5 cells and FS4 cells. Other useful mammalian host cell lines include Chinese hamster ovary (CHO) cells, including dhfr-CHO cells (Urlaub et al., Proc Natl Acad Sci USA 77, 4216 (1980)), and myeloma cell lines such as YO, NS0, P3X63, and Sp2 / 0.For a review of specific mammalian host cells suitable for protein production, see, for example, Yazaki and Wu, Methods in Molecular Biology, Vol. 248 (BKCLo, ed., Humana Press, Totowa, NJ), pp. 255-268 (2003). Host cells include cultured cells, to name just a few, mammalian cultured cells, yeast cells, insect cells, bacterial cells, and plant cells, but also include cells contained in transgenic animals, transgenic plants, or cultured plant or animal tissues. In some embodiments, the host cells are eukaryotic cells, preferably mammalian cells such as Chinese hamster ovary (CHO) cells, human embryonic kidney (HEK) cells, or lymphocytes (e.g., Y0, NS0, Sp20 cells). Standard techniques for expressing exogenous genes in these systems are known in the art. Cells expressing polypeptides containing either the heavy or light chain of an immunoglobulin can be engineered to express the other part of the immunoglobulin chain as well, such that the expressed product is an immunoglobulin having both the heavy and light chains. A method for producing a bispecific antigen-binding molecule used in the present invention comprises culturing a host cell containing a polynucleotide encoding the bispecific antigen-binding molecule or its polypeptide fragment provided herein under conditions suitable for the expression of the bispecific antigen-binding molecule or its polypeptide fragment; culturing a host cell containing a polynucleotide encoding the bispecific antigen-binding molecule or its polypeptide fragment of the present invention; and recovering the bispecific antigen-binding molecule or its polypeptide fragment from the host cell (or host cell culture medium).
[0149] The bispecific antigen-binding molecules used in the present invention, prepared as described herein, can be purified by techniques known in the art, such as high-performance liquid chromatography, ion-exchange chromatography, gel electrophoresis, affinity chromatography, and size exclusion chromatography. The actual conditions used to purify a particular protein will be apparent to those skilled in the art, as they depend in part on factors such as net charge, hydrophobicity, and hydrophilicity. In affinity chromatography purification, antibodies, ligands, receptors, or antigens to which the bispecific antigen-binding molecules bind may be used. For example, in affinity chromatography purification of the fusion protein of the present invention, a matrix containing protein A or protein G may be used. Using sequential protein A or G affinity chromatography and size exclusion chromatography, the antigen-binding molecules can be isolated, essentially as described in the examples. The purity of the bispecific antigen-binding molecules or their fragments can be determined by any variety of well-known analytical methods, including gel electrophoresis and high-pressure liquid chromatography. For example, the bispecific antigen-binding molecules expressed as described in the examples have been shown to be intact and properly assembled, as demonstrated by reduced and unreduced SDS-PAGE.
[0150] Fc domain modification that reduces Fc receptor binding and / or effector function. The Fc domain of the antigen-binding molecule used in this invention consists of a pair of polypeptide chains containing the heavy chain domain of an immunoglobulin molecule. For example, the Fc domain of an immunoglobulin G (IgG) molecule is a dimer, and each subunit contains the CH2 and CH3 IgG heavy chain constant domains. The two subunits of the Fc domain can bind stably to each other.
[0151] The Fc domain confers desirable pharmacokinetic properties to the antigen-binding molecule of the present invention, such pharmacokinetic properties include a long serum half-life and a desirable tissue-to-blood distribution ratio that contribute to good accumulation in target tissue. However, at the same time, this may result in undesirable targeting of the bispecific antigen-binding molecule to cells expressing the Fc receptor rather than the preferred antigen-containing cells. Therefore, in certain embodiments, the Fc domain of the antigen-binding molecule of the present invention exhibits reduced binding affinity to the Fc receptor and / or reduced effector function compared to the Fc domain of natural IgG1. In some embodiments, the Fc does not substantially bind to the Fc receptor and / or does not induce effector function. In certain embodiments, the Fc receptor is the Fcγ receptor. In some embodiments, the Fc receptor is the human Fc receptor. In specific embodiments, the Fc receptor is the activated human Fcγ receptor, more specifically human FcγRIIIa, FcγRI or FcγRIIa, most specifically human FcγRIIIa. In some embodiments, the Fc domain does not induce effector function. The reduction of effector function may include, but is not limited to, one or more of the following: reduction of complement-dependent cell-mediated cytotoxicity (CDC), reduction of antibody-dependent cell-mediated cytotoxicity (ADCC), reduction of antibody-dependent cell phagocytosis (ADCP), reduction of cytokine secretion, reduction of immune complex-mediated antigen uptake by antigen-presenting cells, reduction of binding to NK cells, reduction of binding to macrophages, reduction of binding to monocytes, reduction of binding to polymorphonuclear cells, reduction of direct signaling that induces apoptosis, reduction of dendritic cell maturation, or reduction of T cell priming.
[0152] In certain embodiments, one or more amino acid modifications may be introduced into the Fc region of the bispecific antigen-binding molecule provided herein, thereby generating an Fc region variant. The Fc region variant may include a human Fc region sequence (e.g., human IgG1, IgG2, IgG3, or IgG4 Fc region) containing amino acid modifications (e.g., substitutions) at one or more amino acid positions. In certain embodiments, the present invention provides a bispecific antigen-binding molecule in which the Fc domain contains one or more amino acid substitutions that reduce binding to Fc receptors, particularly to Fcγ receptors.
[0153] In some embodiments, the Fc domain of a bispecific antigen-binding molecule contains one or more amino acid mutations that reduce the binding affinity and / or effector function of the Fc domain to the Fc receptor. Typically, the same one or more amino acid mutations are present in each of the two subunits of the Fc domain. In particular, the Fc domain contains amino acid substitutions at positions E233, L234, L235, N297, P331, and P329 (EU numbering). Specifically, the Fc domain contains amino acid substitutions at positions 234 and 235 (EU numbering) and / or 329 (EU numbering) of the IgG heavy chain. More specifically, the present invention provides an antibody comprising an Fc domain having amino acid substitutions L234A, L235A, and P329G ("P329G LALA", EU numbering) in the IgG heavy chain. The amino acid substitutions L234A and L235A refer to so-called LALA mutations. The amino acid substitution combination "P329G LALA" almost completely eliminates Fcγ receptor binding of the human IgG1 Fc domain, and methods for preparing such mutant Fc domains and determining their properties, such as Fc receptor binding or effector function, are described in International Publication 2012 / 130831.
[0154] Fc domains with reduced Fc receptor binding and / or effector function also include those having one or more substitutions among Fc domain residues 238, 265, 269, 270, 297, 327, and 329 (U.S. Patent No. 6,737,056). Such Fc variants include so-called "DANA" Fc variants having alanine substitutions at residues 265 and 297, and Fc variants having two or more substitutions among amino acid positions 265, 269, 270, 297, and 327 (U.S. Patent No. 7,332,581).
[0155] In another embodiment, the Fc domain is the IgG4 Fc domain. Compared to the IgG1 antibody, the IgG4 antibody exhibits reduced binding affinity and reduced effector function to the Fc receptor. In a more specific embodiment, the Fc domain is the IgG4 Fc domain containing an amino acid substitution at position S228 (Kabat numbering), particularly the amino acid substitution S228P. In a more specific embodiment, the Fc domain is the IgG4 Fc domain containing amino acid substitutions L235E, S228P, and P329G (EU numbering). Such IgG4 Fc domain variants and their Fcγ receptor binding properties are also described in International Publication No. 2012 / 130831.
[0156] Mutant Fc domains can be prepared by deletion, substitution, insertion, or modification of amino acids using genetic or chemical methods well known in the art. Genetic methods may include site-directed mutagenesis of the encoding DNA sequence, PCR, gene synthesis, etc. The exact nucleotide changes can be verified, for example, by sequencing.
[0157] Binding to Fc receptors can be easily determined, for example, by ELISA or by surface plasmon resonance (SPR) using standard equipment such as a BIAcore instrument (GE Healthcare), and such Fc receptors can be obtained by recombinant expression. Alternatively, the binding affinity of an Fc domain or a cell-activating antibody containing an Fc domain to an Fc receptor may be evaluated using a cell line known to express a specific Fc receptor (e.g., human NK cells expressing the FcγIIIa receptor).
[0158] The effector function of an Fc domain, or of a bispecific antigen-binding molecule containing an Fc domain, can be measured by methods known in the art. Suitable assays for measuring ADCC are described herein. Other examples of in vitro assays for evaluating the ADCC activity of a molecule of interest are described in U.S. Patent No. 5500362; Hellstrom et al., Proc Natl Acad Sci USA 83, 7059-7063 (1986) and Hellstrom et al., Proc Natl Acad Sci USA 82, 1499-1502 (1985); U.S. Patent No. 5821337; Bruggemann et al., J Exp Med 166, 1351-1361 (1987). Alternatively, non-radioactive assay methods can be used (e.g., ACTI for flow cytometry). TM See Non-Radioactive Cytotoxicity Assay (CellTechnology, Mountain View, California); and CytoTox 96® Non-Radioactive Cytotoxicity Assay (Promega, Madison, Wisconsin). Useful effector cells for such assays include peripheral blood mononuclear cells (PBMCs) and natural killer (NK) cells. Alternatively, or in addition to the above, the ADCC activity of the molecule of interest may be evaluated in vivo in animal models, for example, as disclosed in Clynes et al., Proc Natl Acad Sci USA 95, 652-656 (1998).
[0159] In some embodiments, the binding of the Fc domain to complement components, specifically to C1q, is reduced. Therefore, in some embodiments where the Fc domain is engineered to have reduced effector function, the reduced effector function includes reduced CDC. C1q binding assays may be performed to determine whether the bispecific antibody of the present invention can bind to C1q and thus possesses CDC activity. See, for example, the C1q and C3c binding ELISAs in International Publication No. 2006 / 029879 and International Publication No. 2005 / 100402. CDC assays may also be performed to evaluate complement activation (see, for example, Gazzano-Santoro et al., J Immunol Methods 202, 163 (1996); Cragg et al., Blood 101, 1045-1052 (2003); and Cragg and Glennie, Blood 103, 2738-2743 (2004)).
[0160] Fc domain modification that promotes heterodimerization The bispecific antigen-binding molecule used in the present invention contains different antigen-binding sites fused to one or the other of two subunits of the Fc domain, and therefore the two subunits of the Fc domain may be contained in two non-identical polypeptide chains. Recombinant co-expression of these polypeptides and subsequent dimerization result in several possible combinations of the two polypeptides. Therefore, in order to increase the yield and purity of the bispecific antibody of the present invention in recombinant production, it would be advantageous to introduce a modification to the Fc domain of the bispecific antigen-binding molecule of the present invention that promotes the binding of a desired polypeptide. Accordingly, the bispecific antigen-binding molecule contains an Fc domain composed of first and second subunits capable of stable binding, and the Fc domain includes a modification that promotes the binding of the first and second subunits of the Fc domain. The site where the protein-protein interaction between the two subunits of the human IgG Fc domain is most extensive is in the CH3 domain of the Fc domain. Therefore, in some embodiments, the modification is located within the CH3 domain of the Fc domain.
[0161] In certain embodiments, the modification is a so-called "knob-into-hole" modification, which includes a "knob" modification in one of the two subunits of the Fc domain and a "hole" modification in the other of the two subunits of the Fc domain. Thus, the bispecific antigen-binding molecule comprises an Fc domain composed of first and second subunits capable of stable binding, wherein the first subunit of the Fc domain contains a knob by the knob-into-hole method, and the second subunit of the Fc domain contains a hole by the knob-into-hole method. In certain embodiments, the first subunit of the Fc domain contains amino acid substitutions S354C and T366W (EU numbering), and the second subunit of the Fc domain contains amino acid substitutions Y349C, T366S, and Y407V (numbered by the Kabat EU index).
[0162] The knob-into-hole technique is described, for example, in U.S. Patent No. 5,731,168; U.S. Patent No. 7,695,936; Ridgway et al., Prot Eng 9, 617-621 (1996); and Carter, J Immunol Meth 248, 7-15 (2001). Generally, the method involves introducing a bump ("knob") at the interface of a first polypeptide and introducing a corresponding cavity at the interface of a second polypeptide so that the bump can be positioned within a cavity ("hole") to promote heterodimer formation and prevent homodimer formation. The bump is constructed by replacing a small amino acid side chain from the interface of the first polypeptide with a larger side chain (e.g., tyrosine or tryptophan). By replacing the large amino acid side chain with a small amino acid side chain (e.g., alanine or threonine), a compensatory cavity of the same or similar size as the bump is created at the interface of the second polypeptide. Accordingly, in one embodiment, in the CH3 domain of the first subunit of the Fc domain of the bispecific antigen-binding molecule of the present invention, an amino acid residue is replaced with an amino acid residue having a larger side chain volume, thereby creating a ridge within the CH3 domain of the first subunit that can be placed in the cavity within the CH3 domain of the second subunit, and in the CH3 domain of the second subunit of the Fc domain, an amino acid residue is replaced with an amino acid residue having a smaller side chain volume, thereby creating a cavity within the CH3 domain of the second subunit that can accommodate the ridge within the CH3 domain of the first subunit. The ridge and cavity can be created, for example, by altering the nucleic acid encoding the polypeptide by site-directed mutagenesis or peptide synthesis. In a particular embodiment, in the CH3 domain of the first subunit of the Fc domain, the threonine residue at position 366 is replaced with a tryptophan residue (T366W), and in the CH3 domain of the second subunit of the Fc domain, the tyrosine residue at position 407 is replaced with a valine residue (Y407V).In one embodiment, in the second subunit of the Fc domain, the threonine residue at position 366 is further replaced with a serine residue (T366S), and the leucine residue at position 368 is replaced with an alanine residue (L368A).
[0163] In a further embodiment, the serine residue at position 354 of the first subunit of the Fc domain is further replaced with a cysteine residue (S354C), and the tyrosine residue at position 349 of the second subunit of the Fc domain is further replaced with a cysteine residue (Y349C). The introduction of these two cysteine residues forms a disulfide bridge between the two subunits of the Fc domain, further stabilizing the dimer (Carter (2001), J Immunol Methods 248, 7-15). In a specific embodiment, the first subunit of the Fc domain contains amino acid substitutions S354C and T366W (EU numbering), and the second subunit of the Fc domain contains amino acid substitutions Y349C, T366S, and Y407V (numbered according to the Kabat EU index).
[0164] In alternative embodiments, modifications that promote the binding of the first and second subunits of the Fc domain include modifications that mediate an electrostatic steering effect, such as those described in International Publication No. 2009 / 089004. Typically, this method involves the substitution of one or more amino acid residues at the interface between the two Fc domain subunits with charged amino acid residues such that homodimerization is electrostatically undesirable and heterodimerization is electrostatically desirable.
[0165] The C-terminus of the heavy chain of the bispecific antigen-binding molecule described herein may be a complete C-terminus ending with the amino acid residue PGK. The C-terminus of the heavy chain may be a shortened C-terminus from which one or two C-terminal amino acid residues have been removed. In a preferred embodiment, the C-terminus of the heavy chain is a shortened C-terminus ending with PG. In some embodiments of all embodiments described herein, the bispecific antibody comprising a heavy chain containing the C-terminal CH3 domain as specified herein comprises a C-terminal glycine-lysine dipeptide (numbered G446 and K447, according to the Kabat EU index). In some embodiments of all embodiments described herein, the bispecific antibody comprising a heavy chain containing the C-terminal CH3 domain as specified herein comprises a C-terminal glycine residue (numbered G446, according to the Kabat EU index).
[0166] Modifications within the Fab domain In one embodiment, the present invention relates to a bispecific antigen-binding molecule comprising (a) a first Fab fragment specifically capable of binding to CD40, (b) a second Fab fragment specifically capable of binding to FAP, and (c) a stable binding Fc domain composed of a first subunit and a second subunit, wherein in one of the Fab fragments, either the variable domain VH and VL are exchanged or the constant domain CH1 and CL are exchanged. The bispecific antibody is prepared according to Crossmab technology.
[0167] Multispecific antibodies with domain substitution / exchange in one binding arm (CrossMab VH-VL or CrossMab CH-CL) are described in International Publication No. 2009 / 080252 and Schaefer, W. et al., PNAS, 108(2011)11187-1191. These multispecific antibodies clearly reduce byproducts resulting from mismatches between the light chain for the first antigen and the wrong heavy chain for the second antigen (compared to methods without such domain exchange).
[0168] In one embodiment, the present invention relates to a bispecific antigen-binding molecule comprising (a) a first Fab fragment specifically capable of binding to CD40, (b) a second Fab fragment specifically capable of binding to FAP, and (c) an Fc domain composed of a first subunit and a second subunit capable of stable binding, wherein in one of the Fab fragments, the constant domains CL and CH1 are substituted for each other such that the CH1 domain is part of the light chain and the CL domain is part of the heavy chain. More specifically, in the second Fab fragment specifically capable of binding to a target cell antigen, the constant domains CL and CH1 are substituted for each other such that the CH1 domain is part of the light chain and the CL domain is part of the heavy chain.
[0169] In certain embodiments, the present invention relates to a bispecific antigen-binding molecule comprising (a) a first Fab fragment specifically bound to CD40 and (b) a second Fab fragment specifically bound to FAP, wherein the constant domains CL and CH1 are substituted for each other such that the CH1 domain is part of the light chain and the CL domain is part of the heavy chain. Such a molecule binds monovalently to both CD40 and FAP.
[0170] In another embodiment, the present invention relates to a bispecific antigen-binding molecule comprising (a) two light chains and two heavy chains of an antibody comprising two Fab fragments specifically bound to the CD40 and Fc domains, and (b) two additional Fab fragments specifically bound to FAP, wherein each of the additional Fab fragments is linked to the C-terminus of the heavy chain of (a) via a peptide linker, wherein the additional Fa fragments are Fab fragments in which variable domains VL and VH are substituted for each other such that the VH domain is part of the light chain and the VL domain is part of the heavy chain.
[0171] Accordingly, in a particular embodiment, the present invention comprises a bispecific antigen-binding molecule comprising (a) two light chains and two heavy chains of an antibody, each comprising two Fab fragments specifically bound to the CD40 and Fc domains, and (b) two additional Fab fragments specifically bound to FAP, wherein the two additional Fab fragments specifically bound to the target cell antigen are crossover Fab fragments in which the variable domains VL and VH are substituted for each other, and the VL-CH chains are each linked to the C-terminus of the heavy chain of (a) via a peptide linker.
[0172] In another embodiment, to further improve precise pairing, a bispecific antigen-binding molecule comprising (a) a first Fab fragment specifically bound to CD40, (b) a second Fab fragment specifically bound to FAP, and (c) an Fc domain composed of first and second subunits capable of stable binding, may include different charged amino acid substitutions (so-called "charged residues"). These modifications are introduced into cross- or non-cross-linked CH1 and CL domains. In a particular embodiment, the present invention relates to a bispecific antigen-binding molecule in which, in one of the CL domains, the amino acid at position 123 (EU numbered) is replaced with arginine (R), the amino acid at position 124 (EU numbered) is replaced with lysine (K), and in one of the CH1 domains, the amino acids at positions 147 (EU numbered) and / or 213 (EU numbered) are replaced with glutamic acid (E).
[0173] Assay The antigen-binding molecules provided herein can be identified, screened, or characterized for their physical / chemical properties and / or biological activity by various assays known in the art.
[0174] 1. Binding assay The binding of the bispecific antigen-binding molecules provided herein to corresponding target-expressing cells can be evaluated, for example, by using mouse fibroblast cell lines expressing human fibroblast-activating protein (FAP) and flow cytometry (FACS) analysis. The binding of the bispecific antigen-binding molecules provided herein to CD40 can be determined using primary B cells.
[0175] 2. Activity assay The bispecific antigen-binding molecule of the present invention is tested for its biological activity. Biological activity may include the efficacy and specificity of the bispecific antigen-binding molecule. Efficacy and specificity are demonstrated by assays that show agonist signaling via the CD40 receptor upon binding to the target antigen. Furthermore, an in vitro T cell priming assay is performed using dendritic cells (DCs) incubated with the bispecific antigen-binding molecule.
[0176] Pharmaceutical compositions, formulations, and routes of administration In further embodiments, the present invention provides a pharmaceutical composition comprising one of the bispecific antigen-binding molecules provided herein, for example, for use in any of the following therapeutic treatments. In one embodiment, the pharmaceutical composition comprises one of the bispecific antigen-binding molecules provided herein and at least one pharmaceutically acceptable additive. In another embodiment, the pharmaceutical composition comprises one of the bispecific antigen-binding molecules provided herein and at least one additional therapeutic agent, for example, as described below.
[0177] The pharmaceutical compositions of the present invention contain a therapeutically effective amount of one or more bispecific antigen-binding molecules dissolved or dispersed in a pharmaceutically acceptable carrier. The terms "pharmaceutically acceptable" or "pharmacologically acceptable" mean molecular entities and compositions that are generally non-toxic to the recipient at the doses and concentrations used, i.e., that do not produce side effects, allergic reactions or other adverse reactions when administered as needed to animals such as humans. The preparation of pharmaceutical compositions containing at least one bispecific antigen-binding molecule and optionally additional active ingredients according to the present invention is illustrated in Remington's Pharmaceutical Sciences (18th Ed. Mack Printing Company, 1990), incorporated herein by reference, and will be known to those skilled in the art in light of this disclosure. In particular, the compositions are lyophilized formulations or aqueous solutions. As used herein, “pharmaceutically acceptable additives” include, as is known to those skilled in the art, any solvent, buffer, dispersion medium, coating, surfactant, antioxidant, preservative (e.g., antimicrobial, antifungal), isotonic agent, salt, stabilizer, and combinations thereof.
[0178] Parenteral compositions include those designed for administration by injection (e.g., subcutaneous, intradermal, intralesional, intravenous, intraarterial, intramuscular, intrathecal, or intraperitoneal injection). For injection, the bispecific antigen-binding molecule of the present invention may be formulated in an aqueous solution, preferably a physiologically compatible buffer such as Hanks' solution, Ringer's solution, or physiological saline buffer. The solution may contain formulations such as suspension agents, stabilizers, and / or dispersants. Alternatively, the bispecific antigen-binding molecule may be in powder form for formulation with a suitable vehicle (e.g., pyrogen-free sterile water) before use. Sterile injection solutions are prepared by incorporating the required amount of the antigen-binding molecule of the present invention into a suitable solvent, along with various other components listed below, if necessary. Sterilization can be easily achieved, for example, by filtration with a sterile filtration membrane. Generally, dispersions are prepared by incorporating various sterile active ingredients into a sterile vehicle containing a basic dispersion medium and / or other components. For sterile powders used in the preparation of sterile injection solutions, suspensions, or emulsions, the preferred preparation method is vacuum drying or freeze-drying techniques to obtain a powder of the active ingredient plus any additional desired ingredients from a pre-sterilized filtered liquid culture medium. The liquid culture medium must be properly buffered as needed, and the liquid diluent must first be isotonic before injecting sufficient saline or glucose. The compositions of the present invention must be stable under manufacturing and storage conditions and protected from contamination by microorganisms such as bacteria and fungi. It will be understood that endotoxin contamination should be kept at a minimum safe level, e.g., less than 0.5 ng / mg of protein.Appropriate pharmaceutically acceptable additives include, but are not limited to, buffers such as phosphoric acid, citrate and other organic acids; antioxidants including ascorbic acid and methionine; preservatives (e.g., octadecyldimethylbenzylammonium chloride; hexamethonium chloride; benzalkonium chloride; benzethonium chloride; phenol, butyl or benzyl alcohol; alkylparabens, e.g., methyl or propylparaben; catechol; resorcinol; cyclohexanol; 3-pentanol; and m-cresol); low molecular weight (less than approximately 10 residues) polypeptides; proteins Examples of substances include: substances such as serum albumin, gelatin, or immunoglobulin; hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as glycine, glutamine, asparagine, histidine, arginine, or lysine; monosaccharides, disaccharides, and other carbohydrates including glucose, mannose, or dextrin; chelating agents such as EDTA; sugars such as sucrose, mannitol, trehalose, or sorbitol; salt-forming counterions such as sodium; metal complexes (e.g., Zn-protein complexes); and / or nonionic surfactants such as polyethylene glycol (PEG). The aqueous injection suspension may also contain compounds that increase the viscosity of the suspension, such as sodium carboxymethylcellulose, sorbitol, or dextran. Optionally, the suspension may also contain suitable stabilizers or agents to increase the solubility of the compound and enable the preparation of high-concentration solutions. In addition, the suspension of the active compound can be prepared as a suitable oily injection suspension. Suitable lipophilic solvents or vehicles include fatty oils such as sesame oil, synthetic fatty acid esters such as ethyl oleate (etyl cleats) or triglycerides, or liposomes.
[0179] The active ingredient can be encapsulated in microcapsules prepared, for example, by coacervation technology or interfacial polymerization, such as hydroxymethylcellulose microcapsules or gelatin microcapsules, and poly(methyl methacrylate) microcapsules, in colloidal drug delivery systems (e.g., liposomes, albumin microspheres, microemulsions, nanoparticles, and nanocapsules), or in macroemulsions. Such techniques are disclosed in Remington's Pharmaceutical Sciences (18th Ed. Mack Printing Company, 1990). Sustained-release preparations may be prepared. A suitable example of a sustained-release preparation involves a semipermeable matrix of a solid hydrophobic polymer containing a polypeptide, which is in the form of a molded article (e.g., a film) or microcapsules. In certain embodiments, sustained absorption of an injectable composition can be achieved by the use of an absorption-delaying agent (e.g., aluminum monostearate, gelatin, or a combination thereof) in the composition.
[0180] The pharmaceutically acceptable, exemplary additives of the present invention further include intrastitial drug dispersion agents, such as soluble neutral-active hyaluronidase glycoproteins (sHASEGP), such as human soluble PH-20 hyaluronidase glycoprotein, such as rHuPH20 (HYLENEX®, Baxter International). Certain exemplary sHASEGPs and methods of use, including rHuPH20, are described in U.S. Patent Applications Publications 2005 / 0260186 and 2006 / 0104968. In some embodiments, sHASEGP is combined with one or more additional glycosaminoglycansases (e.g., chondroitinases).
[0181] An example of a lyophilized antibody preparation is described in U.S. Patent No. 6,267,958. Examples of aqueous antibody preparations are described in U.S. Patent No. 6,171,586 and International Publication No. 2006 / 044908, the latter of which contains histidine acetate buffer.
[0182] In addition to the compositions described above, antigen-binding molecules can also be formulated as depot preparations. Such sustained-release formulations can be administered by implantation (e.g., subcutaneous or intramuscular) or intramuscular injection. Therefore, for example, fusion proteins can also be formulated using suitable polymers or hydrophobic materials (e.g., as emulsions in acceptable oils) or ion-exchange resins, or as poorly soluble derivatives, such as poorly soluble salts.
[0183] The pharmaceutical compositions containing the bispecific antigen-binding molecules of the present invention can be prepared by conventional mixing, dissolution, emulsification, encapsulation, containment, or lyophilization processes. The pharmaceutical compositions can be formulated conventionally using one or more physiologically acceptable carriers, diluents, or additives, or using aids that facilitate the processing of proteins into pharmaceutically usable preparations. The appropriate formulation depends on the selected route of administration.
[0184] Bispecific antigen-binding molecules can be incorporated into compositions in the form of free acids or bases, neutral or salt forms. Pharmaceutically acceptable salts are those that substantially retain the biological activity of the free acid or base. These include acid addition salts, such as those formed with free amino groups of proteinaceous compositions, or those formed with inorganic acids such as hydrochloric acid or phosphoric acid, or organic acids such as acetic acid, oxalic acid, tartaric acid, or mandelic acid. Salts formed with free carboxyl groups can be derived from inorganic bases such as sodium hydroxide, potassium hydroxide, ammonium hydroxide, calcium hydroxide, or ferric hydroxide; or from organic bases such as isopropylamine, trimethylamine, histidine, or procaine. Pharmaceutical salts are more readily soluble in aqueous and other protic solvents than their corresponding free base forms.
[0185] The compositions herein may also contain more than one active ingredient necessary for the specific symptom being treated, preferably those having complementary activities that do not adversely affect each other. Such active ingredients are appropriately present in combination in amounts effective for the intended purpose.
[0186] Preparations used for in vivo administration are generally sterile. Sterility can be easily achieved, for example, by filtering through a sterile filtration membrane.
[0187] Combination therapy with radiotherapy using CD40 agonists targeting FAP. A bispecific agonist CD40 antigen-binding molecule containing at least one antigen-binding domain capable of specifically binding to tumor-associated antigens can be administered by any appropriate means, including parenteral administration, intrapulmonary administration, intranasal administration, and, if desired for local treatment, intrafocal administration. In particular, the bispecific agonist CD40 antigen-binding molecule can be administered by parenteral infusion, especially intravenous infusion.
[0188] Parenteral administration includes intramuscular, intravenous, intra-arterial, intraperitoneal, or subcutaneous administration. Dosage may be by any preferred route, e.g., intravenous or subcutaneous injection, depending in part on whether the administration is short-term or long-term. Various dosing schedules, including but not limited to single or multiple doses at various time points, bolus administration, and pulse infusion, are contemplated herein. In some embodiments, the bispecific agonist CD40 antigen-binding molecule is administered parenterally, particularly intravenously. In certain embodiments, the bispecific agonist CD40 antigen-binding molecule is administered by intravenous infusion.
[0189] Bispecific agonist CD40-conjugated molecules are formulated, dose-determined, and administered in accordance with good medical practice. Factors to consider in this regard include the specific disorder being treated, the specific mammal being treated, the individual patient's clinical symptoms, the cause of the disorder, the site of drug delivery, the method of administration, the administration schedule, and other factors known to healthcare professionals. Bispecific agonist CD40-conjugated molecules are, but not necessarily, formulated with one or more drugs currently used to prevent or treat the disorder in question. The effective dose of such other drugs depends on the amount of therapeutic agent present in the formulation, the type of disease or treatment, and the other factors mentioned above. These are generally used in the same doses and routes of administration as described herein, or at approximately 1–99% of the doses described herein, or in any doses and routes that are empirically / clinically deemed appropriate.
[0190] In the prevention or treatment of disease, the appropriate dose of a bispecific agonist CD40-binding molecule (when used in combination with or in conjunction with one or more other additional therapeutic agents) depends on the type of disease being treated, the severity and course of the disease, whether it is administered for preventive or therapeutic purposes, the patient's treatment history, the patient's medical history, the response to the therapeutic agent, and the discretion of the attending physician. The bispecific CD40-binding molecule is preferably administered to the patient as a single dose or over a series of treatments. Depending on the type and severity of the disease, a dose of approximately 1 μg / kg to 15 mg / kg (e.g., 0.1 mg / kg to 10 mg / kg) may be a candidate initial dose for administration to the target, whether by single or multiple individual doses or by continuous infusion. A typical daily dose may range from approximately 1 μg / kg to 100 mg / kg, depending on the factors mentioned above. In repeated administrations over several days or more, treatment will generally continue, depending on the patient's condition, until the desired suppression of the disease is achieved. One exemplary dose of the bispecific CD40 antigen-binding molecule ranges from approximately 0.005 mg / kg to approximately 10 mg / kg. Therefore, one or more doses from approximately 0.5 mg / kg, 1.0 mg / kg, 2.0 mg / kg, 3.0 mg / kg, 4.0 mg / kg, 5.0 mg / kg, 6.0 mg / kg, 7.0 mg / kg, 8.0 mg / kg, 9.0 mg / kg, or 10 mg / kg (or any combination thereof) may be administered to a subject. Such doses may be administered intermittently, for example, weekly, every two weeks, or every three weeks (for example, so that the subject receives approximately 2 to approximately 20 doses or, for example, approximately 6 doses). An initial high loading dose followed by one or more low doses may be administered, or an initial low dose followed by one or more high doses. An exemplary dosing regimen includes administering an initial dose of approximately 10 mg / kg of the agent, followed by approximately 20 mg / kg of the agent every other week. However, other drug regimens may be useful in some cases. The progress of this treatment can be easily monitored using conventional techniques and assays.
[0191] In some embodiments, the administration of the bispecific agonist CD40 antigen-binding molecule is for single-dose administration. In some embodiments, the bispecific agonist CD40 antigen-binding molecule is administered concurrently with radiotherapy. "Concurrently" means at the same time, or within a short period of time, usually less than one hour. In some embodiments, the bispecific agonist CD40 antigen-binding molecule is administered concurrently after radiotherapy. "Post-radiation therapy" means at least three hours after the end of radiation, preferably several days, preferably one day, but within one to two weeks after the end of radiation. In certain embodiments, the administration of the bispecific agonist CD40 antigen-binding molecule is two or more doses. Drugs administered "concurrently" with one or more other drugs are administered on the same treatment day as one or more other drugs, and optionally at the same time as one or more other drugs, within the same treatment cycle. For example, in the case of a therapy administered every three weeks, each drug administered concurrently is administered on day one of the three-week cycles. In one embodiment, administration of a bispecific agonist CD40 antigen-binding molecule comprises an initial dose of a first dose of the bispecific agonist CD40 antigen-binding molecule and one or more subsequent doses of a second dose of the bispecific agonist CD40 antigen-binding molecule, wherein the first dose is not lower than the second dose.
[0192] When radiotherapy and the bispecific agonist CD40 antigen-binding molecule are administered sequentially, they are given in two separate doses separated by a "specific period." The term "specific period" means anywhere from one hour to 15 days. For example, the bispecific agonist CD40 antigen-binding molecule can be administered within approximately 1, 2, 3, 4, 5, 6, or 7 days after the radiotherapy dose, or within 1 to 24 hours, and in some embodiments, the specific period is 1 to 3 days or 2 to 8 hours.
[0193] In certain embodiments, radiotherapy is administered before the administration of the bispecific agonist CD40 antigen-binding molecule. In some embodiments, radiotherapy is administered simultaneously with the administration of the bispecific agonist CD40 antigen-binding molecule.
[0194] Treatment method and composition In one embodiment, a method is provided for treating a solid tumor in an individual, comprising administering an effective amount of the bispecific agonist CD40 antigen-binding molecule described herein and an effective amount of the radiotherapy described herein to the target.
[0195] In such embodiments, the method further comprises administering an effective amount of at least one additional therapeutic agent to the subject. Suitable additional agents include one or more of the following: anthracycline drugs such as doxorubicin and epirubicin (Famorubicin®); taxane drugs such as paclitaxel (Taxol®) and docetaxel (Taxotere®); fluorouracil (5FU); cyclophosphamide; methotrexate; cisplatin; and capecitabine. Other suitable additional therapeutic agents include the kinase inhibitors lapatinib (Tykerb) and neratinib (Nerlinx). In further embodiments, a method for tumor reduction is provided herein, comprising administering an effective amount of a bispecific agonist CD40 antigen-binding molecule described herein and radiotherapy to a subject as described herein. The “subject” or “individual” described in any of the above embodiments is preferably human.
[0196] In some embodiments, the present invention provides a bispecific agonist CD40 antigen-binding molecule described herein for use in methods for treating or delaying the progression of cancer, wherein the bispecific agonist CD40 antigen-binding molecule described herein is used in combination with radiotherapy. In some embodiments, the bispecific agonist CD40 antigen-binding molecule described herein and radiotherapy are combined with additional therapeutic agents.
[0197] In a further embodiment, a combination therapy for use in cancer immunotherapy is provided, comprising the bispecific agonist CD40 antigen-binding molecule described herein and the radiotherapy described herein.
[0198] In further embodiments, the use of the bispecific agonist CD40 binding molecule described herein in the manufacture or preparation of a pharmacopoeia for use in combination therapy is provided herein. In some embodiments, the pharmacopoeia is for the treatment of cancer. In some embodiments, the pharmacopoeia is for the treatment of solid tumors. In further embodiments, the pharmacopoeia is for use in a method of tumor reduction, comprising administering an effective amount of the pharmacopoeia to an individual having a solid tumor. In such embodiments, the method further comprises administering an effective amount of at least one additional therapeutic agent to the individual. In some embodiments, the pharmacopoeia is for the treatment of solid tumors.
[0199] In certain embodiments, an individual has cancer characterized by FAP expression in the tumor stroma. In some embodiments, the tumor may include stroma that overexpresses FAP. In some embodiments, the cancer includes a solid tumor. In some embodiments, the solid tumor is an advanced and / or metastatic solid tumor. In some embodiments, the FAP-expressing cancer is selected from the group consisting of head and neck cancer, melanoma, lung cancer, kidney cancer, breast cancer, colon cancer, ovarian cancer, cervical cancer, pancreatic cancer, liver cancer, prostate cancer, bladder cancer, and gastric cancer. In some embodiments, the cancer is a head and neck cancer. In some embodiments, the cancer is non-small cell lung cancer (NSCLC). In some embodiments, the solid tumor is a tumor from a recurrent cancer after prior treatment. In some embodiments, the tumor is from a recurrent head and neck cancer after prior treatment.
[0200] The treatment may aim to prevent the development or growth of solid tumors. Thus, the bispecific agonist CD40 antigen-binding molecules described herein can be used in combination with radiotherapy to prophylactically treat individuals against the recurrence of solid tumors. In some embodiments, the bispecific agonist CD40 antigen-binding molecules described herein act synergistically with radiotherapy.
[0201] The bispecific agonist CD40-binding molecules described herein are formulated, dose-determined, and administered in accordance with medical practice standards. Factors to be considered in this regard include the specific disorder being treated, the specific mammal being treated, the individual patient's clinical symptoms, the cause of the disorder, the site of drug delivery, the method of administration, the administration schedule, and other factors known to healthcare professionals. Antibodies are formulated, but not necessarily, with one or more drugs currently used to prevent or treat the disorder in question. The effective dose of such other drugs depends on the amount of antibody present in the formulation, the type of disorder or treatment, and the other factors mentioned above. These are generally used in the same doses and routes of administration as described herein, or at approximately 1–99% of the doses described herein, or in any doses and routes that are empirically / clinically deemed appropriate.
[0202] Manufactured product (kit) In another aspect of the present invention, a kit is provided comprising materials useful for the treatment, prevention, and / or diagnosis of the aforementioned disorders. The kit comprises at least one container and a label or accompanying documentation attached to or accompanying the container. Suitable containers include, for example, bottles, vials, syringes, IV solution bags, etc. These containers may be formed from a variety of materials such as glass or plastic. The container may contain a composition effective for the treatment, prevention, and / or diagnosis of the condition, either alone or in combination with another composition, and may have a sterile access port (for example, the container may be an IV solution bag or vial with a stopper that can be punctured with a subcutaneous needle). The activator in the kit is the bispecific agonist CD40 antigen-binding molecule described herein. Furthermore, the kit includes instructions for using the bispecific agonist CD40 antigen-binding molecule described herein in combination with radiotherapy. The label or accompanying documentation indicates how the composition of the present invention is used to treat a selected condition and provides instructions for using the composition in combination therapy.
[0203] Alternatively or additionally, the kit may further comprise a second (or third) container containing pharmaceutically acceptable buffers, such as bacteriostatic water for injection (BWFI), phosphate-buffered saline, Ringer's solution, and glucose solution. The kit may further comprise other materials desirable from a commercial and user perspective, including other buffers, diluents, filters, needles, and syringes. TIFF2023549316000003.tif255170TIFF2023549316000004.tif255170TIFF2023549316000005.t if255170TIFF2023549316000006.tif255170TIFF2023549316000007.tif255170TIFF20235493160 00008.tif255170TIFF2023549316000009.tif255170TIFF2023549316000010.tif255170TIFF202 3549316000011.tif255170TIFF2023549316000012.tif255170TIFF2023549316000013.tif107170
[0204] General information regarding the nucleotide sequences of human immunoglobulin light and heavy chains is provided below: Kabat, EA, et al., Sequences of Proteins of Immunological Interest, 5th ed., Public Health Service, National Institutes of Health, Bethesda, MD (1991). The amino acids of the antibody chain are numbered and referred to according to the numbering system by Kabat (Kabat, EA, et al., Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, MD (1991)). ***
[0205] The following are examples of the methods and compositions of the present invention. It is understood that various other embodiments may be carried out based on the general description provided above.
[0206] Recombinant DNA technology DNA was manipulated using standard methods, as described in Sambrook et al., Molecular cloning: A laboratory manual; Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, 1989. Molecular biological reagents were used according to the manufacturer's instructions. General information regarding the nucleotide sequences of the light and heavy chains of human immunoglobulins is found in Kabat, EA et al., (1991) Sequences of Proteins of Immunological Interest, Fifth Ed., NIH Publication No. 91-3242.
[0207] DNA sequencing The DNA sequence was determined by double-strand sequencing.
[0208] gene synthesis The desired gene segments were generated by PCR using appropriate templates, or synthesized by automated gene synthesis from synthetic oligonucleotides and PCR products by Geneart (Regensburg, Germany). If the exact gene sequence was unavailable, oligonucleotide primers were designed based on the sequence of the nearest homolog, and the gene was isolated by RT-PCR from RNA derived from appropriate tissues. Gene segments adjacent to specific restriction endonuclease cleavage sites were cloned into standard cloning / sequencing vectors. Plasmid DNA was purified from transformed bacteria, and its concentration was determined by UV spectroscopy. The DNA sequences of the subcloned gene fragments were confirmed by DNA sequencing. Gene segments with appropriate restriction sites were designed to enable subcloning into corresponding expression vectors. All constructs were designed to have a 5' terminal DNA sequence encoding a leader peptide targeting a protein for secretion in eukaryotic cells.
[0209] Cell culture technology Standard cell culture techniques were used, as described in Current Protocols in Cell Biology (2000), Bonifacino, JS, Dasso, M., Harford, JB, Lippincott-Schwartz, J. and Yamada, KM (eds.), John Wiley & Sons, Inc.
[0210] All genes are transiently expressed under the control of a chimeric MPSV promoter consisting of an MPSV core promoter combined with a CMV promoter enhancer fragment. The expression cassette also contains a synthetic poly(A) signal at the 3' end of the cDNA. The expression vector also contains the oriP region for episomal replication in EBNA (Epstein-Barr virus nuclear antigen)-containing host cells.
[0211] Protein purification Following standard protocols, proteins were purified from filtered cell culture supernatant. Briefly, the antibodies were applied to a Protein A-Sepharose column (GE Healthcare) and washed with PBS. Antibody elution was achieved at pH 2.8, and the sample was neutralized immediately thereafter. Agglutinated proteins were separated from monomeric antibodies in PBS or in 20 mM histidine, 150 mM NaCl (pH 6.0) by size exclusion chromatography (Superdex 200, GE Healthcare). The monomeric antibody fractions were pooled and concentrated (if necessary) using, for example, a Millipore Amicon Ultra (30 MWCO) centrifugal concentrator, and frozen at -20°C or -80°C. Some of these samples were provided for subsequent protein analysis and analytical characterization by, for example, SDS-PAGE, size exclusion chromatography (SEC), or mass spectrometry.
[0212] SDS-PAGE The NuPAGE® Pre-Cast gel system (Invitrogen) was used according to the manufacturer's instructions. In particular, 10% or 4-12% NuPAGE® Novex® Bis-TRIS Pre-Cast gel (pH 6.4) and NuPAGE® MES (reduced gel, containing NuPAGE® antioxidant running buffer additive) or MOPS (non-reduced gel) running buffer were used.
[0213] Size exclusion chromatography for analysis Size-exclusion chromatography (SEC) to determine the aggregation and oligomeric state of antibodies was performed by HPLC chromatography. Briefly, the protein A-purified antibody was applied to a Tosoh TSKgel G3000SW column in 300 mM NaCl, 50 mM KH2PO4 / K2HPO4 (pH 7.5) of an Agilent HPLC 1100 system or to a Superdex 200 column (GE Healthcare) in 2×PBS of a Dionex HPLC system. The eluted protein was quantified by the integration of UV absorbance and peak area. BioRad Gel Filtration Standard 151-1901 was used as the standard.
[0214] Mass spectrometry In this section, the characterization of multispecific antibodies (VH / VL CrossMab) including VH / VL exchange will be described with an emphasis on accurate assembly. Analysis of the predicted primary structure was performed by electrospray ionization mass spectrometry (ESI-MS) of deglycosylated intact CrossMab and deglycosylated / plasmin digested CrossMab or deglycosylated / LysC limited digested CrossMab.
[0215] VH / VL CrossMab was deglycosylated using N-glycosidase F at 37 °C for up to 17 hours at a protein concentration of 1 mg / ml in phosphate or Tris buffer. Plasmin digestion or LysC (Roche) limited digestion was performed using 100 μg of deglycosylated VH / VL CrossMab in Tris buffer (pH 8) for 120 hours at room temperature and 40 minutes at 37 °C, respectively. Before mass spectrometry, the samples were desalted by HPLC on a Sephadex G25 column (GE Healthcare). The total mass was determined by ESI-MS on a maXis 4G UHR-QTOF MS system (Bruker Daltonik) equipped with a TriVersa NanoMate source (Advion).
[0216] Determination of binding and binding affinity of multispecific antibodies to corresponding antigens using surface plasmon resonance (SPR) (BIACORE). The binding of the generated antibodies to the corresponding antigens is investigated by surface plasmon resonance using a BIACORE instrument (GE Healthcare Biosciences, Uppsala, Sweden). In short, for affinity measurement, goat anti-human IgG, JIR 109-005-098 antibody, is immobilized on a CM5 chip by amine coupling, and the antibody against the corresponding antigen is displayed. Binding was measured in HBS buffer (HBS-P (10 mM HEPES, 150 mM NaCl, 0.005% Tween 20, pH 7.4) at 25°C (or alternatively, 37°C)). Antigens (R&D Systems or in-house purified) were added in solution at various concentrations. Binding was measured by antigen injection for 80 seconds to 3 minutes; dissociation was measured by washing the tip surface with HBS buffer for 3 to 10 minutes, and the KD value was measured using the Langmuir 1:1 binding model. Negative control data (e.g., buffer curves) were subtracted from the sample curve to correct for system-specific baseline drift and reduce noise signals. The corresponding Biacore Evaluation Software was used for sensorgram analysis and affinity data calculation. [Examples]
[0217] Example 1 Preparation, purification, and characterization of bispecific antigen-binding molecules targeting fibroblast-activating protein (FAP) and CD40. Bispecific antigen-binding molecules targeting fibroblast-activating protein (FAP) and CD40 were prepared as described in International Publication No. 2018 / 185045, International Publication No. 2020 / 070041, or International Publication No. 2020 / 070035.
[0218] In particular, the following molecules were created. a) Bispecific antigen-binding molecules targeting fibroblast-activating protein (FAP) and CD40 Bispecific FAP-CD40 antibodies were prepared in a 2+1 format (Figure 1D) consisting of two CD40 binding sites combined with one FAP binding site at the C-terminus of Fc, or in a 4+1 format (Figure 1A or 1B) consisting of four CD40 binding sites combined with one FAP binding site at the C-terminus of Fc. The bispecific CD40-FAP antibodies contained anti-FAP clone 212 disclosed in International Publication No. 2020 / 070041, or FAP clones 4B9 and 28H1 described in International Publication No. 2012 / 020006. Heterodimerization was achieved using knob-into-hole technology to generate 4+1 and 2+1 molecules. The S354C / T366W mutation was introduced into the first heavy chain HC1 (Fc knob heavy chain), and the Y349C / T366S / L368A / Y407V mutation was introduced into the second heavy chain HC2 (Fc hole heavy chain). Regardless of the bispecificity format, IgG1 was deactivated using effector silent Fc (P329G; L234, 234A) according to the method described in International Publication No. 2012 / 130831 to eliminate binding to the Fcγ receptor. The sequences of the bispecificity molecules are shown in Table 1. As a control molecule, a non-targeted version was also prepared as appropriate by replacing the FAP clone with germline DP47. TIFF2023549316000014.tif114170b) Mouse surrogates and control molecules Similarly, bispecific FAP-CD40 antibodies containing one CD40 clone and FAP clone 28H1 that bind to mouse CD40 (FGK4.5) were prepared and used in mouse studies. These molecules were prepared in a 2+1 format (Figure 1D) consisting of two CD40 binding moieties combined with one FAP binding moiety at the C-terminus of Fc, or in a 4+1 format (Figure 1B) consisting of four CD40 binding moieties combined with one FAP binding moiety, with VH and VL connected at the C-terminus of Fc. The sequences of these bispecific molecules are shown in Table 2. As control molecules, non-targeted versions were also prepared as appropriate by replacing the FAP clone with germline DP47. TIFF2023549316000015.tif101170
[0219] Example 2 In vivo antitumor efficacy of FAP-targeted anti-CD40 antigen-binding molecules in combination with radiotherapy, as demonstrated in the mEERL95 tumor model. 2.1 Materials and Methods The ability of a bispecific FAP-targeted anti-CD40 antigen-binding molecule to achieve therapeutic efficacy, either alone or in combination with a fractional radiotherapy regimen, was tested in mice possessing the mEERL95 tumor cell line, a clinically relevant mouse model of HPV-associated head and neck squamous cell carcinoma (HNSCC).
[0220] Female C57BL / 6J mice aged 7-11 weeks were purchased from Janvier Labs. Humanized hCD40Tg mice were provided by Roche Glycart (Zurich). Batf3- / - mice were generously donated by Dr. Hans Acha Orbea (University of Lausanne) and were bred at the University of Lausanne facilities. All animal experiments were conducted under license VD3173j, approved by the Veterinary Authority of Vaud, Switzerland.
[0221] The mEERL95 cell line was derived from a tumor explant of a mEERL-possessing C57BL / 6J female (Mermod et al., Int. J. Cancer 2018, 142, 2518-2528) and cultured in DMEM / nutrient mixture F-12 (Thermo Fisher Scientific) medium supplemented with 5% fetal bovine serum (FBS, Life Technologies) and 1× human keratinocyte proliferation adjuvant (HKGS, Thermo Fisher Scientific). TC-1 cells (Lin et al., Cancer Research 1996, 56, 21-26) were kindly provided by TCWu (Johns Hopkins University) in 2009 and were cultured in 10% FBS (Life Technologies), penicillin / streptomycin (Life Technologies), and 5×10⁶ cells. -5Cells were cultured in RPMI 1640 medium supplemented with M2-mercaptoethanol (Life Technologies). Both cell lines were cultured in an incubator at 37°C and 5% CO2 and routinely tested for mycoplasma contamination. Cells were harvested when 90% confluence was reached and inoculated into mice.
[0222] Tumor models and in vivo therapies 1 × 10⁶ samples were resuspended in 30 μL of HBSS (Hank's Balanced Salt Solution, Thermo Fisher Scientific) and 20 μL of Matrigel (Corning). 5 Individual mEERL95 or TC1 cells were subcutaneously injected into the subchinnic region of mice. The tumors were irradiated with a small fractionation regimen consisting of two consecutive 6 Gy irradiations (2 × 6 Gy) on days 10 and 11 after tumor transplantation. The dose was delivered using an Xrad-225CX-PXi instrument with a 15 mm collimator capable of localized irradiation of the tumors.
[0223] On day 11, mice were treated with a single intravenous injection of either a bispecific anti-muCD40 antibody targeting FAP (FAP-CD40) or a corresponding non-targeted anti-CD40 control antibody (DP47-CD40) at concentrations of 18.3 mg / kg and 10 mg / kg in PBS, respectively. mEERL95-containing huCD40Tg mice were irradiated with a 2 × 6 Gy regimen and treated with a single intravenous injection of PBS containing 13 mg / kg of FAP-huCD40. Tumor size was monitored twice weekly using calipers, and the volume was calculated using the following formula: V = (vertical × horizontal) 2 ) / 2(V=tumor volume)
[0224] For the depletion study, 200 μg each of anti-CD8β mAb (clone H35-17-2), anti-CD4 (clone GK1.5), or Rat IgG2a (clone 2A3, BioXCell), used as immunoglobulin isotype controls, was administered to mEERL95-bearing mice two days before the start of treatment and on the day of treatment initiation. These antibodies were administered every three days for two weeks. The efficiency of depletion was confirmed by flow cytometry of peripheral blood lymphocytes on day 18. In the in vivo experiment to block IL-12, 500 μg of anti-IL-12 (clone C17.8, BioXCell), diluted in PBS, was administered daily to mice for one week starting from the day of therapeutic antibody administration. The same amount of rat IgG2a (clone 2A3, BioXCell) was used as an immunoglobulin isotype control.
[0225] Tumor Rechallenge To characterize the development of immunological memory, 10 samples were resuspended in PBS. 6 individual mEERL95 or 10 5 Individual TC-1 tumor cells were subcutaneously transplanted into the flanks of mice that had rejected the primary tumor after treatment. Tumor inoculation was performed approximately 40 days after the development of a full response. Tumor growth was measured every 2-3 days using a caliper.
[0226] Cell isolation Tumors and regional lymph nodes were collected on days 10, 16, or 18 after tumor transplantation. The collected tumors and lymph nodes were incubated with 1 mg / ml Collagenase-D and 40 μg / ml DNase-I (Sigma-Aldrich) for 45 minutes and 20 minutes, respectively, at 37°C. Deagglutination was then performed mechanically, and the mixture was filtered using a 70 μm cell strainer (Falcon, BD Bioscience) to obtain single-cell suspensions. Tumor-infiltrating lymphocytes were further separated from stromal cells using a 35% Percoll gradient. If necessary, erythrocytes were lysed with RBC buffer (Qiagen) for 3 minutes at RT before flow cytometry staining.
[0227] Flow cytometry Single-cell suspensions were first incubated with FcR-Block (anti-CD16 / 32 clone 2.4G2, homemade) on ice for 15 minutes in FACS buffer (PBS containing 2% FCS and 2 mM EDTA). To characterize the immunization population, samples were surface-stained on ice in the dark for 20 minutes with the following antibody panel: Biolegend CD11c-BV421 (clone N418), CD8-BV510 (clone 53-6.7), F4 / 80-BV605 (clone BM8), NK1.1-BV650 (clone PK136), and CD11b-BV7. 11 (clone M1 / 70), CD4-BV785 (clone RM4-5), CD19-BV785 (clone 6D5), Ly6G-FITC (clone 1A8), CD45-PerCP (clone 30-F11), Ly6C-AF700 (clone HK1.4), IA / IE-APC-Cy7 (clone M5 / 114.15.2), and B220-APC (clone RA3-B2); CD80-Pe-Vio770 (clone 16-10A) from Miltenyi Biotec; CD103-PE (clone 2E7), CD3-PE-Cy5.5 (clone 145-2C11), and Foxp3-PeFluor-610 (clone FJK-165) from eBioscience. Intracellular staining for Foxp3 was performed using the Foxp3 / Transcription Factor Staining Buffer Set (eBioscience) according to the manufacturer's instructions. LIVE / DEAD were used as survival markers. TM I used the Fixable Blue Dead Cell Stain Kit (Thermo Fisher Scientific).
[0228] For the ex vivo stimulation assay, lymphocytes derived from tumors and lymph nodes were co-cultured with mEERL95 cells in a 10:1 ratio. mEERL95 cells were pre-incubated with IFN-γ (200 ng / ml; ImmunoTools) for 24 hours. Co-culture was performed in the presence of 1 μg / ml anti-CD28 (clone 37.51) and 10 μg / ml anti-PD1 (clone RMP1-14, BioXCell), and maintained in a combined medium at 37°C for 16 hours. Unstimulated cells were used as a negative control. GolgiPlug and GolgiStop were added to the cells 4 hours before the start of staining (both in a 1:1000 ratio; BD Biosciences). After surface staining with CD45-BV650 (clone 104, BioLegend), CD3- (clone 17A2, eBioscience), CD8- (clone 53-6.7, eBioscience), and CD4- (clone GK1.5, BioLegend), the cells were fixed and permeabilized on ice for 20 minutes with fixation buffer (BioLegend). Subsequently, the cell suspension was stained on ice for 30 minutes with the following intracellular antibodies diluted with Perm / wash buffer 1× (BioLegend): IFNγ-PerCp-Cy5.5 (clone XMG1.2, eBioscience), TNFα-PB (clone MP6-XT22, BioLegend), and Granzyme B-PerCp-Cy5.5 (clone QA16A02, BioLegend). Samples were obtained using either an LSRII-SORP or a Fortessa flow cytometer (BD Biosciences). Data analysis was performed using FlowJo v10 (FlowJo LLC).
[0229] Immunofluorescence and Imaging tumor fragments in Cellpath TMEmbedded in an OCT freezing section embedding matrix (Cell Path, Newton, Powys, UK) and frozen on dry ice. 10-micrometer frozen sections were fixed with 2% paraformaldehyde (PFA, Sigma) for 10 minutes and washed three times with phosphate-buffered saline (PBS). The primary antibody was incubated in PBS containing 0.5% bovine serum albumin (BSA, Sigma), 0.3% Triton X-100 (AppliChem, Germany), and 1% serum from the same host species as the secondary antibody. The slides were stored overnight in a humid chamber at 4°C. The samples were washed three times with PBS and then stained with the secondary antibody at RT for 1 hour. The tissue slices were washed three more times with PBS and mounted with Prolong TM Gold anti-fading reagent. After immunofluorescence, the slides were digitized with a ZEISS Axio Scan Z1. Downstream analysis was performed using a custom-made script in FIJI (Schindelin et al., Nature Methods 2012, 9, 676 - 682), an open-source platform for bioimage analysis. Briefly, the total area of the sections was estimated using DAPI staining, and the tumor area was measured using E-cadherin staining. For the quantification of well-defined cells such as immune cells, the infiltration index was calculated based on the number of positive cells detected per analysis area. For groups of indistinguishable cells such as mesenchymal cells, quantification was performed by calculating the ratio of the size of the immunostaining positive area divided by the total area of the analysis area.
[0230] Immunohistochemistry Lymph nodes were harvested, fixed overnight at 4°C with 1% PFA, washed twice with PBS, and incubated in 30% sucrose solution at 4°C for 3–6 hours. The lymph nodes were then embedded in OCT embedding matrix (Cell Path, Newton, Poysshire, UK) and frozen on dry ice. 8-micrometer frozen sections were directly incubated with primary antibody against mouse FAP (clone 4B9, Roche Glycart) at 4°C for 16 hours. After washing, the samples were incubated with biotin-conjugated goat anti-rabbit antibody as a secondary antibody and exposed using the Vectastin ABS kit (Vector Labs).
[0231] Multiplex assay Cytokine and chemokine concentrations from serum and tumors are measured using LegendPlex. TM Mouse Proinflammatory Chemokine Panel and LegendPlex TM Measurements were taken using the Mouse Inflammation Panel (both from Biolegend) according to the manufacturer's instructions. Analysis was performed using LegendPlex. TM The data analysis was performed using data analysis software (Biolegend, San Diego, California).
[0232] RNA extraction, real-time gene expression analysis DirectZol TMTotal RNA was extracted from tumor fragments using the RNA MiniPrep Kit (ZymoResearch). Reverse transcription was performed using M-MLV reverse transcriptase (Invitrogen), and quantitative real-time PCR (q-PCR) was performed using Fast SyberGreen PCR Master Mix (Thermo Fisher Scientific) on an ABI Prism 7500 Fast instrument (Thermo Fisher Scientific). qPCR was performed using primers (forward: 5'-GTCACCTGATCGGCAATTTGT-3', reverse: 5'-CCCCATTCTGAAGGTCGTAGAT-3') of mouse Fap cDNA normalized to mouse Tbp levels (forward: 5'-CCTTGTACCCTTCACCAATGAC-3', reverse: 5'-ACAGCCAAGATTCACGGTAGA-3'). The expression levels were expressed by the following formula. 2 ΔCt(Ct tbp-Ctfap) (In the formula, Ct corresponds to the number of cycles.)
[0233] To investigate the expression of immune-related genes in the tumor microenvironment, 100 ng of total RNA extracted from tumors on day 14 was hybridized to the nCounter® PanCancer immunoprofiling panel (NanoString Technologies). The number of genes was determined using nSolver. TM 2.6 The data was normalized using NanoString Technologies (Seattle) software, selecting housekeeping genes from the panel.
[0234] statistical analysis Differences in immune cell frequency, tumor growth, and mouse survival rates were analyzed using GraphPad Prism (GraphPad Software, La Jolla, California). T-tests, ANOVA for multiple comparisons, or corresponding nonparametric tests (Mann-Whitney or Kruskal-Wallis) were used. Log-rank tests were used for survival analysis. P-values less than 0.05 were considered statistically significant.
[0235] 2.2 Results FAP-CD40 in combination with RT therapy is safe and efficient, and does not require FAP-mediated crosslinking to mediate the control of tumor growth. To test the therapeutic potential of a CD40 bispecific antibody targeting FAP (FAP-CD40), an orthotopic head and neck tumor model (mEERL95) previously created (Mermod et al., Int. J. Cancer 2018, 142, 2518-2528) that replicates the major clinical aspects of the disease, including FAP-positive stroma, was used. In the initial experiment, the antitumor efficacy and safety of FAP-CD40 were investigated according to the scheme shown in Figure 2A, using FAP-CD40 alone, in combination with or without fractionated radiotherapy (consisting of two consecutive 6 Gy irradiations). A non-targeted DP47-CD40 control bispecific antibody (DP47 being a germline control) showed no antitumor effect in tumor-bearing mice, as did treatment with PBS alone (Figures 2C and 2D). Conversely, FAP-CD40 resulted in complete tumor reduction in 40% of treated mice, followed by tumor recurrence in one mouse (Figure 2E). These results indicate that crosslinking via FAP is necessary for FAP-CD40 to be therapeutically effective.
[0236] Local radiotherapy alone (Figure 2F) or local radiotherapy combined with control DP47-CD40 antibody (Figure 2G) resulted in delayed tumor growth and increased survival compared to the control group, i.e., PBS-untreated and DP47-CD40-treated mice (Figures 2C and 2D). However, from day 20 after mEERL95 tumor transplantation, 2×6Gy and 2×6Gy+DP47-CD40-treated tumors began to recur, and objective complete response (CR) was not achieved. Interestingly, all tumor-bearing mice responded to the combination of radiotherapy (2×6Gy) and FAP-CD40 antibody, inducing complete tumor reduction and sustained control in 83% (5 / 6) of these animals (Figure 2H). Additional administration of anti-FAP-CD40 on day 13 did not improve the combination outcome (Figures 2K and 2L). Overall, mice treated with FAP-CD40 monotherapy showed a significantly higher overall survival rate (2 out of 5 complete remissions) compared to the PBS and DP47-CD40 control groups (Figure 2B). Notably, all responder mice in the combination therapy remained recurrence-free even after long-term observation (over 90 days). This indicates that the combination therapy with FAP-CD40 radioimmunotherapy not only resulted in a high tumor reduction rate but also extended the survival time of the animals (Figure 2B).
[0237] The efficacy of FAP-CD40 antibody, either as monotherapy or in combination with fractional radiotherapy, was accompanied by the absence of systemic toxicity, a common characteristic of treatment with CD40 agonist monoclonal antibodies (Vonderheide et al., J. Clin. Oncol. 2007, 25(7), 876-883; Medina-Echeverz et al., Cancer Immunol. Res. 2015, 3(5), 557-566, or Vonderheide et al., Oncoimmunology 2013, 2(1):e23033). In a second comparative experiment, tumor-carrying mice treated with FAP-CD40 antibody did not show weight loss, whereas a single injection of CD40 mAb (at the same molar concentration), either in combination with or without RT, induced significant weight loss accompanied by tumor growth control comparable to that achieved by bispecific FAP-CD40 antibody therapy. The results of the second experiment are shown in Figures 3A to 3F, and Figure 3G shows the corresponding changes in body weight.
[0238] Efficient FAP-CD40 activity requires the presence of FAP-expressing fibroblasts in the tumor stroma. As shown in Figure 4A, the prolyl endopeptidase FAP is highly expressed in cancer-associated fibroblasts (CAFs) of human HNSCC and has been reproduced in the mEERL95 model. To further investigate whether FAP-CD40-mediated antitumor activity required FAP-expressing stromal fibroblasts, mouse TC-1 lung cancer cells expressing mutant H-ras, HPV16 E6 and E7 proteins (Lin et al., Cancer Research 1996, 56, 21-26) but lacking FAP expression (Dupperet et al., Clin. Cancer Res. 2018, 24(5), 1190-1201) were used. Transplantation of TC-1 tumor cells into the submental region resulted in tumors with αSMA-expressing CAFs surrounding the tumor and αSMA-positive, FAP-negative cells in several locations within the tumor (Figures 4A and 4B). Similar to the results of immunohistochemical staining, mRNA expression levels of the Fap gene were significantly lower in TC-1 tumors (Figure 4B).
[0239] Consistently, contrary to the results observed in the mEERL95 model, TC-1 tumors did not respond to FAP-CD40 alone, but showed only 9% (1 / 11) complete remission (CR) with RT alone or in combination with 2 × 6 Gy and FAP-CD40 (Figures 4D-4G). To evaluate access of FAP-CD40 antibodies to TC-1 tumors, Alexa647-labeled anti-FAP-CD40 antibodies were intraperitoneally injected into locally irradiated TC-1 and mEERL95-bearing tumor mice. The antibody was detected in both tumors 4 days post-administration. No significant difference in fluorescence intensity was observed between the TC-1 and mEERL95 tumors (Figure 4H), which showed similar CD40 mRNA expression levels (Figure 4C). These results suggest that while FAP-CD40 can target CD40-expressing cells present in the TC-1 tumor microenvironment, it cannot promote protective immunity because CD40 signaling is not activated without FAP-mediated crosslinking.
[0240] Since FAP is present in the stromal compartment of lymph nodes, particularly in reticular cells (FRCs) (Denton et al., Proc.Natl.Acad.Sci. USA 2014, 111(33), 12139-12144), we investigated the levels of FAP in the regional lymph nodes of these two tumor models. FAP expression was detected by IHC in the cervical lymph nodes of both mEERL95 and TC-1 submental tumors 10 days after inoculation (Figure 4I). The frequency and expression levels of FAP on FRCs (gp38+CD31-) measured by flow cytometry were similar in TC-1-carrying mice and mEERL95-carrying mice (Figures 4J and 4K). These results highlight the necessity of FAP expression in the tumor stroma.
[0241] The combination of FAP-CD40 and radiotherapy promotes long-term anti-tumor protective immunity. To determine whether the combination of radiotherapy (2 × 6 Gy) with anti-FAP-CD40 treatment can induce tumor-specific long-term protective immunological memory in mEERL95 tumor-carrying mice, allogeneic tumors were rechallenged in the right flank of mice that rejected the primary mEERL95 tumor during the combination therapy (long-term responders) (Figure 5A). All mice controlled tumor growth and ultimately rejected the tumor. This indicates the existence of specific immunological memory (Figure 5B). Since mEERL95 cells express the HPV16 E7 protein, the inventors hypothesized that this protein might be the immunodominant target antigen of the observed immunological memory. To test this hypothesis, a second rechallenge was performed in the left flank of cured mice using a TC-1 cell line that also expresses the E7 protein (Figure 5A). Only 3 out of 8 mice were able to reject the TC1 cells, suggesting that E7 may not be the immunodominant antigen in this situation (Figure 5C). Furthermore, approximately 40-60% of long-term responder mice (that rejected mEERL95 primary tumors with FAP-CD40 monotherapy or in combination with RT) presented E7-specific T lymphocytes in in vitro PBMC proliferation (Figure 5D). In fact, the frequency of E7-specific CD8 T cells (detected by specific tetramer staining) decreased in the mEERL95 tumor microenvironment when combined with FAP-CD40 compared to untreated tumors (Figure 5E).
[0242] Based on these promising results, and with the aim of accelerating the clinical application of this combination therapy, the antitumor properties of a surrogate bispecific antibody (FAP-huCD40) composed of an anti-mouse FAP moiety and targeting the human CD40 receptor were further tested in experiments. Therefore, mEERL95 tumor cells were inoculated into the subchineal region of transgenic mice expressing the human CD40 receptor (huCD40 Tg mice). The tumors were locally irradiated with 6 Gy twice consecutively, following the same schedule as wild-type tumor-carrying mice. Subsequently, the mice were administered an ip injection of FAP-huCD40 antibody concurrently with the second radiotherapy session (Figure 6A). Complete remission was not observed, and FAP-huCD40 as a monotherapy agent showed no difference in tumor growth or survival rate compared to untreated mice (Figures 6B and 6D). Mice receiving 2 × 6 Gy showed slower tumor growth, induced tumor reduction, and increased survival rate compared to FAP-CD40 mice and control mice. However, none of the treatments completely rejected the tumor (Figures 6B and 6E). The combination of 2 × 6 Gy and FAP-huCD40 resulted in a 40% complete remission rate (4 / 10) and significantly extended long-term survival compared to the other groups (Figures 6F and 6B).
[0243] The combination of FAP-CD40 and radiotherapy remodels the tumor immunomicroenvironment into a less immunosuppressive landscape. Based on the initial experiment (Figure 2A), cellular and molecular immune components associated with the antitumor effect of the combination therapy were investigated. Intratumoral immune infiltration was analyzed 8 days after the first radiotherapy administration. Using a flow cytometry-based 16-color antibody panel, an overall increase in the number of immune cells (CD45+ cells) per mg of tumor was observed in all treatment groups compared to PBS and DP47-CD40 (Figure 7A). Compared to PBS and DP47-CD40 controls, the number of CD8 T cells increased significantly with irradiation. This increase was less pronounced in FAP-CD40 monotherapy and combination therapy (Figure 7B). The number of regulatory T cells (Tregs) present in the tumor increased only with radiotherapy compared to control mice (Figure 7C), resulting in an increased CD8 / Treg ratio in the FAP-CD40, RT, and combination therapy groups (Figure 7D). Interestingly, the CD8 cell / macrophage ratio increased only in the FAP-CD40+2×6Gy group, supporting the idea that this combination alters the balance to favor CD8 T cell infiltration into tumors (Figure 7E). In this regard, while the frequencies of CD4 T cells (Figure 7F), dendritic cells (DC, Figure 7G), and NK cells (Figure 7H) decreased in each treatment group compared to untreated mice, the number per 1 mg of tumor was similar across all groups.
[0244] Furthermore, increased IFNγ production by CD8 and CD4 T cells from tumor-infiltrating lymphocytes (TILs) of tumors treated with FAP-CD40 and RT was observed in an ex vivo restorative assay against mEERL95 cells (Figures 8A and 8D). TNFα and granzyme B were enhanced in all T cell subsets exhibiting effector and cytotoxic phenotypes (Figures 8B, 8C, 8E, and 8F). Proliferation of CD8 TILs, measured as Ki67-positive cells (Figure 8G), was increased in all treatment groups compared to the control, while PD-1 expression remained low in a FAP-CD40-dependent manner, resulting in a less exhausted phenotype (Figure 8H). The combination therapy enhanced the memory phenotype of CD8 T cells from regional lymph nodes (CD62L + CD44 + This promoted (Figure 8I).
[0245] This combination therapy significantly increased molecular remodeling of the tumor microenvironment compared to untreated tumors by upregulating 39 immune-related genes and downregulating 39 others. This molecular imprinting induced by the combination therapy encompassed induction of expression in various pathways involved in adaptive immune responses, antigen processing, interferon signaling, inflammation, chemokines, and cytokines or DC function. Tumors treated with FAP-CD40 therapy, including upregulation of Cd40, Ccl22, Il12b, Irf8, and Ccr7, in combination with 2 × 6 Gy showed significant enrichment of dendritic cell-specific inflammatory gene signatures. Multiplex cytokine / chemokine assays confirmed the combination therapy-induced upregulation of intratumoral levels of IFNγ and specific chemokines (such as CXCL9 and CXCL10) (Figures 9A, 9B, and 9C). Furthermore, 2×6Gy+FAP-CD40 induced the formation of maturation markers such as CD80 and CD86 on the surface of DCs infiltrated by mEERL95 (Figures 9E and 9F).
[0246] In summary, these data indicate that the remarkable efficacy of FAP-CD40 therapy in combination with 2 × 6 Gy RT is associated with reduced immunosuppression, increased CD8 T cell infiltration and proliferation, cytokine production, and extensive remodeling of the tumor immune landscape, including DC maturation.
[0247] The effectiveness of combination therapy depends on CD8 T cells and cross-priming DCs, while relapse prevention depends on CD4 T cells. The contribution of T lymphocytes to the antitumor efficacy of combination therapy was investigated through selective depletion in vivo. Starting 48 hours prior to treatment initiation, mEERL95 tumor-carrying mice were administered either anti-CD8β, anti-CD4, or the corresponding IgG control antibody via ip injection every 3 days. Depletion treatment of mice with CD8 T lymphocyte-targeting antibodies resulted in the loss of the curative effect observed with combination therapy (Figure 10C). Mice with CD4 T cell depletion showed complete remission by 30 days post-treatment (Figure 10D). However, compared to 5 out of 7 mice (71%) in the IgG control group, 2 out of 7 mice (28%) in this group experienced tumor recurrence (Figure 10B) and had a shortened survival time (Figure 10E). These results highlight the essential role of CD4 T cells in the formation of a sustained antitumor response.
[0248] The enrichment of DC maturation transcriptional signatures in tumors during combination therapy suggested the role of activated Batf3-dependent DCs in the CD8 T cell-mediated response and the necessity of CD8 T cell-cDC1 crosstalk. Therefore, we attempted to test this combination therapy in the absence of such an immune population. As shown in Figures 10F-10I, the therapeutic effect of the combination of RT (2 × 6 Gy) and FAP-CD40 treatment was abolished in Batf3- / - mice (cDC1 deficient). The antitumor effect of the combination therapy was abolished in some treated Batf3- / - mice compared to untreated tumor-carrying Batf3- / - mice, although the tumor growth rate was reduced in some treated Batf3- / - mice compared to untreated tumor-carrying Batf3- / - mice. This indicates that crosspriming DCs are necessary for a robust protective response mediated by FAP-CD40.
[0249] Blocking IL-12 during the T-cell effector phase negates the effectiveness of combination therapy. IL-12b is one of the genes that are differentially expressed in tumors during combination therapy, and considering the known cytolytic activity of IL-12, we investigated its functional relationship to the therapeutic response to the combination of RT (2 × 6 Gy) and FAP-CD40. Therefore, IL-12 blocking antibodies were administered for 7 days starting one day before radiotherapy. As shown in Figure 11C, tumor reduction occurred in all mice with combination therapy and IL-12 neutralization, but tumor growth resumed in 85% of mice (6 out of 7). This strongly supports the important role of IL-12 in maximizing the antitumor effect of combination therapy. Interestingly, IL-12 blockade did not affect the initial response, which appears to be primarily due to radiotherapy. Loss of therapeutic efficacy due to IL-12 neutralization was accompanied by decreased serum levels of specific chemokines produced by dendritic cells, such as CXCL9, CXCL10, CCL4, and CCL22, which are associated with T cell recruitment, migration, and priming (Figures 11D-11G).
[0250] 2.3 Discussion of Results The combination of bispecific FAP-CD40 antibody with radiotherapy has been shown to be a safe and effective novel strategy for enhancing radiotherapy and achieving sustained protective immunological memory in HPV+ HNSCC. A key element of this combination is based on limiting the activity of the CD40 agonist against the tumor microenvironment by targeting FAP-expressing stromal cells. The inventors were able to identify an appropriate treatment regimen and showed that the CD8 T cell-DC1 axis is the primary cellular mechanism of action upon IL12 induction in the tumor. In summary, these results provide a strong biological basis for the clinical application of this therapeutic approach. Furthermore, the remarkable effect mediated by human CD40 signaling in combination with radiotherapy and the bispecific surrogate FAP-huCD40 antibody supports the applicability of this approach not only to the treatment of head and neck cancer patients but also to patients with other cancer types characterized by stromal accumulation of FAP-expressing fibroblasts.
[0251] Furthermore, we investigated the effects and mechanisms of action of this therapy on the tumor immune cell landscape. The reason for selecting an orthotopic model of head and neck cancer (mEERL95) was, firstly, that this orthotopic model mimics human disease in that it has a high prevalence of primary tumor recurrence, and secondly, that high levels of FAP are observed in the mEERL95 stroma. This last characteristic was key to verifying the therapeutic efficacy of the FAP-CD40 antibody.
[0252] FAP-CD40 is FAP + CD40 co-stimulation is induced only during cell cross-linking. The unique characteristic of this bispecific antibody, which targets the CD40 therapeutic antibody to tumor regions where FAP-expressing cells and CD40-expressing cells co-localize, is key to avoiding the classic pattern of systemic toxicity seen with the use of CD40 agonists. FAP (fibroblast-activated protein) is an endopeptidase mainly expressed by protumoral activated fibroblasts in the tumor stroma, but can also be found in other stromal compartments such as the FRC of lymph nodes. Treatment of a TC-1 tumor model in which the minimal efficacy of this combination therapy coincided with low intratumoral FAP expression revealed that cross-linking in the tumor stroma via FAP is essential for the antitumor effect of the FAP-CD40 antibody. The FAP-CD40 antibody was detected in the tumor region by in vivo fluorescence imaging, but its presence in neighboring lymph nodes could not be formally ruled out. However, the similar presence of FAP-positive cells in the regional lymph nodes of TC-1 tumors and mEERL95 tumors, and their diametrically opposed responses to treatment, suggests that FAP-CD40 + This indirectly demonstrates that RT-mediated antitumor immune activation occurs in the tumor beds of these tested tumor models. It is interesting to investigate how FAP-CD40 functions in immunologically "cold" tumors.
[0253] The magnitude of efficacy reported in mEERL95 tumors and the absence of recurrence in responder mice warrant further investigation at the biological level. Long-term survival in animals treated with FAP-CD40 and RT, and rejection of allogeneic tumors in rechallenged cured mice, are consistent with the induction of T-cell memory phenotypes observed in local lymph nodes, supporting the effect of this combination on long-term immunological memory. While the identification of specific antigens was beyond the scope of the study, the inventors suggest that mEERL95 is related to HPV + Given this fact, the involvement of E7, a clear antigen, was ruled out. These data were consistent with other reports that administration of this peptide alone or in combination with other immunotherapies enhances the E7-specific response in preclinical tumor models.
[0254] Furthermore, the absence of the effect of this combination in T-cell depleted mice confirmed that the T-cell population is important for treatment outcomes. CD8 T cells were necessary for the antitumor effect of the combo, while CD4 T lymphocytes are essential for generating a sustained response, preventing relapse, and subsequently for robust immunological CD8-T memory, as demonstrated in vaccine and viral infection settings (Ahrends et al., Nat. Commun. 2019, 10(1), 5531). These findings are supported by previous preclinical studies that have shown CD4 T cell-mediated immune responses to be important in anti-CD40 therapy.
[0255] The therapeutic effect of combination therapy with radiotherapy and anti-FAP-CD40 was accompanied by significant remodeling of the tumor immune landscape. The decrease in regulatory T cells and macrophages indicated that this combination promoted a more immunosuppressive environment favorable to the function of effector T lymphocytes. In this regard, restimulated TILs from tumors treated with FAP-CD40 and radiotherapy showed elevated intratumoral levels of IFNγ (consistent with increased production of the cytokine) and low levels of PD-1 expression. In fact, IFNγ (Garris, Immunity 2018, 49(6), 1149-1161), which is hypothesized to be a key factor in the CD40-mediated antitumor response when used in combination with IL-12, was specifically induced when used in combination with FAP-CD40. Interestingly, neutralization of IL-12 during the effector phase of this response abolished the therapeutic effect of the combination therapy, indicating that FAP-CD40 is dependent on this cytokine for efficacy. Activated cross-priming dendritic cells are known to be the primary IL-12-producing cells in humans and mice (Maier et al. Nature 2020, 580, 257-262). In this sense, two notable findings highlight the importance of these cells in the mechanism of action of this combination therapy. First, enrichment of activated cross-priming dendritic cell-specific gene signatures in the tumor microenvironment following combination therapy with FAP-CD40 and radiotherapy; and second, loss of antitumor response in Batf3ko mice lacking cDC1 cells. These observations are consistent with previous studies reporting the dependence of anti-CD40 therapy on cross-priming dendritic cells (Garris, Immunity 2018, 49(6), 1149-1161). While macrophages have already been described as being involved in CD40-mediated responses (Beatty et al., Science 2011, 331, 1612-1616), the decrease in their number and the important role of IL-12 suggest that the radioimmunotherapy effect in our setting is mainly mediated by dendritic cells.
[0256] The results obtained with this combination therapy regarding safety and antitumor response support the clinical application of this new treatment approach, which combines radiotherapy, a standard treatment, with a novel and safe molecularly engineered CD40-targeted immunotherapy.
[0257] Example 3 In vivo antitumor efficacy of FAP-targeted anti-CD40 antigen-binding molecules in combination with radiotherapy, as demonstrated in an SV2 lung tumor model. 3.1 Materials and Methods We investigated the ability of a bispecific FAP-targeted anti-CD40 antigen-binding molecule to achieve therapeutic efficacy in mice possessing the SV2 tumor cell line, a mouse model of non-small cell lung cancer (NSCLC), when used in combination with a fractional radiotherapy regimen.
[0258] Ten-week-old male C57BL / 6J mice were purchased from Charles River Labs. All animal experiments were conducted under license VD3173.1 approved by the Veterinary Authority of Vaud, Switzerland. The SV2 cell line was used for KP tumors (Kras LSL.G12D / wt ;p53 frt / frt The cells were derived from Meylan Lab. and obtained from there. The SV2 cell line was transduced by OVA as described above (Martinez-Usatorre A, Romero P, Generation of affinity ranged antigen-expressing tumor cell lines, Methods Enzymol. 2020, 632, 503-519, doi: 10.1016 / bs.mie.2019.12.001. Epub 2019 Dec 18. PMID: 32000912) and cultured in DMEM medium supplemented with 10% FBS (Life Technologies) containing GlutaMAX (Thermo Fisher Scientific). The cells were cultured in an incubator at 37°C and 5% CO2.
[0259] Tumor models and in vivo therapies Mice were given 1 x 10⁶ mice resuspended in PBS (Thermo Fisher Scientific). 6 SV2-OVA cells were intravenously injected into the tail vein. On day 12, 1 × 10⁶ cells isolated from the naive spleen were administered. 5 OT1 cells were intravenously injected into mice. The lungs were irradiated with a small fractionation regimen consisting of two consecutive 6 Gy irradiations on days 13 and 14 after tumor cell transplantation. The dose was delivered using an Xrad-225CX-PXi instrument with a 20 mm collimator capable of localized lung irradiation. On days 14 and 18, mice were treated with intraperitoneal injection of 18.3 mg / kg of anti-FAP-CD40 (P1AD9139) in PBS. Tumor size was followed up twice weekly using a U-CT system (MILabs), and image analysis was performed using Imalytics Preclinical.
[0260] 3.2 Results The combined use of FAP-CD40 and RT significantly slows tumor growth in the SV2 lung tumor model. To investigate the therapeutic potential of a CD40 bispecific antibody targeting FAP (FAP-CD40), mice were transplanted with 1.5 million SV2-OVA cells and administered two suboptimal doses of 6 Gy each, along with two doses of FAP-CD40. Prior to treatment, mice were administered 100,000 OT1 cells intravenously. The treatment schedule is shown in Figure 3A. The combination of RT and anti-FAP-CD40 was observed to slow tumor growth compared to RT alone (Figure 3B). Furthermore, this combination extended the survival time by more than 20 days compared to untreated mice (Figure 3C).
Claims
1. A medicament comprising a bispecific agonist CD40 antigen-binding molecule for treating a solid tumor in an individual, said medicament being used in combination with radiation therapy, said bispecific agonist CD40 antigen-binding molecule comprising at least one antigen-binding domain capable of specifically binding to a tumor-associated antigen.
2. The pharmaceutical described in claim 1, wherein the bispecific agonist CD40 antigen-binding molecule comprises at least one antigen-binding domain capable of specifically binding to CD40 and at least one antigen-binding domain capable of specifically binding to fibroblast activation protein (FAP).
3. The pharmaceutical according to claim 1 or 2, which is for administration simultaneously or sequentially with radiation therapy.
4. The pharmaceutical according to any one of claims 1 to 3, which is for administration after radiation therapy.
5. The pharmaceutical composition according to any one of claims 1 to 4, wherein the radiation therapy comprises local radiation therapy selected from external beam radiation therapy or brachytherapy.
6. The method of claim 1 , wherein the radiation therapy comprises localized hypofractionated radiation therapy.
7. The method of any one of claims 1 to 6, wherein the radiation therapy comprises localized hypofractionated radiation at a dose ranging from 1.8 to 20 Gy.
8. The method of any one of claims 1 to 6, wherein the radiation therapy comprises localized hypofractionated radiation at a dose in the range of 2x6 Gy.
9. The pharmaceutical composition of any one of claims 1 to 8, wherein the solid tumor is selected from the group consisting of head and neck cancer, melanoma, lung cancer, kidney cancer, breast cancer, colon cancer, ovarian cancer, cervical cancer, pancreatic cancer, liver cancer, prostate cancer, bladder cancer, gastric cancer, glioblastoma, and sarcoma.
10. The pharmaceutical composition according to any one of claims 1 to 9, wherein the solid tumor is head and neck cancer.
11. The method according to any one of claims 1 to 9, wherein the solid tumor is lung cancer, in particular non-small cell lung cancer (NSCLC).
12. The pharmaceutical of any one of claims 1 to 10, wherein the bispecific agonist CD40 antigen-binding molecule is an antigen-binding molecule comprising an IgG Fc domain, specifically an IgG1 Fc domain or an IgG4 Fc domain, and the Fc domain comprises one or more amino acid substitutions that reduce the binding affinity of the antibody to an Fc receptor and / or the effector function.
13. The pharmaceutical of claim 12, wherein the bispecific agonist CD40 antigen binding molecule comprises an Fc domain of the human IgG1 subclass having the amino acid mutations L234A, L235A and P329G (numbered according to the Kabat EU index).
14. The bispecific agonist CD40 antigen binding molecule, comprising at least one antigen-binding domain capable of specifically binding to CD40, the antigen-binding domain comprising a heavy chain variable region (VH1) comprising (i) a CDR-H1 having the amino acid sequence of SEQ ID NO:1, (ii) a CDR-H2 having the amino acid sequence of SEQ ID NO:2, and (iii) a CDR-H3 having the amino acid sequence of SEQ ID NO:
3. H (iv) a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 4, (v) a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 5, and (vi) a CDR-L3 comprising the amino acid sequence of SEQ ID NO:
6. L The pharmaceutical composition according to any one of claims 1 to 13, comprising a cytotoxic T cell proliferation inhibitor (CTL) and ...
15. The pharmaceutical of any one of claims 1 to 14, wherein the bispecific agonist CD40 antigen binding molecule comprises at least one antigen-binding domain capable of specifically binding to CD40, the antigen-binding domain comprising a VH comprising the amino acid sequence of SEQ ID NO:7 and a VL comprising the amino acid sequence of SEQ ID NO:
8.
16. The bispecific agonist CD40 antigen binding molecule comprising at least one antigen-binding domain capable of specifically binding to FAP, the antigen-binding domain comprising: (a) a heavy chain variable region (VH1) comprising (i) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 9, (ii) a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 10, and (iii) a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 11; H and a light chain variable region (V FAP) comprising (iv) a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 12, (v) a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 13, and (vi) a CDR-L3 comprising the amino acid sequence of SEQ ID NO:
14. L FAP), or (b) a heavy chain variable region (VH) comprising (i) CDR-H1 comprising the amino acid sequence of SEQ ID NO: 17, (ii) CDR-H2 comprising the amino acid sequence of SEQ ID NO: 18, and (iii) CDR-H3 comprising the amino acid sequence of SEQ ID NO: 19; H and a light chain variable region (V FAP) comprising (iv) a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 20, (v) a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 21, and (vi) a CDR-L3 comprising the amino acid sequence of SEQ ID NO:
22. L FAP), or (c) a heavy chain variable region (VH1) comprising (i) a CDR-H1 comprising the amino acid sequence of SEQ ID NO:25, (ii) a CDR-H2 comprising the amino acid sequence of SEQ ID NO:26, and (iii) a CDR-H3 comprising the amino acid sequence of SEQ ID NO:27; H (iv) a CDR-L1 comprising the amino acid sequence of SEQ ID NO:28, (v) a CDR-L2 comprising the amino acid sequence of SEQ ID NO:29, and (vi) a CDR-L3 comprising the amino acid sequence of SEQ ID NO:
30. L FAP) and The pharmaceutical composition according to any one of claims 1 to 15, comprising:
17. The bispecific agonist CD40 antigen binding molecule, comprising at least one antigen-binding domain capable of specifically binding to FAP, the antigen-binding domain comprising a heavy chain variable region (VH1) comprising (i) a CDR-H1 comprising the amino acid sequence of SEQ ID NO:9, (ii) a CDR-H2 comprising the amino acid sequence of SEQ ID NO:10, and (iii) a CDR-H3 comprising the amino acid sequence of SEQ ID NO:
11. H (iv) a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 12, (v) a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 13, and (vi) a CDR-L3 comprising the amino acid sequence of SEQ ID NO:
14. L The pharmaceutical composition according to any one of claims 1 to 16, comprising:
18. The bispecific agonist CD40 antigen binding molecule comprising at least one antigen-binding domain capable of specifically binding to FAP, the antigen-binding domain comprising: (a) a heavy chain variable region (V H FAP) and a light chain variable region (V L FAP), (b) a heavy chain variable region (V H FAP) and a light chain variable region (V L FAP), or (c) a heavy chain variable region (V H FAP) and a light chain variable region (V L FAP) The pharmaceutical composition according to any one of claims 1 to 17, comprising:
19. The bispecific agonist CD40 antigen binding molecule of claim 1 (i) at least one antigen-binding domain capable of specifically binding to CD40, comprising a heavy chain variable region (V H CD40) and a light chain variable region (V L an antigen-binding domain comprising an antigen binding domain (e.g., a nucleotide sequence of the nucleotide sequence of interest, such as nucleotide sequence 100 or 1100) of interest (e.g., nucleotide sequence 101 or 102); (ii) at least one antigen-binding domain capable of specifically binding to FAP, comprising a heavy chain variable region (V H FAP) and a light chain variable region (V L and an antigen-binding domain comprising the FAP; A pharmaceutical composition according to any one of claims 1 to 18.
20. The bispecific agonist CD40 antigen binding molecule of claim 1, (a) at least two Fab fragments capable of specific binding to CD40, the Fab fragments being fused at their C-terminus to the N-terminus of an Fc region; and (b) one antigen-binding domain capable of specifically binding to FAP, the antigen-binding domain being fused at its N-terminus to the C-terminus of the Fc region; The pharmaceutical composition according to any one of claims 1 to 19, comprising:
21. The bispecific agonist CD40 antigen binding molecule of claim 20, (a) at least two Fab fragments capable of specific binding to CD40, the Fab fragments being fused at their C-terminus to the N-terminus of an Fc region; and (b) a cross-fab fragment capable of specifically binding to FAP, the cross-fab fragment being fused to the C-terminus of the Fc region; The pharmaceutical composition according to any one of claims 1 to 20, comprising:
22. The pharmaceutical of claim 21, wherein the bispecific agonist CD40 antigen binding molecule comprises a cross-fab fragment capable of specific binding to FAP, and a VH-C kappa chain of the cross-fab fragment is fused to the C-terminus of the Fc region.
23. The pharmaceutical of any one of claims 1 to 22, wherein the bispecific agonist CD40 antigen-binding molecule comprises four Fab fragments capable of specific binding to CD40, two of the Fab fragments being fused to each other and fused at their C-terminus to the N-terminus of the Fc region.
24. (i) an individual, when treated with a therapeutically effective amount of a bispecific agonist CD40 antigen binding molecule in combination with radiation therapy, has an increased survival rate compared to an individual receiving the bispecific agonist CD40 antigen binding molecule as monotherapy or an individual receiving radiation therapy as monotherapy; or (ii) the size of a solid tumor in an individual is reduced by more than the additive amount of reduction in said size due to treatment with the bispecific agonist CD40 antigen binding molecule used as monotherapy and radiation therapy used as monotherapy; A pharmaceutical composition according to any one of claims 1 to 23.
25. 1. A pharmaceutical composition for use in the treatment of solid tumors comprising a pharma- tically effective amount of a bispecific agonist CD40 antigen-binding molecule, said treatment comprising in combination with radiation therapy, said bispecific agonist CD40 antigen-binding molecule comprising at least one antigen-binding domain capable of specifically binding to a tumor-associated antigen.
